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ABSTRACT
In the everlasting battle against cancer the development of drugs targeting new therapeutic
pathways is of crucial importance. In the attempt to develop new anticancer agents we have
synthesized a library of anthraquinone compounds that show selectivity against leukemia.
Mechanistic evaluation of the lead compound reveal that this class of compounds achieve their
effects through inhibition of MDM2-MDM4 heterodimer and upregulation of the tumor suppressor
p53. Computer aided rational design resulted in the development of a number of compounds with
activities in the nanomolar range against various cancer cells. Analysis of the physicochemical
properties of selected compounds allowed for their evaluation as potential drug candidates. The
successful development of non-toxic formulations permits for the further in vivo investigation of
the compounds.

Click reactions have found wide spread applications in sensing, materials chemistry,
bioconjugation, and biolabeling. A number of very useful click reactions have been discovered,
which allow for various applications. In bioconjugation applications, the ability to conduct a
secondary conjugation will be very useful in, e.g., protein pull down and binding site identification.
Along this line, we describe a neighboring group-assisted facile condensation between an aldehyde
and a vicinal aminothiol moiety, leading to the formation of benzothiazoles. The conversion is
completed within 5 minutes at low micromolar concentrations at ambient temperature. The facile
reaction was attributed to the presence of a neighboring boronic acid, which functions as an
intramolecular Lewis Acid in catalyzing the reaction. The boronic acid group is compatible with
most functional groups in biomolecules and yet can also be used for further functionalization via
a large number of well-known coupling reactions.

INDEX WORDS: Rhein, MDM2, MDM4, p53, anticancer, Click chemistry, Boronic acids,
Biorthogonal conjugation
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1
1.1

NOVEL ANTICANCER AGENTS THAT UPREGULATE P53

Background and introduction
Cancer is one of the leading causes of death in modern society and the medical and scientific

communities throughout the world have been engaged in an ongoing battle with this deadly disease
for decades. Although, incremental progress in controlling this modern-day “plague” has been
achieved and the grand statistics for 2015 have shown a decrease in mortality, the number of global
cancer incidence steadily keeps rising.1 Furthermore, the incidence in adolescent acute solid tumor
and leukemia have been increasing by approximately 0.6 % per year since 1975.1 Thus, new and
more efficient therapeutic strategies against cancer are of immediate need. Herein, we disclose the
development of series of anthraquinone-based compounds that show potency against a number of
cancer cell lines. These compounds show preferential inhibition against leukemia cell lines as well
as efficacy against drug resistant cancer cells. The developed lead compound induces cellular death
through the inhibition of MDM2/MDM4 interactions, consequently elevating p53 levels in the
cell, leading to apoptosis.
1.1.1 p53
One of the key factors in the mammalian system responsible for the cellular viability in a
“stress” situations is the transcription factor p53. This so-called “genome guardian” is a tumor
suppressor protein that is 43.7 kDa in size and its levels in normal cells are tightly regulated. 2 In
addition to protein suppression through transcription, p53 possesses regulatory cytoplasmic
activity.3,4 p53 has been shown to interact with proteins from the Bcl-2 family, thus activating, in
a non-transcriptional manner, the pro-apoptotic BH3 proteins.5 There are also reports indicating
the importance of p53 in double-stranded RNA degradation, autophagy inhibition, and improved
mitochondrial permeability of the Bcl-2 proteins.6 Thus, regulation of this protein in the
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mammalian cell is of extreme importance. There is a number of ways to regulate p53 activity;
through translocation and degradation via ubiquitin ligases, post-translational modifications,
transcriptional co-activator, etc.7 However, the key player in the p53 regulatory process is MDM2;
an active E3 ubiquitin ligase. The importance of this ligase has been exemplified in a number of
studies where deletion of Mdm2 gene resulted in early embryonic death due to p53-induced
apoptosis.8 Although tightly regulated under physiological cellular environment, in stress
conditions p53 regulation is swiftly abolished and activated p53 establishes a stress response
(Figure 1). Activation of p53 has been shown in response to DNA damage, genotoxic disturbances,
abnormal cell proliferation, hypoxia, and nutrient depravation.4,9-12 There is a number of ways that
p53 suppresses tumor development: apoptosis, autophagy, senescence, and promotion of growth
arrest.13,14 In the case of DNA damage, for example due to radiation, two major kinases ATM
(ataxia telangiectasia mutated) and Chk2 activate p53 through subsequent phosphorylation
events.15-17 Overexpression of p53 in this case will directly signal for either programmed cell death
through transcription of the Bax gene or stimulation of other pro-apoptotic proteins from the Bcl2 family.13 Abnormal cell proliferation and growth activate p53 through the p14ARF protein.18 This
protein inhibits the negative regulation of p53 and is a product of increased mitotic signaling,
normally due to the production of the Ras and Myc oncogenes during the process of cellular
division.18 These events result in cell cycle arrest through p53 dependent expression of p21, a
cyclin-dependent kinase (CDK) inhibitor. Unfortunately, about 50% of the cancer cells have
developed p53 mutations, thus keeping it dormant.2,19 Despite that, the majority of cancers control
p53 levels by overexpressing its lead negative regulator; MDM2. 2,20 Overexpression of the MDM2
ubiquitin ligase and its homolog MDM4 are benchmark source of inactivation/regulation of the
tumor suppressor p53.10 The p53 protein in normal cells is present at low concentration and has a
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short half-life (10 – 15 min).2 There is a constant cycle of proteosomal-dependent degradation and
production of p53.2 There are numbers of E3 ubiquitin ligases that play part in this process,
however, the major contributor to the p53 degradation is MDM2.21-23 The inhibition of MDM2
allows the buildup of p53 to be quickly achieved under stress conditions in normal cells.
Furthermore, this process is clearly observed under stress conditions such as, hypoxia, pH shock,
heat stress, genotoxic stress, and ribosomal stress.24,25 Cancer cells that possess wild-type p53 have
developed a mechanism where MDM2 levels are kept high, resulting in down regulation of p53
and inhibition of pro-apoptotic response. This makes MDM2 an attractive therapeutic target.

Figure 1.1.1 A cartoon representation of the p53’s response to cellular stress.

1.1.2 MDM2/MDM4
The MDM2 (murine double minute 2) protein was first isolated from 3T3DM
mouse cell lines in the 1980s.2 Shortly after the protein was isolated it was found that it can bind
and inhibit p53 tumor suppressor.26 MDM2 is an E3-ubiquitin ligase from the RING (Really
Interesting New Gene) family that exists as a homodimer under physiological conditions. MDM2
consists of 491 amino acids and has three major domains: the C-terminal RING domain (the E3
ligase domain), a Zinc finger domain, and the p53-binding N-terminal domain (Figure 2). As a p53
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inhibitor, the regulation of MDM2 is very strictly controlled. MDM2 undergoes post-translational
modifications under cellular stress, so the p53 protein concentrations can be stabilized or
increased.2 On the other hand when cells are under physiological conditions and there is lack of
external cellular stress, MDM2 inactivates p53 in two major ways. The first and most obvious way
of p53 regulation by the MDM2 is through the E3 ubiquitin ligase activity; meaning that p53 is
being ubiquitinated and proteosomally degraded.27,28 The second method of p53 inactivation by
MDM2 is shown to be through binding to the transactivation domain of p53 and blocking its
transcriptional activity.26,29 Studies have shown that MDM2 itself is oncogenic and can cause
tumor formations in nude mice when overexpressed.30 MDM2 has been found to be overexpressed
in a number of cancer cells containing wild-type p53 including, but not limited to, leukemia cells,
osteosarcomas and sarcomas.31,32 Direct regulation of MDM2 can be achieved via prosttranslational modifications such as inactivation through phosphorylation by ATM or Chk2
kinases.17 Another major regulatory way of this ligase is through a negative feedback loop that
uses overexpressed p53 to abolish the MDM2 gene transcription (Figure 3).33 An interesting fact
is that MDM2 can regulate itself through self-ubiquitination as well.24 This can be achieved via
post-translational modifications (phosphorylation, SUMOlation, etc.) independent from MDM2’s
activity against p53.34,35 Weissman and co-workers showed that the self-ubiquitination activity of
MDM2 is RING independent.35 The RING domain is a common structural feature of the RING E3
ubiquitin ligase family. In an experiment where the RING region of MDM2 was replaced with
PRAJA1 domain, the p53 ubiquitination was abolished but the self-ubiquitination activity was
retained.35 This clearly shows the complexity of the p53-MDM2 network.
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Figure 1.1.2 A cartoon representation of the MDM2 and MDM4 primary structures.

A number of p53 and MDM2 knockout studies has given proof that MDM2 is in fact a
direct negative regulator of p53.36-38 As previously mentioned, a crucial structural feature of
MDM2 is the RING domain.39 The transfer of ubiquity from E2 ligases to a target protein is not
the only essential function of this domain, it is also utilized as a handle for protein-protein
interactions; MDM2 uses the RING region to form stable heterodimeric structures with its
homolog MDM4.2 Although MDM4 is a structural homolog of MDM2, it does not carry E3 ligase
activity. However, it has been proposed that through the heterodimer of the two homologs, MDM2
and MDM4, has enhanced E3 ubiquitin ligase activity compared to the MDM2 homodimer.40,41 In
fact, evidence has shown that the MDM2-MDM4 complex is responsible for polyubiquitination of
p53 compared to monoubiquotination by sole MDM2 homodimer.2,42 In addition, MDM2 serves
as negative regulator of MDM4 through direct ubiquitination.42,43 MDM4 is a 90% homolog of
MDM2 and has been found to be overexpressed in a number of cancer cells that contain the p53
wild-type protein.2,44,45 This fact suggests that MDM4 plays an important role in the regulation of
p53. In fact MDM4 binds to p53 and directly regulates its activity.24,46 There are two major theories
that place MDM4 in the regulation pathway of p53.2 The first theory deals with the idea that
MDM2 and MDM4 play distinct roles in the regulation of p53 and the second theory is that the
MDM2-MDM4 complex is the main p53 regulatory machine.2 Both theories are supported by
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experimental results and the question of what is the exact mechanism of p53 regulation regarding
MDM2 and MDM4 stays open. Various in vivo tests show that MDM2 inhibits the apoptotic
activity of p53 and MDM4 inhibits the cell arrest activity of p53.47-49 On the other hand a number
of structural studies have shown that MDM2 and MDM4 depend on each other not only for
improvement of the E3 ligase activity, but also the fact that they must function as a unit and control
p53 during embryotic development.19,50-52 It has also been reported that MDM2 and MDM4 form
energetically much more stable heterodimer as compared to the MDM2 homodimer.53 As the
question for the exact regulation of p53 stays open, it is clear that the disruption of the p53-MDM2MDM4 regulatory cycle is an attractive therapeutic strategy.

Figure 1.1.3 A cartoon representation of the MDM2-p53 regulatory loop.
1.1.3 Compounds targeting MDM2-p53 interactions as anticancer therapeutic strategy
In addition to the fact that MDM2 and MDM4 are overexpressed in over 50% of cancers,
their importance in the negative regulation of the vital tumor suppressor p53 makes these two
proteins very critical anticancer targets. In fact there is a number of academic and industrial groups
that have been actively pursuing this idea and as of 2015 there are seven compounds that reached
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clinical trials.54 The development of small molecules to successfully block protein-protein
interactions (PPIs) is one of the biggest challenges in medicinal chemistry. Generally speaking
protein-protein interactions are dynamic processes and occur on a relatively large and hydrophobic
surface area of the proteins. Thus, it is understandable that in order to be efficient, a small molecule
inhibitor of PPIs must be an extremely specific and potent binder. This section of the chapter
briefly describes some of the most potent MDM2-p53 inhibitors.
1.1.3.1 Nutlin and nutlin-based analogs as MDM2 binders
The breakthrough discovery in the field of MDM2-p53 inhibition was done by Hoffman
La Roche with the development of nutlin.54 This compound has an IC50 = 90 nM (enzymatic
inhibition) and was the first small molecule to be co-crystalized with MDM2. The crystal structure
of this binding truly opened the door for the development of a number of active compounds
targeting this binding pocket. Nutlin and its analogs target the N-terminal residues of MDM2 that
form a hydrophobic pocket (Phe19, Trp23, Leu26), which has been shown to be the key interface
in the MDM2-p53 interactions. Although, nutlin showed cellular growth inhibition in the range of
1-2 µM IC50 and lack of obvious toxicity at 200 mg/kg twice a day for 20 days in mouse models,
it needed improvement in its pharmacokinetic properties.54,55 An optimized version of nutlin
(RO5045337) with a lower molecular weight reached phase I clinical trials after showing
improvement in MDM2 binding affinity (IC50 = 18 nM), pharmacokinetic properties, improved
metabolic profile, and improved redox stability (Figure 4).55,56 Despite the fact that the compound
showed potency, the phase I results indicated that the drug candidate showed some hematological
toxicity, making it unsuitable for further development.
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1.1.3.2 Pyrrolidine-containing MDM2 inhibitors
La Roche developed a second compound (RO5503781) that reached phase I clinical trials
(Figure 4).57,58 This compound was developed based on the crystal structure of nutlin bound to
MDM2; however, the compound is structurally very different. RO5503781 retains the general
three aromatic rings peripheral groups responsible for pi-pi interactions in the binding pocket.
However, the five membered core is pyrrolidine rather than being an imidazole ring. This of course
is a basis for a completely new class of compounds targeting the inhibition of MDM2-p53
interactions. RO5503781 has an IC50 = 6 nM, 80 % oral bioavailability, and good tolerance in
mice. The reported maximum tolerated dose is 500 mg, in a 5 day schedule, twice daily. 58 The
compound did exhibit side effects, such as neutropenia, and diarrhea at the maximum tolerated
dose. The disclosed side effects were well within the acceptable limits, and as of 2015, the
compound was scheduled to progress to phase II clinical trials.
1.1.3.3 Spirooxindole-containing MDM2 inhibitors
An MDM2 inhibitor (SAR405838) developed by Shaomeng Wang’s group at University
of Michigan was advanced to clinical trials by Sanofi S.A. in 2012 (Figure 4).54,59 This compound
contains a central pyrolidine ring; however, a spirooxindole structural feature significantly
distinguishes this compound from the previously discussed MDM2 inhibitors. The compound was
developed through computational design and docking studies, in an attempt to obtain a strong fit
in the Phe19, Trp23, Leu26 binding pocket of MDM2. Co-crystal structure of compound
SAR405838 and MDM2 showed that in addition to the mimicked interactions of the p53 binding
residues to Phe19, Trp23, Leu26 the compound is stabilized in the pocket through additional
interactions.59 For example, the 2-fluoro-3-chlorophenyl is actively involved in a pi-pi stacking
with a histidine group of MDM2, the Cl attached to the oxindole ring participates in hydrophobic
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interactions. These structural features allow for the compound to have MDM2 binding constant of
about 0.88 nM with cellular IC50 range of 100-200 nM in various cancer cell lines.59 The phase I
clinical trial results have not been disclosed at this point, however, the compound has shown
significant tumor regression at 100 mg/kg daily dose through oral administration in animal
models.60 SAR405838 is the most successful example among a number of spirooxindole MDM2
inhibitors that have been developed thus far.
1.1.3.4 Piperidinone-containing MDM2 inhibitors
Virtual exploration of the Phe19, Trp23, Leu26 binding pocket of MDM2 led to the
discovery of another class of active p53-MDM2 interaction inhibitors. This class of compounds
and in particular AMG 232 developed by Amgen is structurally different not only by the central
core ring, but also with the branched chains (Figure 4).61 The only resemblance of this compound
with the active analogs from the spirooxindole, pyrrolidine, and nutlin based MDM2 inhibitors is
the two aromatic side chains containing Cl on positions 2 and 3 respectively. AMG 232 and
inhibitors from its class contain a piperidinone core ring, a six membered cyclic amide. This
structural feature introduces a hydrogen bond acceptor in the core structure. In addition, a free
carboxylic acid and a sulfonyl group were introduced as side chains. These structural features not
only allow for additional hydrogen bond and salt bridge formations in the MDM2 binding pocket,
but also contribute to the bioavailability and pharmacokinetic properties of the compound. AMG
232 has enzymatic IC50 of 0.6 nM and cellular growth inhibition of 9.1 nM in the p53 wild-type
SJSA-1 cell line.61 The compound has shown complete tumor regression in in vivo models through
oral administration of 60 mg/kg daily and 16 mg/kg twice daily dose in SJSA-1 and HCT-116
xenograft mice models.61,62 To our best knowledge, as of 2015 no significant side toxicity or side
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effects of this compound have been reported, and its pharmacokinetic and pharmacodynamics
properties are being further investigated.
1.1.3.5 Dihydroisoquinolinone-based MDM2 inhibitors
Another very potent class of MDM2 inhibitors developed from virtual screening and
computational design based on the Phe19, Trp23, Leu26 binding pocket came from Novartis with
their discovery of CGM097 (Figure 4).63 This is a compound that has a dihyrdoisoquinolinone core
structure. The cyclic amide fragment resembles the piperidinone cores of the class of compounds
described in section 1.3.4; however, CGM097 and the analogs from its class are much more
constrained as per the presence of a fused aromatic system. The presence of 4-chloropehyl ring is
another reoccurring structural feature that is of importance in making the hydrophobic contact in
the MDM2 binding pocket. These functionalities resulted in excellent binding with an affinity of
CGM097 to MDM2 of about 1.7 nM. These results were supported by promising proliferation
inhibition values in the range of 200-300 nM for various p53 wild-type cancer cell lines.64 The
developed compound did not show significant toxicity. However, a minor fraction in animals
(mouse and monkey) studies indicated perturbations in the organs with high cellular turnover (i.e.
bone marrow, the lymphoid organs, the GI tract, etc.).64 The results were considered sufficiently
promising that the compound was advanced to phase I clinical trials.
1.1.3.6 Additional potent MDM2 inhibitors and compounds in clinical trial
Two additional inhibitors with undisclosed chemical structures SCH 900242 and MK-8242
have been reported in clinical trials by Daiichi Sankyo Inc. and Merk respectively.54 These
compounds are being tested in advanced leukemia and solid-state tumor patience in combination
with cytarabine. There is a large number of other potent agents that are designed to mimic the p53
helical region that binds to the Phe19, Trp23, Leu26 binding pocket, but have not really reach the
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potential to be considered drug candidates. The importance of this therapeutic target is clear and
there is a number of outstanding reviews that go into details describing each class of
compounds.54,65,66 Some of the most noteworthy classes that may lead to compounds entering
clinical trials are chalcones, benzodiazepine, isoindolinone, chromenotriazolopyrimidine, and
dihydroimidazothiazol-containing compounds. In addition, a number of the reported compounds
with the following structures have shown dual inhibition of MDM2 and MDM4 binding to p53:
cis-imidazolines, indolyl-hydantoins, pyrrolopyrimidines, and oxalopiperidinone lactams.54
Although highly potent, none of the compounds that belong to the listed classes have yet reached
clinical trials.

Figure 1.1.4 Selected examples of potent MDM2-p53 PPI inhibitors.
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1.1.3.7 Peptides as MDM2 inhibitors.
As it was discussed earlier in this chapter, generally speaking disruption of PPI by small
molecules is very difficult. In the case of MDM2 inhibitor development, a vast majority of small
molecules have been designed based on the structure of the Phe19, Trp23, Leu26 binding pocket.
It has been shown that this pocket binds an α-helical region of p53, thus substantial effort has been
applied towards the development of successful molecular mimics of this helical interaction with
MDM2. Since the natural substrate of this binding pocket is a helical peptide, the development of
synthetic peptides as MDM2 binders has been attempted as well. Thus, employing the strategy of
synthetically binding or “stapling” peptides, so that they retain specific structure (i.e. α-helix),as
MDM2 binders has shown promise. The downside of this strategy is that synthetic linear peptides
can exist in various conformations under physiological conditions. The idea of structurally
constraining small peptides as active agents has been extensivelly explored in the field of
antibiotics development.67-69 Two examples of stapled peptides targeting MDM2-p53 interactions
stand out in the literature: SAH-p53-8 and ATSP-7041. After a number of modifications in an
attempt to develop stabilized α-helix (SHA) of p53 as a potent PPI inhibitor Walensky and coworkers developed SAH-p53-8.70 The developed peptides used olefin metathesis to staple
strategically incorporated hydrocarbons together and stabilize the helical structure. SAH-p53-8 is
a compound that actively permeates cellular membrane and has proliferation inhibition of 8.5 µM
against SJSA-1cell line. The in vitro data clearly shows p53 dependent apoptosis of the cancer
cells after treatment with the designed peptide.70 In addition, the peptide was reported to be more
potent MDM4 binder (KD = 2.3 nM) than MDM2 (KD = 55 nM).71 In vivo experiments showed the
significant inhibition of tumor growth in a JEG-3 xenograft mouse model and lack of significant
toxicity to normal cells.71 The lack of detailed pharmacokinetic (PK) and pharmacodynamics (PD)
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data for SAH-p53-8 does not allow for this compound to be advanced to clinical trials at this point.
Another very potent stapled peptide as dual MDM2, MDMX inhibitor was developed by Aileron
Therapeutics, Inc.72 The peptide successfully induces apoptosis through the p53 signaling network.
ATSP-7041 was developed through a similar olefin metathesis as utilized by Walensky’s lab. In
vitro and in vivo studies showed the efficacy of this peptide in reducing tumor growth.72 The
compound was tested in 3 animal models, mouse, rat, and monkey and exhibited promising PK
and PD profiles.72 These peptides serve as examples that the dual inhibition of MDM2 and MDM4
interactions with p53 might be an alternative in the development of new anticancer strategy.
1.1.3.8 Inhibitors of the MDM2 E3 Ligase
In addition to MDM2-p53 PPI inhibition and the dual MDM2/MDM4-p53 PPI inhibition,
a third strategy to activate the p53 pathway has emerged in the recent years; selective inhibition of
the MDM2 activity. This strategy aims to develop selective binders to the E3 active center (the
RING domain) of MDM2, thus inactivating its ligase activity towards p53 upon binding. To our
best knowledge, there have only been two reports of MDM2 inhibitors that activate the p53
apoptotic pathway upon binding to the E3 ligase RING domain.42,73,74 Both groups came across
these two classes of compound after high-throughput screening of libraries of compounds against
RING E3 ligases. In 2005 Weissman and co-worker reported the first pyrimido-dione-quinoline
as MDM2 RING domain binder.74 This compound opened a new class of inhibitors, which possess
a flat aromatic core structure. The first generation of compounds (HLI98) described by Weissman
generally suffered from poor water solubility, hindering the ability to devleop the compounds as
potent therapeutic agents (Figure 5). In terms of proof of principle, these compounds showed
selective inhibition of MDM2 in the 20-50 µM (PRE cells) range and mechanistic studies clearly
indicated the activation of the p53 pathway.74 The same group reported the water soluble HLI373,
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possessing pyrimido-dione-quinoline and improved IC50 value of 3 µM against PRE cells.73 The
compound, however, showed off-target effects that did not allow for their further development as
therapeutic agent.

Figure 1.1.5 Selected MDM2 ligase inhibitors.

Utilizing Foster resonance energy transfer (FRET)-based high-throughput assay, a
quinoline-based MDM2-MDM4 RING-RING PPI inhibitors were reported by Wang and coworkers in 2015 (Figure 5).42 These inhibitors showed significant upregulation of p53 and
downregulation of MDM2 in leukemia cell lines. In addition to the reported IC50 = 0.5 µM against
lymphoma cell lines (wt-p53); interestingly the self-ubiquitination activity of MDM2 was retained.
The retention of self-ubiquitination activity is evidence for the specific blockage of MDM2MDM4 RING-RING interactions, but not MDM2-MDM2 interactions. The inhibition of MDM2MDM4 PPIs with the purpose of activation of p53 is truly a novel anticancer therapeutic strategy.
The therapeutic evaluation of the reported compounds, MMRi6 and MMri64, needs to be further
investigated; however, the mechanistic evidence of their action truly opens a new therapeutic
ground for exploration.
1.1.4 Anthraquinone compounds used as anticancer agents
The development of novel (in terms of mechanism of action and structural scaffold)
nontoxic, target-specific anticancer agents is of great need. In attempt to solve this issue, a number
of scientists across the world have turned to nature for a solution. Though evolutionary
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development, nature has found a way to control abnormalities in earth’s eco-system. One of the
ways that nature does that is through the enzymatic/evolutionary development of natural products,
which have served as active agents against a number health-threatening conditions. With this in
mind and in the search of new anticancer therapies we looked to nature and into the anthraquionebased natural product rhein.
Rhein is a natural product isolated from the ground plant Rhubarb, which belongs to the
Rheum family. Compounds that have structural similarities to rhein, such as doxorubicin,
daunorubicin and mitoxanthrone, have been successfully marketed as anticancer drugs (Figure
5).75-77 These compounds belong to the anthracycline family and have been extensively used in
clinical settings for the treatment of various cancers. Despite the excellent anticancer activity,
however, they have shown serious side effects such as cardiotoxicity.75,77 Generally speaking the
compounds from the anthracycline family have been reported to follow one or more of the
following mechanisms of action: a) DNA intercalation and inhibition of its synthesis, b) DNA
damage through free radical generation, c) binding of DNA, d) DNA alkylation/cross-linking, e)
DNA damage through topoisomerase II inhibition, and f) direct topoisomerase II inhibition.78 A
common belief is that the cardiotoxicity of doxorubicin and daunorubicin derives from their redox
chemistry leading to free radical formation and the subsequent lipid peroxidation.78 It is well
known that single electron addition to the dienone ring of the anthracycline core generates reactive
oxygen species (ROS), which lead to cellular damage. The generation of ROS and oxidative DNA
damage has been observed at supraclinical concentrations of doxorubicin; however, at low
micromolar concentration the effects of DNA damage through topoisomerase inhibition is
predominant. The generation of ROS at high treatment concentrations is of major concern and
potentially the cause of the potentially lethal side effects developed by patients treated with this
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family of drugs. Recent findings that carbon monoxide can ameliorate doxorubicin’s cardiotoxicity
through mitochondrial biogenesis also lends insight into the mechanism of the cardiotoxic actions
of doxorubicin.79,80 Clinical studies have shown that 36% of patients treated with multiple doses
of 500 mg/m2 doxorubicin develop cardiomyopathy.81

Figure 1.1.6 Rhein and selected clinically used anthaquinone anticancer agents.

There is no question of the efficiency of this class of drugs against various cancers;
however, the observed lethal side effects are a serious issue that needs to be addressed. Studies
have shown that rhein is well tolerated by the human body when used as a laxative, but it has
relatively low anticancer activity with IC50 in the range of 12~120 µM.82-86 The low, but promising
anticancer activity of rhein and its lack of toxicity make this molecule an excellent starting point
for the development of chemical analogs, which can potentially become drug candidates. The
development of a new anticancer agent based on the clinically used anthraquinone scaffold, yet
lacking intrinsic toxicity to normal cells, is a plausible strategy. The following sections of this
chapter describe the utilization of this strategy to develop novel, active anticancer compounds
based on rhein.
1.1.5 References
(1)

http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/

(2)

Miriam Shadfan, V. L.-P., Zhi-Min Yuan Transl Cancer Res. 2012, 1, 88.

2015.

17

(3)

Chipuk, J. E.; Bouchier-Hayes, L.; Kuwana, T.; Newmeyer, D. D.; Green, D. R.

Science 2005, 309, 1732.
(4)

Vousden, K. H.; Lane, D. P. Nature Rev. Mol. Cell Biol. 2007, 8, 275.

(5)

Yee, K. S.; Vousden, K. H. Carcinogenesis 2005, 26, 1317.

(6)

Green, D. R.; Kroemer, G. Nature 2009, 458, 1127.

(7)

Laptenko, O.; Prives, C. Cell Death Differ. 2006, 13, 951.

(8)

Marine, J. C.; Francoz, S.; Maetens, M.; Wahl, G.; Toledo, F.; Lozano, G. Cell

Death Differ. 2006, 13, 927.
(9)

Levine, A. J.; Hu, W.; Feng, Z. Cell Death Differ. 2006, 13, 1027.

(10)

Levine, A. J.; Oren, M. Nat. Rev. Cancer 2009, 9, 749.

(11)

Nordstrom, W.; Abrams, J. M. Cell Death Differ. 2000, 7, 1035.

(12)

Derry, W. B.; Putzke, A. P.; Rothman, J. H. Science 2001, 294, 591.

(13)

Vousden, K. H.; Prives, C. Cell 2009, 137, 413.

(14)

Donehower, L. A.; Lozano, G. Nat. Rev. Cancer 2009, 9, 830.

(15)

Vogelstein, B.; Lane, D.; Levine, A. J. Nature 2000, 408, 307.

(16)

Carr, A. M. Science 2000, 287, 1765.

(17)

Cheng, Q.; Chen, J. Cell Cycle 2010, 9, 472.

(18)

Sherr, C. J.; Weber, J. D. Curr. Opin. Genet. Dev. 2000, 10, 94.

(19)

Huang, L.; Yan, Z.; Liao, X.; Li, Y.; Yang, J.; Wang, Z.-G.; Zuo, Y.; Kawai, H.;

Shadfan, M.; Ganapathy, S.; Yuan, Z.-M. P. Natl. Acad. Sci. 2011, 108, 12001.
(20)

Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. Science 1991, 253, 49.

(21)

Wang, X.; Jiang, X. Febs Lett. 2012, 586, 1390.

(22)

Scheffner, M. J. Pharm. Thera. 1998, 78, 129.

18

(23)

Brooks, C. L.; Gu, W. Mol. Cell 2006, 21, 307.

(24)

Wade, M.; Wang, Y. V.; Wahl, G. M. Trends Cell Biol. 2010, 20, 299.

(25)

Zhang, Y.; Lu, H. Cancer Cell 2009, 16, 369.

(26)

Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J. Cell 1992,

69, 1237.
(27)

Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Nature 1997, 387, 296.

(28)

Honda, R.; Tanaka, H.; Yasuda, H. Febs Lett. 1997, 420, 25.

(29)

Oliner, J. D.; Pietenpol, J. A.; Thiagalingam, S.; Gvuris, J.; Kinzler, K. W.;

Vogelstein, B. Nature 1993, 362, 857.
(30)

Fakharzadeh, S. S.; Trusko, S. P.; George, D. L. EMBO 1991, 10, 1565.

(31)

Cordoncardo, C.; Latres, E.; Drobnjak, M.; Oliva, M. R.; Pollack, D.; Woodruff,

J. M.; Marechal, V.; Chen, J. D.; Brennan, M. F.; Levine, A. J. Cancer Res. 1994, 54, 794.
(32)

Leach, F. S.; Tokino, T.; Meltzer, P.; Burrell, M.; Oliner, J. D.; Smith, S.; Hill, D.

E.; Sidransky, D.; Kinzler, K. W.; Vogelstein, B. Cancer Res. 1993, 53, 2231.
(33)

Piette, J.; Neel, H.; Marechal, V. Oncogene 1997, 15, 1001.

(34)

de Bie, P.; Ciechanover, A. Cell Death Differ. 2011, 18, 1393.

(35)

Fang, S. Y.; Jensen, J. P.; Ludwig, R. L.; Vousden, K. H.; Weissman, A. M. J.

Biol. Chem. 2000, 275, 8945.
(36)

Montes De Oca Luna, R.; Wagner, D. S.; Lozano, G. Nature 1995, 378, 203.

(37)

Jones, S. N.; Roe, A. E.; Donehower, L. A.; Bradley, A. Nature 1995, 378, 206.

(38)

Ringshausen, I.; O'Shea, C. C.; Finch, A. J.; Swigart, L. B.; Evan, G. I. Cancer

Cell 2006, 10, 501.
(39)

Geyer, R. K.; Yu, Z. K.; Maki, C. G. Nat. Cell Biol. 2000, 2, 569.

19

(40)

Stad, R.; Ramos, Y. F. M.; Little, N.; Grivell, S.; Attema, J.; van der Eb, A. J.;

Jochemsen, A. G. J. Biol. Chem. 2000, 275, 28039.
(41)

Sharp, D. A.; Kratowicz, S. A.; Sank, M. J.; George, D. L. J. Biol. Chem. 1999,

274, 38189.
(42)

Wu, W.; Xu, C.; Ling, X.; Fan, C.; Buckley, B. P.; Chernov, M. V.; Ellis, L.; Li,

F.; Munoz, I. G.; Wang, X. Cell Death Dis 2015, 6, e2035.
(43)

Pan, Y.; Chen, J. D. Mol. Cell. Biol. 2003, 23, 5113.

(44)

Danovi, D.; Meulmeester, E.; Pasini, D.; Migliorini, D.; Capra, M.; Frenk, R.; de

Graaf, P.; Francoz, S.; Gasparini, P.; Gobbi, A.; Helin, K.; Pelicci, P. G.; Jochemsen, A. G.;
Marine, J. C. Mol. Cell. Biol. 2004, 24, 5835.
(45)

Riemenschneider, M. J.; Buschges, R.; Wolter, M.; Reifenberger, J.; Bostrom, J.;

Kraus, J. A.; Schlegel, U.; Reifenberger, G. Cancer Res. 1999, 59, 6091.
(46)

Toledo, F.; Wahl, G. M. Int. J. Bio. Cell Biol. 2007, 39, 1476.

(47)

Parant, J.; Chavez-Reyes, A.; Little, N. A.; Yan, W.; Reinke, V.; Jochemsen, A.

G.; Lozano, G. Nature Gen. 2001, 29, 92.
(48)

Grier, J. D.; Xiong, S. B.; Elizondo-Fraire, A. C.; Parant, J. M.; Lozano, G. Mol.

Cell. Biol. 2006, 26, 192.
(49)

Chavez-Reyes, A.; Parant, J. M.; Amelse, L. L.; Luna, R. M. D.; Korsmeyer, S. J.;

Lozano, G. Cancer Res. 2003, 63, 8664.
(50)

Priest, C.; Prives, C.; Poyurovsky, M. V. Nucleic Acids Res. 2010, 38, 7587.

(51)

Gu, J. J.; Kawai, H.; Nie, L. G.; Kitao, H.; Wiederschain, D.; Jochemsen, A. G.;

Parant, J.; Lozano, G.; Yuan, Z. M. J. Biol. Chem. 2002, 277, 19251.

20

(52)

Pant, V.; Xiong, S.; Iwakuma, T.; Quintas-Cardama, A.; Lozano, G. PNAS 2011,

108, 11995.
(53)

Liu, T.; Zhang, H. L.; Xiong, J.; Yi, S.; Gu, L. B.; Zhou, M. X. Mol. Cancer 2015,

(54)

Zhao, Y.; Aguilar, A.; Bernard, D.; Wang, S. J. Med. Chem. 2015, 58, 1038.

(55)

Vu, B.; Wovkulich, P.; Pizzolato, G.; Lovey, A.; Ding, Q.; Jiang, N.; Liu, J.-J.;

14, 12.

Zhao, C.; Glenn, K.; Wen, Y.; Tovar, C.; Packman, K.; Vassilev, L.; Graves, B. Med. Chem.
Lett. 2013, 4, 466.
(56)

ClinicalTrials.gov identifiers for RG7112: NCT00559533, NCT00623870,

NCT01677780, NCT01164033, NCT01605526, NCT01143740, and NCT01635296.
(57)

Ding, Q.; Zhang, Z.; Liu, J.-J.; Jiang, N.; Zhang, J.; Ross, T. M.; Chu, X.-J.;

Bartkovitz, D.; Podlaski, F.; Janson, C.; Tovar, C.; Filipovic, Z. M.; Higgins, B.; Glenn, K.;
Packman, K.; Vassilev, L. T.; Graves, B. J. Med. Chem. 2013, 56, 5979.
(58)

Siu, L. L.; Italiano, A.; Miller, W. H.; Blay, J.-Y.; Gietema, J. A.; Bang, Y.-J.;

Mileshkin, L. R.; Hirte, H. W.; Reckner, M.; Higgins, B.; Jukofsky, L.; Blotner, S.; Zhi, J.;
Middleton, S.; Nichols, G. L.; Chen, L. C. J. Clin. Oncol. 2014, 32.
(59)

Wang, S.; Sun, W.; Zhao, Y.; McEachern, D.; Meaux, I.; Barriere, C.; Stuckey, J.

A.; Meagher, J. L.; Bai, L.; Liu, L.; Hoffman-Luca, C. G.; Lu, J.; Shangary, S.; Yu, S.; Bernard,
D.; Aguilar, A.; Dos-Santos, O.; Besret, L.; Guerif, S.; Pannier, P.; Gorge-Bernat, D.;
Debussche, L. Cancer Res. 2014, 74, 5855.
(60)

ClinicalTrials.gov identifiers for MI-77301/SAR405838: NCT01636479 and

NCT01985191.

21

(61)

Sun, D.; Li, Z.; Rew, Y.; Gribble, M.; Bartberger, M. D.; Beck, H. P.; Canon, J.;

Chen, A.; Chen, X.; Chow, D.; Deignan, J.; Duquette, J.; Eksterowicz, J.; Fisher, B.; Fox, B. M.;
Fu, J.; Gonzalez, A. Z.; De Turiso, F. G.-L.; Houze, J. B.; Huang, X.; Jiang, M.; Jin, L.; Kayser,
F.; Liu, J.; Lo, M.-C.; Long, A. M.; Lucas, B.; McGee, L. R.; McIntosh, J.; Mihalic, J.; Oliner, J.
D.; Osgood, T.; Peterson, M. L.; Roveto, P.; Saiki, A. Y.; Shaffer, P.; Toteva, M.; Wang, Y.;
Wang, Y. C.; Wortman, S.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Yu, M.; Zhao, X.; Zhou, J.;
Zhu, J.; Olson, S. H.; Medina, J. C. J. Med. Chem. 2014, 57, 1454.
(62)

ClinicalTrials.gov identifiers for AMG 232: NCT01723020 and NCT02016729.

(63)

Holzer, P.; Masuya, K.; Furet, P.; Kallen, J.; Valat-Stachyra, T.; Ferretti, S.;

Berghausen, J.; Bouisset-Leonard, M.; Buschmann, N.; Pissot-Soldermann, C.; Rynn, C.; Ruetz,
S.; Stutz, S.; Chene, P.; Jeay, S.; Gessier, F. J. Med.Chem. 2015, 58, 6348.
(64)

Holzer, P.; Masuya, K.; Furet, P.; Kallen, J.; Valat-Stachyra, T.; Ferretti, S.;

Berghausen, J.; Bouisset-Leonard, M.; Buschmann, N.; Pissot-Soldermann, C.; Rynn, C.; Ruetz,
S.; Stutz, S.; Chene, P.; Jeay, S.; Gessier, F. J. Med. Chem. 2015, 58, 6348.
(65)

Wang, W.; Hu, Y. Med. Res. Rev. 2012, 32, 1159.

(66)

Vassilev, L. T. Trends Mol. Med. 2007, 13, 23.

(67)

Boman, H. G. Annu. Rev. Immunol. 1995, 13, 61.

(68)

Fischbach, M. A.; Walsh, C. T. Chem. Rev. 2006, 106, 3468.

(69)

Hancock, R. E. W.; Chapple, D. S. Antimicrob. Agents Ch. 1999, 43, 1317.

(70)

Bernal, F.; Tyler, A. F.; Korsmeyer, S. J.; Walensky, L. D.; Verdine, G. L. J. Am.

Chem. Soc. 2007, 129, 5298.
(71)

Bernal, F.; Wade, M.; Godes, M.; Davis, T. N.; Whitehead, D. G.; Kung, A. L.;

Wahl, G. M.; Walensky, L. D. Cancer Cell 2010, 18, 411.

22

(72)

Chang, Y. S.; Graves, B.; Guerlavais, V.; Tovar, C.; Packman, K.; To, K.-H.;

Olson, K. A.; Kesavan, K.; Gangurde, P.; Mukherjee, A.; Baker, T.; Darlak, K.; Elkin, C.;
Filipovic, Z.; Qureshi, F. Z.; Cai, H.; Berry, P.; Feyfant, E.; Shi, X. E.; Horstick, J.; Annis, D. A.;
Manning, A. M.; Fotouhi, N.; Nash, H.; Vassilev, L. T.; Sawyer, T. K. P. Natl. Acad. Sci. 2013,
110, E3445.
(73)

Kitagaki, J.; Agama, K. K.; Pommier, Y.; Yang, Y.; Weissman, A. M. Mol.

Cancer Ther. 2008, 7, 2445.
(74)

Yang, Y. L.; Ludwig, R. L.; Jensen, J. P.; Pierre, S. A.; Medaglia, M. V.;

Davydov, I. V.; Safiran, Y. J.; Oberoi, P.; Kenten, J. H.; Phillips, A. C.; Weissman, A. M.;
Vousden, K. H. Cancer Cell 2005, 7, 547.
(75)

Tan, J. H.; Zhang, Q. X.; Huang, Z. S.; Chen, Y.; Wang, X. D.; Gu, L. Q.; Wu, J.

Y. Eur. J. Med. Chem. 2006, 41, 1041.
(76)

Katzhendler, J.; Gean, K.-F.; Bar-ad, G.; Tashma, Z.; Ben-shoshan, R.; Ringel, I.;

Bachrach, U.; Ramu, A. Eur. J. Med. Chem. 1989, 24, 23.
(77)

Huang, H. S.; Chin, H. F.; Yeh, P. F.; Yuan, C. L. Helv Chim Acta 2004, 87, 999.

(78)

Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Pharmacol. Rev.

2004, 56, 185.
(79)

Bartz, R. R.; Suliman, H. B.; Piantadosi, C. A. Front. Physiol. 2015, 6, 8.

(80)

Ji, X.; Damera, K.; Zheng, Y.; Yu, B.; Otterbein, L. E.; Wang, B. J. Pharm. Sci.,

105, 406.
(81)

Lefrak, E. A.; Pitha, J.; Rosenheim, S.; Gottlieb, J. A. Cancer 1973, 32, 302.

(82)

Ip, S. W.; Weng, Y. S.; Lin, S. Y.; Mei-Dueyang; Tang, N. Y.; Su, C. C.; Chung,

J. G. Anticancer Res 2007, 27, 379.

23

(83)

Cui, X. R.; Tsukada, M.; Suzuki, N.; Shimamura, T.; Gao, L.; Koyanagi, J.;

Komada, F.; Saito, S. Eur. J. Med. Chem. 2008, 43, 1206.
(84)

van Gorkom, B. A. P.; Timmer-Bosscha, H.; de Jong, S.; van der Kolk, D. M.;

Kleibeuker, J. H.; de Vries, E. G. E. Brit J Cancer 2002, 86, 1494.
(85)

Cichewicz, R. H.; Zhang, Y. J.; Seeram, N. P.; Nair, M. G. Life Sci 2004, 74,

(86)

Shi, P.; Huang, Z. W.; Chen, G. C. Am J Chinese Med 2008, 36, 805.

1791.

1.2

Mechanistic studies of the lead compound BW-AQ-101
*All biological and mechanistic work described in this section was performed exclusively

by Dr. Muxiang Zhou’s lab at Emory University. The author of the chapter contributed with
synthetic route optimization, preliminary MTT screening against six cell lines, and computational
analysis.
In the pursuit of novel active agents form the anthraquinone family our initial efforts
resulted in the development of a few active compounds.1 One in particular (BW-AQ-101) stood
out as a potent agent against leukemia cell lines; IC50 = 0.69 µM against Molt4 cells. These
preliminary findings gave us the stimulus to develop a more efficient synthetic route to BW-AQ101 and further examine its biological activity and mechanism of action. The synthetic
development of a more efficient route was previously disclosed by the author and will not be
covered in this section.2 Extensive examination against number solid and leukemia cell lines
showed that compound BW-AQ-101 has selectivity over leukemia cell lines (Figure 1.2.1). The
compound showed low micromolar IC50 values against solid tumor cell lines (Hela, KB, Cos 7,
and drug resistant T98G) and mid nanomolar activity against selected leukemia cell lines (Molt4,
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K562, EU-1). Understanding the mechanism of action of a given compound is of extreme
importance in the drug development process. Although there is a number of examples of active
agents that have reached clinical trials and even market, the targeted therapeutics strategy has been
proven to be the key to the development of safe and efficient drug candidates.3,4 Therefore, in
collaboration with Dr. Zhou (Emory University) we explored the possible mechanism of action of
this compound. As previously described p53 is the key player in cellular response upon cellular
stress. Our effort was focused on the examination of the p53 signaling network upon cellular
treatment with BW-AQ-101.

Compound
BW-AQ-101

Hela
(µM)
2.2

KB
(µM)
16

Cos7
(µM)
3.0

T98G
(µM)
>13

Molt4
(µM)
0.69

K562
(µM)
0.93

EU1
(µM)
0.83

Figure 1.2.1 Structure and activity (based on MTT assay) of BW-AQ-101.

Because BW-AQ-101 showed potency against leukemia cell lines, the investigation of its
mechanism of action was done by utilizing a number of leukemia cell lines. Five previouslycharacterized acute lymphoblastic leukemia (ALL) cell lines were selected; Sup-B13, EU-1 and
EU-3 cells that have the wt-p53; EU-6 that has a p53 mutation; and EU-8 that has a p53-null
phenotype. All cell lines except EU-8 express MDM2 and MDM4. Interestingly BW-AQ-101
showed strong cytotoxic effect in all cell lines expressing wt-p53 and MDM2 and considerably
less effect on the other two cell lines (data not shown). This was the first indication that the active
compound induces apoptosis in p53-dependent manner. In this line of thought, it was hypothesized
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that BW-AQ-101 interrupts the p53-MDM2-MDM4 regulatory cycle, causing apoptosis. Western
blot assays indicated significant downregulation of MDM2 in the p53 wild type cell lines treated
with the compound, which supported the established hypothesis (Figure 1.2.2 A). In addition, BWAQ-101 did not show significant effect on the expression of MDM4. As previously discussed, p53
and MDM2 exist in a “love-hate” regulatory cycle, where p53 expresses MDM2 when needed and
on the other hand MDM2 downregulates p53 through ubiquitination. Thus, the evaluation of the
transcriptional effect of BW-AQ-101 on MDM2 was curtail. RT-PCR experiments demonstrated
that the MDM2 mRNA level was significantly elevated by BW-AQ-101. Furthermore, BW-AQ101 showed no direct inhibitory effect on MDM2 mRNA expression (Figure 1.2.2 B). These
results lead to the conclusion that the transcriptional activity of p53 was not abolished. On the
contrary, the enhanced MDM2 mRNA expression upon BW-AQ-101 treatment was a result of p53
activation.

26

Figure 1.2.2 Effects of BW-AQ-101 on p53, MDM2 and MDM4;
A) Western blot assays for expression of proteins, as indicated in four MDM2-positive ALL
cell lines, treated with 1 µM BW-AQ-101 for 24 h. C, control; T, treatment. B) The mRNA levels
of MDM2 and p53 at different time intervals upon treatment with 1 µM BW-AQ-101. C) IP-western
blot assays of EU-1 cells upon treatment with 1 µM BW-AQ-101

Since it was indicated that BW-AQ-101 appears to induce MDM2 protein degradation, and as
discussed in the introductory chapter, the regulation of MDM2 protein stabilization is mainly
controlled by its own C-terminal RING domain. Computational tools were utilized to exploit
potential interactions between the developed compound and the RING domain of MDM2. One of
the key aspects that should be kept in mind is that MDM2 forms a homodimer or a heterodimer
with MDM4 through direct RING-RING domain interactions. The purpose of the molecular
modeling analysis was to see whether there was a potential binding pocket for BW-AQ-101 in the
MDM2 RING domain. The molecular docking was examined using a simulated aqueous
environment. After a careful analysis of the homodimer of MDM2, two identical and symmetric
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binding pockets formed by the two MDM2 RING domains’ interactions were revealed (Figure
1.2.3A). However, the heterodimeric structure of MDM2-MDM4 showed absence of any cavities
(Figure 1.2.3B). It has been reported that the MDM2 RING domains are very unstable in solution
and that they easily form dimeric or other types of aggregate structures; therefore, it is safe to
assume that the binding pockets seen in the homodimer exist under physiological conditions. The
BW-AQ-101 docking study was in good agreement with the observed activity, and did not show
any sites for possible covalent modifications. The computational results gave insight into the
possible mechanism of action of BW-AQ-101. The docking studies revealed clear binding pocket
and potential for stable interactions of the compound with the MDM2 RING domain. However,
the residues involved in these interactions do not play part in the MDM2-MDM4 heterodimer
formation (Figure 1.2.3 C, D). The fact that the MDM2 RING domains predominantly exist in
dimeric or more complex aggregate forms entails for constant, dynamic conformational changes
that allow for the formation of complexes and their stabilizations. The conformational changes
open large surface areas that can serve as interfaces for the formation of stable MDM2-MDM4
heterodimer. We hypothesize that upon binding of BW-AQ-101 to the MDM2 RING homodimer,
the MDM2 RING structure “locks” into a folded conformation, which prevents unfolding and thus
inhibits MDM2-MDM4 heterodimer formation.

Figure 1.2.3 The binding pocket of MDM2:
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A) MDM2 homodimer showing the relative cavity depth of the binding pocket (blue: no
cavity; yellow: cavity). B) MDM2-MDM4 heterodimer, showing the lack of a cavity by coloring
the surface of the MDM2 RING residues involved in cavity formation in the homodimeric form. C)
MDM2 homodimer (orange) and the binding pocket forming amino acid residues (blue). D)
MDM2 (orange)-MDM4 (cyan) heterodimer and the MDM2 amino acid residues (blue)
participating in pocket formation in the homodimeric form. The image shows the absence of a
binding cavity as well as lack of direct interactions between the pocket-forming amino acid
residues of MDM2 (blue) with the MDM4 monomer (cyan).

In order to validate the computational results, two types of binding assays were performed;
fluorescent titration and ITC assays. After titration of BW-AQ-101 to the GST-MDM2 RING
protein a Kd = 0.31 µM was obtained from the fluorescence assay (data not shown). The control
titration of BW-AQ-101 to the GST protein itself, did not result in any binding. The ITC assays,
showed similar binding affinity of Kd = 0.29 µM and confirmed that BW-AQ-101 binds to the
MDM2 RING domain. ITC experiment with MDM4 did not detect binding of BW-AQ-101
(Figure 1.2.4). Furthermore, both the fluorescent titration and ITC assays for detection of possible
binding between BW-AQ-101 and an MDM2 fragment (residues 1 - 424) with deletion of the
RING domain, were performed and no binding activity was detected (data not shown). In order
to validate the theory that BW-AQ-101 binds to the MDM2 homodimer and blocks MDM4
interaction, co-immunoprecipitation (Co-IP) experiments were performed. Previous studies had
demonstrated that the MDM2 protein becomes stabilized in the heterodimer form (MDM2MDM4).5 Binding of BW-AQ-101 to MDM2 may disrupt the formation of the MDM2-MDM4
heterodimer, resulting in MDM2 destabilization. Co-IP and Western blot assays, showed that BWAQ-101 dissociated MDM2 from the MDM2-MDM4 complex (Figure 1.2.2C). Because BW-AQ101 has an anthraquinone core, these experiments were performed against doxorubicin. MDM2
and MDM4 were unaffected in a co-ip experiment with doxorubicin (Figure 1.2.2C). Thus, the
result suggest that BW-AQ-101, but not doxorubicin, was able to dissociate these two proteins.
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Naturally another comparison between the two compounds has to be made to verify that the
mechanism of action of BW-AQ-101 is truly as proposed above. Flat aromatic, polycyclic
compounds are known DNA binders and it is well know that doxorubicin induces apoptosis
through DNA damage. In order to verify that BW-AQ-101 does not interact with DNA in the
utilized concentrations, a comet assay was performed. The assay indicated that at 1 µM
concentration, doxorubicin induced clear DNA damage after 4 hours, while BW-AQ-101 exhibited
only DNA fragmentation after 8 hour treatment (Figure 1.2.5).

Figure 1.2.4 ITC binding assay of BW-AQ-101 against: A) MDM2 and B) MDM4
The computational results as well as the mechanistic experiments described above show
strong evidence that the lead compound BW-AQ-101 is indeed a MDM2 RING binder. The
compound does not show significant DNA damage and correlation between molecular modeling
and binding assays agree with the hypothesis that the compound induces apoptosis through
disruption of the p53-MDM2 regulatory mechanism. These observations give an indication that a
new class of compounds inhibiting the p53-MDM2 regulation may be developed based on the lead
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compound BW-AQ-101. The correlation between in vitro and in silico binding studies allows us
to develop a computational model and design other active rhein-based anticancer agents.

Figure 1.2.5 Comet assay of EU-1 cells
Cells were treated with 1 µM of either AQ-101 or doxorubicin, for 4 h and 8 h. Red arrow
indicates DNA damage, blue arrow indicates nuclear fragmentation/apoptosis.

1.2.1 Experimental section
Compound-protein binding assay
The binding properties between AQ-101 and the MDM2/MDM4 RING domains were
examined by both fluorescent titration (data not shown) and isothermal titration calorimetry (ITC)
assays. The expression and purification of the MDM2 and MDM4 RING domain proteins was
performed as described previously. 6

ITC assay
The MDM2 RING protein in a Hepes buffer (10 mM Hepes, pH 7.2 and 150 mM NaCl)
solution was placed in a loading 96 DeepWell PP plate (Nunc, Thermo Fisher Scientific). The test
compound (120 μL of 24 µM stock solution) was automatically transferred by the auto-iTC200
instrument (MicroCal, GE) into the sample cell. The compound solution (2 μL) was titrated
stepwise into the protein sample cell using a syringe, for a total of 16 injections (excepting the first
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injection, which was 0.4 μL). The equilibrium time between two adjacent injections was 210 s.
The binding stoichiometry (n), dissociation constant (Kd) and thermodynamic parameters (ΔH and
ΔS) were determined by fitting the titration curve to a one-site binding mode, using the Origin
software provided by the manufacturer.

Cells
This study used five established cell lines derived from children with acute lymphoblastic
leukemia. Four of these cell lines (EU-1, EU-3, EU-6 and EU-8) were established at Emory University (Atlanta, GA, USA), and one (SUP-B13) was obtained from Stephen D. Smith (University
of Kansas Medical Center, Kansas City, KS, USA). All ALL cell lines were authenticated and
their p53 phenotypes were as follows: Sup-B13, EU-1 and EU-3 cells (wt-p53); EU-6 (mutant
p53); and EU-8 (p53-null). Four of the p53-positive cell lines, including the p53-mutant EU-6,
express MDM2; whereas MDM2 is not expressed in the EU-8 cells (Zhou et al., 1995). The 293T
cell line, purchased from the American Type Tissue Collection (ATCC) was used for gene
transfection assays.
Fresh leukemia samples were selected from 16 pediatric patients treated for ALL (either at
diagnosis or first relapse), with peripheral total white blood cell (WBC) counts higher than 100 x
106/mL (Table s1). Normal human bone marrow mononuclear (NBMM) cells were obtained from
5 donors following informed consent. Of the 16 ALL patients, 13 had B-cell precursor (BCP) ALL
and 3 had T-ALL, as diagnosed by standard immunologic, morphologic and cytochemical criteria.
Mononuclear cells were separated by centrifugation in Ficoll-Hypaque (1.077g/mL). Leukemic
blasts from patient samples were further isolated by removing adherent monocytes. Specimens
collected for these studies contained more than 90% blasts, following purification. Cells and cell
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lines were grown in standard culture medium (RPMI 1640 containing 10% fetal bovine serum
(FBS), 2 mmol/L L-glutamine, 50 U/mL penicillin, and 50 g/mL streptomycin), at 370 C in 5%
CO2.

Comet assay
To test whether AQ-101 induces DNA damage, we used a single-cell gel-electrophoresis
Comet assay (Trevigen), a method as previously described.7 Briefly, cells with or without AQ-101
treatments were gently harvested, embedded in an agarose layer on a microscope slide, and lysed
to remove cellular proteins. DNA was uncoiled under alkaline conditions, electrophoresed for 20
min and then stained with fluorescent dye. In contrast to undamaged nuclear DNA, damaged DNA
demonstrates a characteristic ‘comet tail’ in this assay which is directly proportional to the amount
of damaged DNA.

Quantitative RT-PCR
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen). Firststrand cDNA synthesis was performed with a mixture of random monomers and oligo-dT as
primers. Amplification was performed with a 7500 Real-Time PCR System (Applied Biosystems),
using the QuantiFast SYBR Green RT-PCR kit (Qiagen), according to the manufacturer’s
instructions. All gene-specific primers were purchased from Qiagen.

Molecular modeling
The NMR structure of the MDM2 RING homodimer is available through the Protein Data
Bank (PDB) under the ID 2HDP.8 The X-ray RING structure of the MDM2-MDM4 heterodimer
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is also available through the PDB (ID 2VJE), with a resolution of 2.2 Å.9 We performed molecular
docking to see whether there was a potential binding pocket for AQ-101 in the MDM2 RING
protein. The target protein and AQ-101 were prepared by removing of all zinc ions, water residues,
and other ligands. All hydrogen atoms were added and the protein termini were fixed.
Minimization was performed by using Sybyl X 2.0 and applying standard parameters: Powell
method, Tripos force field, and Pullman charges. Simulated water environment was used by
assigning the dielectric constant to 80. Docking was performed by Surflex-Dock module in Sybyl
X 2.0. Virtual preparation of the heterodimeric structure was performed following the abovedescribed protocol.

MTT assay
HeLa and Cos7 cell lines were cultured in DMEM medium and T98G and KB cell lines in
MEM medium. All other the cell lines (EU1, Molt4, K562) were cultured in RPMI-1640 medium.
The medium was supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. For
the cytotoxicity assays, cells were seeded into 96- well plate (3.0 × 104 for all solid state cell lines
and 3 × 105 for all leukemia cell lines in 100 µL per well). The compounds were dissolved or
suspended in DMSO to make 10 mM stock solutions. The stock solution was diluted using DMSO
to various concentrations. 1µL of each concentration was diluted 100 fold with medium into the
well plate keeping the DMSO < 1% throughout the experiment. Addition of compounds was
performed after adherent cells reached 40-50 % confluence. After incubation for 24 h. at 37 o C in
humidified atmosphere with 5 % CO2, 10 µL of MTT (5 mg/mL in PBS) was added. After addition
of MTT the cells were incubated for another 4 h. The culture medium was then aspirated and 100
µL of DMSO was added to each well. The 96-well plate was read by microarray reader for optical
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density at 490 nm. All tests were performed in triplicates and IC50 values were estimated from the
averaged response curves.
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1.3

Design and synthesis of novel potent anthraquinone compounds as anticancer agents
Compound BW-AQ-101 showed potent activity against leukemia cell lines and evidence

that it disrupts the p53-MDM2 regulatory cycle. Unfortunately, this compound shows poor
solubility under physiological conditions (3µM in phosphate buffer (PBS)). Compounds’
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solubility is one of the key aspects in the drug development process. The structure of BW-AQ-101
consists of a flat, polycyclic, aromatic system with two free phenolic groups. This type of structures
are prone to pi-pi stacking, which decreases the compound’s solubility. In addition to the pi-pi
stacking, the two phenolic groups located in an α-position to a hydrogen bond acceptor (the
carbonyl groups of the anthraquinone core) are capable of inter and/or intramolecular hydrogen
bond formation. These interactions can further stabilize the packing and significantly contribute to
the poor solubility of the compound. With this in mind and the idea that potential derivatives of
BW-AQ-101 will be successful MDM2 RING binders, a series of compounds with various
substituents at the 1 and 8 positions of the anthraquinone core were designed and synthesized. We
aimed to alkylate the two phenolic groups with various substituents in order to break the hydrogen
bonding. In addition the alkylation of the 1 and 8 positions of the anthraquinone moiety will
introduce flexible functional groups, thus interrupting stacking and improving general water
solubility. The herein disclosed compounds were carefully evaluated in silico against the structure
of the MDM2 RING domain. All chemical modifications sought improvement of solubility and
binding to the pocket of MDM2 RING domain.
The designed compounds are separated into nine groups based on the substituents on the 1
and 8 positions of the anthraquinone core (see sections 1.1.31-1.1.39). All of the synthesized
compounds follow a common four step synthetic route with slight variations (Scheme 1.3.1). The
synthesis of the BW-AQ-101 analogs starts with the alkylation of commercially available rhein
(1) with various alkylating agents (Scheme 1.3.1). All alkylating agents used for this step are
commercially available except for 2-azidoethyl 4-methylbenzenesulfonate used for the synthesis
of 1,8-bis(2-azidoethoxy)anthracene-9,10-diones (21a and 21b) (Figure 1.3.5). The detailed
synthetic route towards compounds 21a and 21b is described in section 1.3.5 below. All
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compounds described in sections 1.2.1-1.3.4 and 1.3.6-1.3.7 follow the four step synthetic route to
the aniline type of intermediate (5) (Scheme 1.3.1). The commercially available rhein (1) is reacted
with a commercially available alkylating agent, consisting of either Br or Cl as a leaving group,
under basic conditions (K2CO3) in the presence of catalytic amount of NaI. The reaction is stirred
overnight at 60 oC – 70 oC in dimethylformamide (DMF) and in all cases results in quantitative
yields of intermediates 2. The second step of the synthetic route involves a hydrolysis in 0.5 N/1
N NaOH in ethanol/water (1:1, v/v) solution to form the free carboxylic acid (3) in quantitative
yield. Carboxylic acid (3) is then reacted with diphenylphosphoryl azide (DPPA) in the presence
of triethyl amine (TEA) to form the acyl azide (4). Due to the lack of stability, intermediate 4 was
not purified and directly used as a crude starting material for the next step. The conversion of
compound 4 to 5 occurs through a Curtius rearrangement. In all of the below-described classes of
compounds, intermediate 5 was used without purification. The slight variations in reaction time
between the different classes of compounds is mostly based on poor solubility of the starting
materials.

Scheme 1.1 General synthetic route to various active anthraquinones

The first class of compounds described in this section are the 1,8-dimethoxyanthracene9,10-dione-based analogs of BW-AQ-101. Four of the five compounds that belong to this group
were synthesized following the general synthetic route described in Scheme 1.3.1. Compounds 8a8d were synthesized through an acylation reaction from aniline (6). Compounds 8a-8d were
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obtained through acylation of compound 6 with chloroacetyl chloride, 2,2,2-trifluoroacetyl
chloride, acetyl chloride, or acryloyl chloride respectively (Scheme 1.3.2 and Figure 1.3.1).

Scheme 1.2: General synthetic route to compounds 8a-8d

Compound 11 was prepared via classic Sonogashira reaction and following previously
reported procedures.1 Starting material (9) was synthesized by Dr. Chaofeng Dai from Prof.
Binghe Wang’s lab, thus details procedure and characterization of the compound is not included
in

this

work.

Compound

(9)

was

reacted

with

alkyne

(10)

using

tetrakis(triphenylphosphine)palladium and copper (I) iodide under basic conditions. The reaction
was stirred overnight at 60˚C giving product (11).

Scheme 1.3 Synthesis of compound 11 through Sonogashira coupling
* Compound 11 was synthesized following published procedure.1

All synthesized compounds that belong to the 1,8-dimethoxyanthracene-9,10-dione class
are summarized in figure 1.3.1. The biological activity of these compounds is described in
Section 1.4. of this chapter.
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Figure 1.3.11,8-dimethoxyanthracene-9,10-dione analogs

1.3.1.1 Experimental section
Rhein (1) was purchased from Nanjing Zelang Medical Technology Co and directly used
without further purification. Other starting materials were purchased from Sigma-Aldrich, VWR,
or Acros. Analytical-grade solvents were used for all reactions except for moisture-sensitive
reactions in which anhydrous solvents were used. TLC analysis was conducted on silica gel plates
(Silica G UV254); and column chromatography was carried out on flash silica gel (230−400 mesh).
NMR spectra were recorded at 400 MHz for 1H and 100 MHz for 13C on Bruker Avance NMR
spectrometers with TMS (δ = 0.00 ppm) or residual solvent as the internal reference. Data are
reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet),
coupling constant, and integration. High-resolution mass spectrometry (HRMS) was performed
using electrospray ionization (ESI).
General experimental procedure for the synthesis of compounds 8a-8d:
Compound 6 (1.0 eq.) was dissolved and stirred in 1, 4-dioxane at room temperature
followed by addition of the corresponding acyl halide (7, 1.5 eq.). After reaction completion, the
reaction mixture was diluted with distilled water/ice. Yellow to orange solids precipitated out and
were isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and
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complete removal of water by putting the crude product in high vacuum pump system, or by
vacuum filtration. The crude product was purified by silica gel column chromatography using a
dichloromethane (DCM)/ethyl acetate (EtAc) gradient mixture to afford the pure product 8a-8d.
8a

(BW-AQ-112),

2-chloro-N-(4,5-dimethoxy-9,10-dioxo-9,10-dihydroanthracen-2-

yl)acetamide:
Isolated yield over two steps 45 %. 1H NMR (DMSO-d6): δ 10.80 (s, 1H), 7.85 (d, J = 1.6
Hz, 1H), 7.759 (d, J = 1.6 Hz 1H), 7.72-7.50 (m, 2H), 7.49 (d, J = 8.4 Hz, 1H), 4.32 (s, 2H), 3.89
(s, 3H) 3.86 (s, 3H);

13

C NMR (DMSO-d6): δ 183.50, 180.54, 165.98, 160.35, 159.26, 143.89,

135.31, 134.46, 134.43, 123.78, 119.59, 119.52, 118.64, 108.64, 108.34, 56.74, 56.54, 44.08.
HRMS (ESI-TOF) m/z [M+1]+ calcd. for C18H14ClNO5 360.0633, found 360.0619.
8b

(BW-AQ-132),

N-(4,5-dimethoxy-9,10-dioxo-9,10-dihydroanthracen-2-yl)-2,2,2-

trifluoroacetamide:
Isolated yield over two steps 50 %. 1H NMR (DMSO-d6): δ 8.09 (d, J = 1.6 Hz, 1H), 7.80
(d, J = 2 Hz, 1H), 7.74 (t, J = 8.0 Hz, 1H), 7.68 (d, J = 7.2 Hz, 1H), 7.53 (d, J = 8 Hz, 1H), 3.90
(s, 3H), 3.89 (s, 3H);

C NMR (DMSO-d6): δ 183.30, 180.66, 160.08, 159.30, 141.83, 135.36,
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134.70, 134.41, 123.72, 121.04, 119.61, 118.72, 110.23, 110.13, 56.79, 56.72. HRMS (ESI-TOF)
m/z [M+1]+ calcd. for C18H12F3NO5 380.0740, found 380.0724.
8c (BW-AQ-134), N-(4,5-dimethoxy-9,10-dioxo-9,10-dihydroanthracen-2-yl)acetamide:
Isolated yield over two steps 47 %. 1H NMR (DMSO-d6): δ 10.46 (s, 1H), 7.84 (d, J = 1.6
Hz, 1H), 7.78 (d, J = 1.6 Hz, 1H), 7.72-7.63 (m, 2H), 7.49 (d, J = 7.6 Hz, 1H), 3.89 (s, 3H), 3.85
(s, 3H), 2.10 (s, 3H);

C NMR (DMSO-d6): δ 183.68, 180.57, 169.78, 160.38, 159.25, 144.75,

13

135.24, 134.49, 134.39, 123.85, 119.49, 118.98, 118.62, 108.37, 107.91, 66.81, 56.73, 56.46,
24.73. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C18H15NO5 326.1023, found 326.1007.
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8d (BW-AQ-232), N-(4,5-dimethoxy-9,10-dioxo-9,10-dihydroanthracen-2-yl)acrylamide:
Isolated yield over two steps 52 %. 1H NMR (DMSO-d6): δ 10.69 (s, 1H), 7.95 (d,
J = 2 Hz, 2H), 7.93 7.66 (m, 2H), 7.53-7.50 (m, 1H), 6.49-6.42 (m, 1H), 6.36-6.31 (m, 1H), 5.875.84 (m, 1H), 3.90 (s, 3H), 3.88 (m, 2H); 13C NMR (DMSO-d6): δ 183.65, 180.61, 164.35, 160.38,
159.28, 144.52, 135.30, 134.50, 134.48, 131.78, 128.85, 123.89, 119.58, 119.38, 118.67, 108.84,
108.43, 66.82, 56.77, 56.54. HRMS (ESI-TOF) m/z [M+Na]+ calcd. for C19H15NO5 360.0848,
found 360.0856.
8e (BW-AQ-130), N-(3-(4,5-dimethoxy-9,10-dioxo-9,10-dihydroanthracen-2-yl)prop-2yn-1-yl)-2,2,2-trifluoroacetamide:
Isolated yield over two steps 60 %. 1H NMR (DMSO-d6): δ 10.13 (s, 1H), 7.73 (t, J = 8.0
Hz, 1H), 7.65-7.59 (m, 2H), 7.52 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 1.2 Hz, 1H), 4.35 (d, J = 5.6 Hz,
2H), 3.92 (s, 3H), 3.90 (s, 3H); 13C NMR (DMSO-d6): δ 182.97, 180.96, 159.25, 159.22, 134.82,
134.74, 134.28, 131.99, 131.90, 129.27, 129.16, 127.66, 123.78, 121.20, 120.97, 119.55, 89.11,
81.71, 57.02, 56.77, 29.94. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C21H14F3NO5 418.0897,
found 418.0881.
1.3.2 Synthesis of 1,8-diethoxyanthracene-9,10-dione compounds
The 1,8-diethoxyanthracene-9,10-dione
analogs (14a-14h) synthesized

class of compounds consist of eight

from aniline 12. Compound 12 was synthesized following

synthetic scheme 1.3.1. The aniline (12) was then reacted with the corresponding acyl chloride
(Scheme 1.3.4) in 1,4-dioxane at room temperature to give compounds 14a-14g at various yields
(Figure 1.3.2, see the experimental section for yields).

41

Scheme 1.4 General synthetic route to compounds 14a-14g

Compound 14a was used as a starting material in the synthesis of azide 14h (Scheme 1.3.5).
A substitution reaction between 14a and excess of sodium azide in acetone resulted in compound
14h. The reaction was stirred at room temperature overnight to give 14h in quantitative yields.

Scheme 1.5 Synthesis of compound 14h

All synthesized compounds that belong to the 1,8-diethoxyanthracene-9,10-dione class are
summarized in figure 1.3.2. The biological activity of these compounds is described in section 1.4.
of this chapter.
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Figure 1.3.2 Synthesis of 1,8-diethoxyanthracene-9,10-dione analogs

1.3.2.1 Experimental section
General experimental procedure for the synthesis of compounds (14a-14g):
Compound 12 (1.0 eq.) was dissolved and stirred in 1, 4-dioxane at room temperature
followed by addition of the corresponding acyl halide (13, 1.5 eq.). After reaction completion, the
reaction mixture was diluted with distilled water/ice. Yellow to orange solids precipitated out and
were isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and
complete removal of water by putting the crude product in high vacuum pump system, or by
vacuum filtration. The crude product was purified by silica gel column chromatography using a
dichloromethane (DCM)/ethyl acetate (EtAc) gradient mixture to afford the pure product 14a-14g.
Experimental procedure for the synthesis of compound 14h:
Compound 14a (1.0 eq.) was dissolved and stirred in acetone at room temperature
followed by addition of sodium azide (2.0 eq.). After overnight stirring, the acetone was partially
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evaporated and the remaining residue was diluted with water/ice. Yellow to orange solid
precipitated out and was isolated either by centrifugation at 5000 rpm for 10 min followed by
decantation and complete removal of water by putting the crude product in high vacuum pump
system, or by vacuum filtration.
14a

(BW-AQ-113),

2-chloro-N-(4,5-diethoxy-9,10-dioxo-9,10-dihydroanthracen-2-

yl)acetamide:
Isolated yield over two steps 50 %. 1H NMR (DMSO-d6): δ 10.78 (s, 1H), 7.85 (s, 1H),
7.77 (s, 1H), 7.67-7.65 (m, 2H), 7.48 (d, J = 6.8 Hz, 1H), 4.31 (s, 2H), 4.18-4.13 (m, 4H), 1.441.38 (m, 6H); 13C NMR (DMSO-d6): δ 183.61, 180.29, 165.98, 159.69, 158.63, 143.75, 135.38,
134.52, 134.35, 123.90, 120.66, 119.70, 118.64, 109.42, 108.69, 65.12, 65.06, 44.08, 15.07, 14.98.
HRMS (ESI-TOF) m/z [M+1]+ calcd. for C20H18ClNO5 388.0946, found 388.0934.
14b

(BW-AQ-114),

2-bromo-N-(4,5-diethoxy-9,10-dioxo-9,10-dihydroanthracen-2-

yl)acetamide:
Isolated yield over two steps 48 %. 1H NMR (DMSO-d6): δ 10.89 (s, 1H), 7.88 (s, 1H),
7.78 (s, 1H), 7.71-7.67 (m, 2H), 7.51 (d, J = 6.8 Hz, 1H), 4.23-4.14 (m, 4H), 4.09 (s, 2H), 1.441.38 (m, 6H); 13C NMR (DMSO-d6): δ 183.33, 179.98, 171.98, 159.06, 158.12, 143.49, 134.87,
134.17, 133.86, 123.52, 120.21, 119.07, 118.17, 109.57, 108.63, 64.67, 64.56, 62.00, 14.58, 14.50.
HRMS (ESI-TOF) m/z [M+1]+ calcd. for C20H18BrNO5 432.0441, found 432.0434.
14c

(BW-AQ-115),

N-(4,5-diethoxy-9,10-dioxo-9,10-dihydroanthracen-2-yl)-2-

iodoacetamide:
Isolated yield over two steps 54 %. 1H NMR (DMSO-d6): δ 10.80 (s, 1H), 7.83 (d, J = 1.6
Hz, 1H), 7.74 (d, J = 1.6 Hz, 1H), 7.68-7.64 (m, 2H), 7.48 (dd, J = 2, 7.2 Hz, 1H), 4.32-4.12 (m,
4H), 3.89 (s, 2H), 1.42-1.38 (m, 6H); 13C NMR (DMSO-d6): δ 183.62, 180.26, 168.04, 159.74,
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158.63, 144.13, 135.36, 134.52, 134.32, 123.90, 120.65, 119.53, 118.63, 109.10, 108.47, 65.12,
65.06, 15.07, 15.0. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C20H18INO5 480.0302, found
480.0291.
14d

(BW-AQ-179),

4-chloro-N-(4,5-diethoxy-9,10-dioxo-9,10-dihydroanthracen-2-

yl)butanamide:
Isolated yield over two steps 30 %. 1H NMR (CDCl3): δ 8.26 (s, 1H), 8.06 (s, 1H), 7.82 (d,
J = 7.6 Hz, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 4.294.22 (m, 4H), 3.68 (t, J = 6 Hz, 2H), 2.67 (t, J = 7.2 Hz, 2H), 2.23 (t, J = 6.4 Hz, 2H), 1.55 (t, J =
6.8 Hz, 6H);

C NMR (DMSO-d6): δ 184.68, 179.63, 161.12, 158.51, 154.29, 135.94, 134.65,

13

133.55, 124.53, 120.84, 118.50, 113.28, 103.95, 102.95, 65.12, 64.44, 55.38, 15.12. HRMS (ESITOF) m/z [M+Na]+ calcd. for C22H22ClNO5 438.1084, found 438.1103.
14e (BW-AQ-182), 2-(benzyloxy)-N-(4,5-diethoxy-9,10-dioxo-9,10-dihydroanthracen-2yl)acetamide:
Isolated yield over two steps 51 %. 1H NMR (CDCl3): δ 8.65 (s, 1H), 8.17 (s, 1H), 7.78 (d,
J = 7.6 Hz, 1H), 7.55 (t, J = 8 Hz, 1H), 7.47 (s, 1H), 7.36 (s, 5H), 7.26 (d, J = 8 Hz, 1H), 4.65 (s,
2H), 4.26-4.18 (m, 4H), 4.09 (s, 2H), 1.53-1.49 (m, 6H);

C NMR (CDCl3): δ 183.85, 181.23,

13

168.27, 160.52, 159.00, 142.00, 136.23, 135.43, 134.71, 133.47, 128.84, 128.60, 128.18, 124.26,
120.19, 119.94, 118.99, 109.65, 108.75, 73.91, 69.42, 65.44, 14.72, 14.57. HRMS (ESI-TOF) m/z
[M+Na]+ calcd. for C27H25NO6 482.1580, found 482.1566.
14f

(BW-AQ-198),

2-chloro-N-(4,5-diethoxy-9,10-dioxo-9,10-dihydroanthracen-2-

yl)propanamide:
Isolated yield over two steps 43 %. 1H NMR (CDCl3): δ 8.60 (s, 1H), 8.16 (d, J = 1.6 Hz,
1H), 7.82 (d, J = 7.6 Hz, 1H), 7.59 (t, J = 8 Hz, 1H), 7.53 (d, J = 1.6 Hz, 1H), 7.30-7.26 (m, 1H),
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4.59-4.57 (m, 1H), 4.29-4.21 (m, 4H), 1.84 (d, J = 7.2 Hz, 3H), 1.56-1.52 (m, 6H);

13

C NMR

(DMSO-d6): δ 183.62, 180.32, 168.62, 159.70, 158.64, 143.81, 135.38, 134.52, 134.37, 123.92,
120.68, 119.75, 118.65, 109.54, 108.85, 65.12, 65.08, 55.15, 21.27, 15.06, 14.99. HRMS (ESITOF) m/z [M+Na]+ calcd. for C21H20ClNO5 424.0928, found 424.0940.
14g

(BW-AQ-199),

2-chloro-N-(4,5-diethoxy-9,10-dioxo-9,10-dihydroanthracen-2-

yl)butanamide:
Isolated yield over two steps 53 %. 1H NMR (CDCl3): δ 8.62 (s, 1H), 8.16 (d, J = 1.6 Hz,
1H), 7.82 (d, J = 7.6 Hz, 1H), 7.59 (t, J = 8 Hz, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.29 (d, J = 8 Hz,
1H), 4.49-4.46 (m, 1H), 4.29-4.21 (m, 4H), 2.25-2.20 (m, 1H), 2.13-2.08 (m, 1H), 1.57-1.52 (m,
6H), 1.12 (t, J = 7.2 Hz, 3H); 13C NMR (DMSO-d6): δ 183.64, 180.35, 168.18, 159.72, 158.65,
143.72, 135.41, 134.54, 134.42, 120.72, 119.85, 118.67, 109.62, 108.88, 65.12, 61.20, 28.01,
15.06, 15.00, 11.06. HRMS (ESI-TOF) m/z [M+Na]+ calcd. for C22H22ClNO5 438.1084, found
438.1096.
14h

(BW-AQ-159),

2-azido-N-(4,5-diethoxy-9,10-dioxo-9,10-dihydroanthracen-2-

yl)acetamide:
Isolated yield 100 %. 1H NMR (CDCl3): δ 8.35 (s, 1H), 8.16 (s, 1H), 7.84 (d, J = 7.6 Hz,
1H) 7.63-7.55 (m, 2H), 7.31 (d, J = 8.0 Hz, 1H), 4.29-4.22 (m, 6H), 1.58 (m, 6H);

13

C NMR

(CDCl3): δ 183.74, 165.26, 160.50, 159.02, 141.73, 135.53, 134.69, 133.57, 119.96, 119.02,
109.73, 108.85, 65.50, 65.43, 52.95, 42.92, 14.72, 14.56. HRMS (ESI-TOF) m/z [M+1]+ calcd. for
C20H18N4O5 395.1350, found 395.1336.
1.3.3 Synthesis of 1,8-dipropoxyanthracene-9,10-dione compounds
The 1,8-dipropoxyanthracene-9,10-dione class of compounds consist of ten analogs (16a16j) synthesized from aniline 15. Compound 15 was synthesized following synthetic scheme
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1.3.1. The aniline (15) was the reacted with the corresponding acyl chloride (Scheme 1.3.6) in 1,4dioxane at room temperature to give compounds 16a-16i at various yields (Figure 1.3.3, see the
experimental section for yields).

Scheme 1.6 General synthetic route to compounds 16a-16i

Compound 16a was used as a starting material in the synthesis of azide 16j (Scheme
1.3.7). A substitution reaction between 16a and excess of sodium azide in acetone resulted in
compound 16j. The reaction was stirred at room temperature overnight to give 16j in quantitative
yields.

Scheme 1.7 Synthesis of compound 16j

All synthesized compounds that belong to the 1,8-dipropoxyanthracene-9,10-dione class
are summarized in figure 1.3.3. The biological activity of these compounds is described in
section 1.4. of this chapter.
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Figure 1.3.3 Synthesis of 1,8-dipropoxyanthracene-9,10-dione analogs

1.3.3.1 Experimental section
General experimental procedure for the synthesis of compounds (16a-16i):
Compound 15 (1.0 eq.) was dissolved and stirred in 1, 4-dioxane at room temperature
followed by addition of the corresponding acyl halide (13, 1.5 eq.). After reaction completion, the
reaction mixture was diluted with distilled water/ice. Yellow to orange solids precipitated out and
were isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and
complete removal of water by putting the crude product in high vacuum pump system, or by

48

vacuum filtration. The crude product was purified by silica gel column chromatography using a
dichloromethane (DCM)/ethyl acetate (EtAc) gradient mixture to afford the pure product 16a-16i.
Experimental procedure for the synthesis of compound 16j:
Compound 16a (1.0 eq.) was dissolved and stirred in acetone at room temperature followed
by addition of sodium azide (2.0 eq.). After overnight stirring, acetone was partially evaporated
and the remaining residue was diluted with water/ice. Yellow to orange solid precipitated out and
was isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and complete
removal of water by putting the crude product in high vacuum pump system, or by vacuum
filtration.
16a

(BW-AQ-116), 2-Chloro-N-(9,10-dioxo-4,5-dipropoxy-9,10-dihydroanthracen-2-

yl)acetamide:
Isolated yield over two steps: 40%. 1H NMR (DMSO-d6): δ 10.77 (s, 1H), 7.85 (s, 1H),
7.76 (s, 1H), 7.66-7.64 (m, 2H), 7.48 (d, J = 6.4 Hz, 1H), 4.31 (s, 2H), 4.07-4.00 (m, 4H), 1.831.75 (m, 4H), 1.06 (d, 6H);

C NMR (DMSO-d6): δ 183.63, 180.26, 165.95, 159.83, 158.77,

13

143.72, 135.34, 134.50, 134.27, 124.02, 120.63, 119.85, 118.58, 109.43, 108.64, 70.81, 70.75,
55.37, 22.53, 22.45, 10.81, 10.76. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C22H22ClNO5
416.1259, found 416.1240.
16b

(BW-AQ-117),

2-Bromo-N-(9,10-dioxo-4,5-dipropoxy-9,10-dihydroanthracen-2-

yl)acetamide:
Isolated yield over two steps: 30%. 1H NMR (DMSO-d6): δ 10.88 (s, 1H), 7.86 (d, J = 2
Hz, 1H), 7.76 (d, J = 2 Hz 1H), 7.68-7.66 (m, 2H), 7.48 (dd, J = 1.6, 6 Hz, 1H), 4.09 (s, 2H),
4.07-4.01 (m, 4H), 1.84-1.76 (m, 4H), 1.08-1.03 (m, 6H);

13

C NMR (DMSO-d6): δ 183.66,

180.29, 166.15, 159.85, 158.78, 143.84, 135.38, 134.52, 134.32, 124.05, 120.68, 119.89, 118.61,
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109.33, 108.58, 70.83, 70.77, 30.73, 22.53, 22.45, 10.82, 10.77. HRMS (ESI-TOF) m/z [M+1]+
calcd. for C22H22BrNO5 460.0754, found 460.0749.
16c

(BW-AQ-118),

N-(9,10-dioxo-4,5-dipropoxy-9,10-dihydroanthracen-2-yl)-2-

iodoacetamide:
Isolated yield over two steps: 35%. 1H NMR (CDCl3): δ 8.39 (s, 1H), 8.15 (s, 1H), 7.79 (d,
J = 7.2 Hz, 1H), 7.58 (t, J = 8.4 Hz, 1H), 7.50 (s, 1H), 7.29 (d, J = 8.4 Hz, 1H), 4.13-4.08 (m, 4H),
3.91 (s, 2H), 1.84-1.76 (m, 4H), 1.96-1.90 (m, 4H), 1.10 (s, 6H);

13

C NMR (CDCl3): δ 184.27,

181.22, 166.08, 160.60, 159.15, 142.53, 135.32, 134.67, 133.51, 124.45, 120.54, 120.05, 118.89,
109.75, 108.70, 71.35, 71.33, 22.51, 22.40, 10.47. HRMS (ESI-TOF) m/z [M+1]+ calcd. for
C22H22INO5 508.0615, found 508.0596.
16d

(BW-AQ-118),

N-(9,10-dioxo-4,5-dipropoxy-9,10-dihydroanthracen-2-yl)-2-

iodoacetamide:
Isolated yield over two steps: 35%. 1H NMR (CDCl3): δ 8.39 (s, 1H), 8.15 (s, 1H), 7.79 (d,
J = 7.2 Hz, 1H), 7.58 (t, J = 8.4 Hz, 1H), 7.50 (s, 1H), 7.29 (d, J = 8.4 Hz, 1H), 4.13-4.08 (m, 4H),
3.91 (s, 2H), 1.84-1.76 (m, 4H), 1.96-1.90 (m, 4H), 1.10 (s, 6H);

13

C NMR (CDCl3): δ 184.27,

181.22, 166.08, 160.60, 159.15, 142.53, 135.32, 134.67, 133.51, 124.45, 120.54, 120.05, 118.89,
109.75, 108.70, 71.35, 71.33, 22.51, 22.40, 10.47. HRMS (ESI-TOF) m/z [M+1]+ calcd. for
C22H22INO5 508.0615, found 508.0596.
16e

(BW-AQ-201),

2-Chloro-N-(9,10-dioxo-4,5-dipropoxy-9,10-dihydroanthracen-2-

yl)butanamide:
Isolated yield over two steps: 52%. 1H NMR (CDCl3): δ 8.77 (s, 1H), 8.15 (d, J = 1.6 Hz,
1H), 7.79 (d, J = 7.6 Hz, 1H), 7.60-7.56 (m, 2H), 7.29 (d, J = 8.4 Hz, 1H), 4.49-4.46 (m, 1H), 4.144.08 (m, 4H), 2.23-2.11 (m, 1H), 2.09-2.05 (m, 1H), 1.96-1.90 (m, 4H), 1.12-1.09 (m, 9H); 13C
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NMR (CDCl3): δ 183.91, 181.18, 167.62, 160.59, 159.12, 141.87, 135.41, 134.65, 133.48, 124.44,
120.76, 119.97, 118.92, 109.76, 108.96, 71.33, 62.55, 28.85, 22.50, 22.40, 10.47, 10.40. HRMS
(ESI-TOF) m/z [M+Na]+ calcd. for C24H26ClNO5 466.1397, found 466.1390.
16f

(BW-AQ-200),

2-Chloro-N-(9,10-dioxo-4,5-dipropoxy-9,10-dihydroanthracen-2-

yl)propanamide:
Isolated yield over two steps: 37%. 1H NMR (CDCl3): δ 8.87 (s, 1H), 8.14 (d, J = 1.6 Hz,
1H), 7.78 (d, J = 7.6 Hz, 1H), 7.57 (t, J = 8 Hz, 2H), 7.29-7.26 (m, 1H), 4.64-4.58 (m, 1H), 4.144.07 (m, 4H), 1.95-1.89 (m, 4H), 1.82 (d, J = 7.2 Hz, 3H), 1.11-1.08 (m, 6H); 13C NMR (CDCl3):
δ 183.88, 181.28, 168.22, 160.54, 159.10, 142.05, 135.38, 134.64, 133.50, 124.40, 120.68, 119.94,
118.92, 109.77, 109.03, 71.31, 55.68, 22.49, 22.38, 22.20, 10.46. HRMS (ESI-TOF) m/z [M+Na]+
calcd. for C23H24ClNO5 452.1241, found 452.1262.
16g

(BW-AQ-215), 3-Chloro-N-(9,10-dioxo-4,5-dipropoxy-9,10-dihydroanthracen-2-

yl)propanamide:
Isolated yield over two steps: 45%. 1H NMR (DMSO-d6): δ 10.59 (s, 1H), 7.88-7.84 (m,
2H), 7.69-7.65 (m, 2H), 7.50 (d, J = 7.4 Hz, 1H), 4.09-4.02 (m, 4H), 3.90 (t, J = 6.0 Hz, 2H), 2.89
(t, J = 6.4 Hz, 2H), 1.84-1.76 (m, 4H), 1.08-1.04 (m, 6H); 13C NMR (DMSO-d6): δ 183.8, 180.3,
169.5, 159.9, 158.8, 144.2, 135.4, 134.6, 134.3, 124.1, 120.7, 119.5, 118.6, 109.2, 108.5, 70.8,
70.7,22.5, 22.5, 10.8, 10.8. HRMS (ESI-TOF) m/z [M+H]+ calcd. for C23H24ClNO5 430.1416,
found 430.1402.
16h (BW-AQ-213), 4-Chloro-N-(9,10-dioxo-4,5-dipropoxy-9,10-dihydroanthracen-2yl)butanamide:
Isolated yield over two steps: 45%. 1H NMR (DMSO-d6): δ 10.50 (s, 1H), 7.88-7.84 (m,
2H), 7.71-7.65 (m, 2H), 7.50 (d, J = 7.6 Hz, 1H), 4.09-4.01 (m, 4H), 3.72 (t, J = 6.4 Hz, 2H), 2.55-
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2.53 (m, 2H), 2.07-2.05 (m, 2H), 1.82-1.78 (m, 4H), 1.08-1.03 (m, 6H); 13C NMR (DMSO-d6): δ
183.8, 180.3, 171.7, 159.9, 158.8, 144.5, 135.3, 134.6, 134.3, 124.1, 120.7, 118.6, 109.2, 108.5,
70.8, 70.7, 34.0, 28.1, 22.5, 22.5, 10.8. HRMS (ESI-TOF) m/z [M+H]+ calcd. for C24H26ClNO5
444.1572, found 444.1555.
16i

(BW-AQ-215),

3-Chloro-N-(9,10-dioxo-4,5-dipropoxy-9,10-dihydroanthracen-2-

yl)propanamide:
Isolated yield over two steps: 45%. 1H NMR (DMSO-d6): δ 10.59 (s, 1H), 7.88-7.84 (m,
2H), 7.69-7.65 (m, 2H), 7.50 (d, J = 7.4 Hz, 1H), 4.09-4.02 (m, 4H), 3.90 (t, J = 6.0 Hz, 2H), 2.89
(t, J = 6.4 Hz, 2H), 1.84-1.76 (m, 4H), 1.08-1.04 (m, 6H); 13C NMR (DMSO-d6): δ 183.8, 180.3,
169.5, 159.9, 158.8, 144.2, 135.4, 134.6, 134.3, 124.1, 120.7, 119.5, 118.6, 109.2, 108.5, 70.8,
70.7,22.5, 22.5, 10.8, 10.8. HRMS (ESI-TOF) m/z [M+H]+ calcd. for C23H24ClNO5 430.1416,
found 430.1402.
16j

(BW-AQ-156),

2-Azido-N-(9,10-dioxo-4,5-dipropoxy-9,10-dihydroanthracen-2-

yl)acetamide:
Isolated yield: 99%. 1H NMR (DMSO-d6): δ 8.62 (s, 1H), 8.11 (s, 1H), 7.79 (d, J = 7.6 Hz,
1H) 7.60-7.56 (m, 2H), 7.29 (d, J = 8.8 Hz, 1H), 4.21 (s, 2H), 7.29 (d, J = 4.4 Hz, 4H), 1.95-1.89
(m, 4H), 1.12-1.09 (m, 6H);

13

C NMR (DMSO-d6): δ 183.73, 180.34, 167.84, 159.88, 158.79,

143.72, 135.41, 134.55, 134.36, 124.10, 120.74, 119.80, 118.63, 109.44, 108.63, 70.85, 70.80,
51.87, 22.53, 22.46, 10.83, 10.79. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C22H22N4O5 423.1663,
found 423.1643.
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1.3.4 Synthesis of 1,8-bis(benzyloxy)anthracene-9,10-dione compounds
The 1,8-bis(benzyloxy)anthracene-9,10-dione class of compounds consists of five analogs
(18a-18e) synthesized from aniline 17. Compound 17 was synthesized following synthetic
Scheme 1.3.1. The aniline (17) was the reacted with the corresponding acyl chloride (Scheme
1.3.8) in 1,4-dioxane at room temperature to give compounds 18a-18d at various yields (Figure
1.3.4, see the Experimental Section for yields). During the synthesis of 18d, the byproduct (HBr)
of the reaction between aniline 17 and bromoacetyl bromide resulted in the deprotection of one of
the bezyl groups attached to either position 1 or 8 of the anthraquinone core.

Scheme 1.8 General synthetic routes to compounds 18a-18d

Compound 18a was used as a starting material in the synthesis of azide 18e (Scheme 1.3.9).
A substitution reaction between 18a and excess of sodium azide in acetone resulted in compound
18e. The reaction was stirred at room temperature overnight to give 18e in quantitative yields.

Scheme 1.9 Synthesis of compound 18e
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All synthesized compounds that belong to the 1,8-bis(benzyloxy)anthracene-9,10-dione
class are summarized in Figure 1.3.4. The biological activity of these compounds is described in
Section 1.4. of this chapter.

Figure 1.3.4 Synthesized of 1,8-bis(benzyloxy)anthracene-9,10-dione analogs

1.3.4.1 Experimental Section
General experimental procedures for the synthesis of compounds (18a-18d):
Compound 17 (1.0 eq.) was dissolved and stirred in 1, 4-dioxane at room temperature
followed by addition of the corresponding acyl halide (13, 1.5 eq.). After reaction completion, the
reaction mixture was diluted with distilled water/ice. Yellow to orange solids precipitated out and
were isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and
complete removal of water by putting the crude product in high vacuum pump system, or by
vacuum filtration. The crude product was purified by silica gel column chromatography using a
dichloromethane (DCM)/ethyl acetate (EtAc) gradient mixture to afford the pure product 18a-18d.
Experimental procedure for the synthesis of compound 18e:
Compound 18a (1.0 eq.) was dissolved and stirred in acetone at room temperature followed
by addition of sodium azide (2.0 eq.). After overnight stirring, the acetone was partially evaporated
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and the remaining residue was diluted with water/ice. Yellow to orange solid precipitated out and
was isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and complete
removal of water by putting the crude product in high vacuum pump system, or by vacuum
filtration.
18a

(BW-AQ-126),

N-(4,5-bis(benzyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-2-

chloroacetamide:
Isolated yield over two steps: 68%. 1H NMR (DMSO-d6): δ 10.82 (s, 1H), 7.89 (s, 2H),
7.69-7.63 (m, 7H), 7.40-7.36 (m, 6H), 5.29 (s, 2H), 5.24 (s, 2H), 4.32 (s, 2H); 13C NMR (DMSOd6): δ 183.41, 180.55, 165.99, 159.34, 158.23, 143.88, 137.38, 137.09, 135.41, 134.58, 134.44,
128.89, 128.76, 128.09, 128.02, 127.43, 127.29, 124.22, 121.09, 119.98, 119.13, 109.85, 109.13,
70.60, 70.49, 44.08. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C30H22ClNO5 512.1259, found
512.1234.
18b

(BW-AQ-129),

N-(4,5-bis(benzyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-2-

iodoacetamide:
Isolated yield over two steps: 85%. 1H NMR (DMSO-d6): δ 10.87 (s, 1H), 7.89-7.66 (m,
2H), 7.73-7.60 (m, 6H), 7.43-7.35 (m, 7H), 5.30 (s, 2H), 5.26 (s, 2H), 3.87 (s, 2H);

13

C NMR

(DMSO-d6): δ 183.48, 180.59, 168.11, 159.38, 158.23, 144.28, 137.38, 137.10, 135.44, 134.61,
134.47, 128.77, 128.10, 128.04, 127.33, 127.30, 124.27, 121.13, 119.85, 119.14, 109.55, 108.92,
70.61, 70.49. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C30H22INO5 604.0615, found 604.0588.
18c

(BW-AQ-128),

N-(4,5-bis(benzyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-

yl)acrylamide:
Isolated yield over two steps: 77%. 1H NMR (DMSO-d6): δ 10.76 (s, 1H), 8.06 (s, 1H),
7.97 (d, J = 1.2 Hz, 1H), 7.73-7.59 (m, 7H), 7.44-7.35 (m, 7H), 6.49-6.33 (m, 2H), 5.87 (d, J = 1.6
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Hz, 1H), 5.85 (s, 2H), 5.84 (s, 2H);

13

C NMR (DMSO-d6): δ 183.55, 180.64, 164.36, 159.36,

158.24, 144.50, 137.39, 137.13, 135.39, 134.64, 134.46, 131.76, 128.89, 128.77, 128.11, 128.04,
127.33, 127.31, 124.33, 121.15, 119.77, 119.15, 109.91, 109.32, 70.62, 70.50, 66.82. HRMS (ESITOF) m/z [M+1]+ calcd. for C31H23NO5 490.1649, found 490.1625.
18d (BW-AQ-127), N-(4-(benzyloxy)-4-hydroxy-9,10-dioxo-9,10-dihydroanthracen-2yl)-2-bromoacetamide:
Isolated yield over two steps: 30%. 1H NMR (DMSO-d6): δ 13.11(s, 1H), 11.02 (s, 1H),
7.95 (d, J = 2 Hz, 2H), 7.91 (t, J = 2 Hz, 1H), 7.68-7.58 (m, 3H), 7.44 (t, J = 7.6 Hz, 2H), 7.367.29 (m, 4H), 5.28 (s, 2H), 4.10 (s, 2H); 13C NMR (DMSO-d6): δ 187.25, 182.21, 166.42, 162.03,
161.22, 145.77, 136.66, 136.43, 136.33, 132.74, 128.92, 128.24, 127.48, 124.90, 118.77, 117.07,
116.31, 110.33, 108.96, 70.67, 30.70. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C23H16BrNO5
466.0285, found 466.0263.
18e (BW-AQ-162), 2-Azido-N-(4,5-bis(benzyloxy)-9,10-dioxo-9,10-dihydroanthracen-2yl)acetamid:
Isolated yield: 98%. 1H NMR (DMSO-d6): δ 10.70 (s, 1H), 7.92 (s, 2H), 7.74-7.61 (m, 7H)
7.44-7.35 (m, 6H), 5.32 (s, 2H), 5.28 (s, 2H), 4.13 (s, 2H); 13C NMR (DMSO-d6): δ 183.51, 180.65,
167.86, 159.39, 158.24, 143.88, 137.39, 137.09, 135.49, 134.63, 134.51, 128.78, 128.12, 128.06,
127.33, 127.31, 124.32, 121.18, 119.94, 119.16, 109.84, 109.11, 70.63, 70.53, 51.89. HRMS (ESITOF) m/z [M+1]+ calcd. for C30H22N4O5 519.1663, found 519.1640.
1.3.5 Synthesis of 1,8-bis(2-azidoethoxy)anthracene-9,10-dione compounds
Two compounds that belong to the 1,8-bis(2-azidoethoxy)anthracene-9,10-dione class
(21a, 21b) were synthesized from aniline 19. Compound 19 was synthesized following synthetic
Scheme 1.3.1. Rhein (1) was reacted with iodomethane (1 eq.) in the presence of sodium

56

bicarbonate (2 eq.), in DMF. The reaction was stirred at room temperature overnight and yielded
intermediate 2; where R at 1 and 8 positions are “H” and at position 3 is “CH3”. The described
intermediate (2) was then reacted with 2-azidoethyl-4-methylbenzenesulfonate (reagent
synthesized following reported protocols2) under basic conditions (K2CO3, NaI, DMF, 60˚C,
overnight) to give intermediate 2 (quantitative yield); where R at the 1 and 8 positions are
“CH2CH2N3” and at position 3 is “CH3.” Aniline 19 was then synthesized as described in Scheme
1.3.1. Compounds 21a was obtained upon reaction of 19 with chloroacetyl chloride in 1,4 –dioxane
at room temperature (Scheme 1.3.10).

Scheme 1.10 Synthesis of compound 21a and 21b

Compound 21a was used as a starting material in the synthesis of azide 21b (Scheme
1.3.10). A substitution reaction between 21a and excess of sodium azide in acetone resulted in
compound 21b. The reaction was stirred at room temperature overnight to give 21b in 98 % yield.
The synthesized compounds that belong to the 1,8-bis(2-azidoethoxy)anthracene-9,10dione class are summarized in Figure 1.3.5. These compounds contain free azido groups allowing
for further functionalization through copper catalyzed of copper free “click” reactions. The
biological activity of these compounds is described in Section 1.4. of this chapter.
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Figure 1.3.5 Synthesized of 1,8-bis(2-azidoethoxy)anthracene-9,10-dione analogs

1.3.5.1 Experimental Section
Experimental procedure for the synthesis of compound 21a:
Compound 19 (1.0 eq.) was dissolved and stirred in 1, 4-dioxane at room temperature
followed by addition of the corresponding acyl halide (20, 1.5 eq.). After reaction completion, the
reaction mixture was diluted with distilled water/ice. Yellow to orange solid precipitated out and
was isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and complete
removal of water by putting the crude product in high vacuum pump system, or by vacuum
filtration. The crude product was purified by silica gel column chromatography using a
dichloromethane (DCM)/ethyl acetate (EtAc) gradient mixture to afford the pure product
21a.Experimental procedure for the synthesis of compound 21b:
Compound 21a (1.0 eq.) was dissolved and stirred in acetone at room temperature followed
by addition of sodium azide (2.0 eq.). After overnight stirring, the acetone was partially evaporated
and the remaining residue was diluted with water/ice. Yellow to orange solid precipitated out and
was isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and complete
removal of water by putting the crude product in high vacuum pump system, or by vacuum
filtration.
21a (BW-AQ-124), N-(4,5-bis(2-azidoethoxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-2chloroacetamide:
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Isolated yield over two steps: 55%. 1H NMR (DMSO-d6): δ 10.81 (s, 1H), 7.92 (d, J = 1.6
Hz,1H), 7.84 (d, J = 1.2 Hz, 1H), 7.72-7.71 (m, 2H), 7.54-7.51 (m, 1H), 4.33 (s, 2H), 4.28-4.21
(m, 4H), 3.72-3.68 (m, 4H);

13

C NMR (DMSO-d6): δ 183.33, 179.86, 166.02, 159.27, 158.20,

143.78, 135.37, 134.53, 134.43, 124.34, 121.50, 120.13, 119.51, 110.37, 109.52, 68.90, 68.86,
50.22, 50.14, 44.06. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C20H16ClN7O5 470.0974, found
470.0954.
21b

(BW-AQ-140),

2-Azido-N-(4,5-bis(2-azidoethoxy)-9,10-dioxo-9,10-

dihydroanthracen-2-yl)acetamide:
Isolated yield: 98%. 1H NMR (DMSO-d6): δ 10.67 (s, 1H), 7.89 (s, 1H), 7.80 (s, 1H), 7.71
(d, J = 4.0 Hz, 2H) 7.52 (t, J = 4.0 Hz, 1H), 4.28-4.21 (m, 4H), 4.11 (s, 2H), 3.72-3.68 (m, 4H);
C NMR (DMSO-d6): δ 183.35, 179.85, 167.84, 159.30, 158.19, 143.74, 135.36, 134.53, 134.40,

13

124.35, 121.51, 119.96, 119.50, 110.23, 109.43, 68.91, 68.85, 51.86, 50.22, 50.14. HRMS (ESITOF) m/z [M+1]+ calcd. for C20H16N10O5 477.1351, found 477.1358.
1.3.6 Synthesis of 1,8-bis(vinyloxy)anthracene-9,10-dione compounds
The 1,8-bis(vinyloxy)anthracene-9,10-dione class of compounds consists of three analogs
(23a-23c) synthesized from aniline 22. Compound 22 was synthesized following synthetic
Scheme 1.3.1. The aniline (22) was then reacted with the corresponding acyl chloride (Scheme
1.3.6) in 1,4-dioxane at room temperature to give compounds 23a and 23b (Figure 1.3.11, see the
experimental section for yields).
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Scheme 1.11 General synthetic route to compounds 23a and 23b

Compound 23a was used as a starting material in the synthesis of azide 23c (Scheme
1.3.12). A substitution reaction between 23a and excess of sodium azide in acetone resulted in
compound 23c. The reaction was stirred at room temperature overnight to give 23c (80% yield).

Scheme 1.12 Synthesis of compound 23c

Unfortunately, this class of compounds was limited to only three analogs due to their lack
of solubility. The attachment of allyl groups to positions 1 and 8 of the antraquinone core resulted
in the development of compounds with poor solubility, thus making them unsuitable drug
candidates; so additional modifications at position 3 were not explored. All synthesized
compounds that belong to the 1,8-bis(vinyloxy)anthracene-9,10-dione class are summarized in
Figure 1.3.6. The biological activity of these compounds is described in Section 1.4. of this chapter.
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Figure 1.3.6 Synthesized of 1,8-bis(vinyloxy)anthracene-9,10-dione analogs.

1.3.6.1 Experimental section
General experimental procedure for the synthesis of compounds 23a and 23b:
Compound 22 (1.0 eq.) was dissolved and stirred in 1, 4-dioxane at room temperature
followed by addition of the corresponding acyl halide (13, 1.5 eq.). After reaction completion, the
reaction mixture was diluted with distilled water/ice. Yellow to orange solids precipitated out and
were isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and
complete removal of water by putting the crude product in high vacuum pump system, or by
vacuum filtration. The crude product was purified by silica gel column chromatography using a
dichloromethane (DCM)/ethyl acetate (EtAc) gradient mixture to afford the pure product 23a and
23b.
Experimental procedure for the synthesis of compound 23c:
Compound 23a (1.0 eq.) was dissolved and stirred in acetone at room temperature followed
by addition of sodium azide (2.0 eq.). After overnight stirring, acetone was partially evaporated
and the remaining residue was diluted with water/ice. Yellow to orange solid precipitated out and
was isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and complete
removal of water by putting the crude product in high vacuum pump system, or by vacuum
filtration.
23a

(BW-AQ-161),

chloroacetamide:

N-(4,5-bis(allyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-2-
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Isolated yield over two steps: 73%. 1H NMR (DMSO-d6): δ 9.56 (s, 1H), 7.81 (s, 1H), 7.817.68 (m, 3H) 7.53-7.50 (m, 1H), 6.14-6.05 (m, 2H), 5.72-5.63 (m, 2H), 5.36-5.30 (m, 2H), 4.73 (t,
J = 4 Hz, 4H), 3.56 (s, 2H);

13

C NMR (DMSO-d63): δ 183.74, 180.41, 159.51, 158.21, 152.33,

144.91, 135.41, 134.61, 134.31, 133.59, 133.38, 124.07, 120.90, 118.91, 118.62, 117.67, 117.53,
108.75, 108.20, 69.59, 66.82. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C22H18ClNO5 412.0946,
found 412.0927.
23b (BW-AQ-163), N,N-(4,5-bis(allyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-2iodoacetamide:
Isolated yield over two steps: 80%. 1H NMR (DMSO-d6): δ 9.51 (s, 1H), 7.77 (s, 1H), 7.68
(d, J = 4.4 Hz, 3H) 7.49 (d, J = 4.4 Hz, 1H), 6.12-6.08 (m, 2H), 5.72-5.63 (m, 2H), 5.33 (t, J = 4
Hz, 2H), 4.72 (s, 4H); 13C NMR (DMSO-d6): δ 183.75, 180.42, 159.51, 158.21, 144.93, 135.42,
134.63, 134.33, 133.59, 133.38, 124.09, 120.93, 118.92, 118.64, 117.68, 117.54, 108.80, 108.23,
69.60. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C22H18INO5 504.0302, found 504.0278.
23c (BW-AQ-164), 2-Azido-N-(4,5-bis(allyloxy)-9,10-dioxo-9,10-dihydroanthracen-2yl)acetamide:
Isolated yield: 80%. 1H NMR (DMSO-d6): δ 9.55 (s, 1H), 7.78 (s, 1H), 7.69 (s, 3H) 7.50
(s, 1H), 6.16-6.06 (m, 2H), 5.72-5.63 (m, 2H), 5.33 (t, J = 4 Hz, 2H), 4.73 (s, 4H);

13

C NMR

(DMSO-d6): δ 183.76, 180.41, 159.50, 158.20, 135.41, 134.62, 134.31, 133.59, 133.38, 124.08,
120.91, 118.91, 118.59, 117.68, 117.53, 108.76, 108.23, 69.60, 69.56.
1.3.7 Synthesis of 1,8-diisobutoxyanthracene-9,10-dione compounds
The 1,8-diisobutoxyanthracene-9,10-dione class of compounds consists of five analogs
(25a-25e) synthesized from aniline 24. Compound 24 was synthesized following synthetic
Scheme 1.3.1. The aniline (24) was then reacted with the corresponding acyl chloride (Scheme
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1.3.13) in 1,4-dioxane at room temperature to give compounds 25a- 25e (Figure 1.3.7, see the
experimental section for yields).

Scheme 1.13 General synthetic route to compounds 25a-25e

All synthesized compounds that belong to the 1,8-diisobutoxyanthracene-9,10-dione class
are summarized in Figure 1.3.7. The biological activity of these compounds is described in
Section 1.4. of this chapter.

Figure 1.3.7 Synthesized of 1,8-diisobutoxyanthracene-9,10-dione analogs

1.3.7.1 Experimental section
General experimental procedure for the synthesis of compounds 25a-25e:
Compound 24 (1.0 eq.) was dissolved and stirred in 1, 4-dioxane at room temperature
followed by addition of the corresponding acyl halide (13, 1.5 eq.). After reaction completion, the
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reaction mixture was diluted with distilled water/ice. Yellow to orange solids precipitated out and
were isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and
complete removal of water by putting the crude product in high vacuum pump system, or by
vacuum filtration. The crude product was purified by silica gel column chromatography using a
dichloromethane (DCM)/ethyl acetate (EtAc) gradient mixture to afford the pure products 25a25e.
25a (BW-AQ-177), 2-Chloro-N-(4,5-diisobutoxy-9,10-dioxo-9,10-dihydroanthracen-2yl)acetamide:
Isolated yield over two steps: 30%. 1H NMR (CDCl3): δ 8.54 (s, 1H), 8.06 (s, 1H), 7.78 (d,
J = 7.6 Hz, 1H), 7.57 (t, J = 8 Hz, 1H), 7.52 (s, 1H), 7.28-7.26 (m, 1H), 4.23 (s, 2H), 3.91-3.87
(m, 4H), 2.98-2.95 (m, 2H), 1.12-1.10 (m, 12H);

C NMR (CDCl3): δ 183.88, 180.96, 164.39,

13

160.47, 159.06, 141.39, 135.44, 134.61, 133.38, 124.67, 121.26, 119.75, 118.77, 109.61, 108.68,
75.97, 42.91, 28.46, 28.40, 19.15. HRMS (ESI-TOF) m/z [M+Na]+ calcd. for C24H26ClNO5
466.1397, found 466.1389.
25b (BW-AQ-183), 2-Bromo-N-(4,5-diisobutoxy-9,10-dioxo-9,10-dihydroanthracen-2yl)acetamide:
Isolated yield over two steps: 25%. 1H NMR (CDCl3): δ 8.68 (s, 1H), 8.08 (d, J = 2 Hz,
1H), 7.77 (d, J = 7.6 Hz, 1H), 7.57 (t, J = 8 Hz, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.28-7.26 (m, 1H),
4.07 (s, 2H), 3.91-3.87 (m, 4H), 2.27-2.19 (m, 2H), 1.16-1.10 (m, 12H);

C NMR (CDCl3): δ

13

184.00, 181.04, 164.25, 160.46, 159.05, 141.84, 135.34, 134.59, 133.40, 124.62, 121.06, 119.78,
118.76, 109.59, 108.67, 76.72, 76.03, 75.96, 29.37, 28.44, 28.38, 19.15. HRMS (ESI-TOF) m/z
[M+Na]+ calcd. for C24H26BrNO5 510.0892, found 510.0887.
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25c (BW-AQ-176), 3-Chloro-N-(4,5-diisobutoxy-9,10-dioxo-9,10-dihydroanthracen-2yl)propanamide:
Isolated yield over two steps: 27 %. 1H NMR (CDCl3): δ 8.42 (s, 1H), 8.24 (s, 1H), 7.77
(d, J = 7.6 Hz, 1H), 7.58 (t, J = 8 Hz, 1H), 7.52 (s, 1H), 7.29-7.27 (m, 1H), 3.92-3.88 (m, 6H),
2.98-2.95 (m, 2H), 2.27-2.20 (m, 2H), 1.13-1.10 (m, 12H); 13C NMR (CDCl3): δ 184.63, 181.07,
168.67, 160.55, 159.08, 142.66, 135.17, 134.64, 133.35, 124.69, 120.51, 119.89, 118.67, 109.90,
108.60, 40.45, 39.38, 28.44, 28.40, 19.17, 19.15. HRMS (ESI-TOF) m/z [M+Na]+ calcd. for
C25H28ClNO5 480.1554, found 480.1565.
25d

(BW-AQ-178),

2-(Benzyloxy)-N-(4,5-diisobutoxy-9,10-dioxo-9,10-

dihydroanthracen-2-yl)acetamide:
Isolated yield over two steps: 35%. 1H NMR (CDCl3): δ 8.61 (s, 1H), 8.16 (d, J = 1.6 Hz,
1H), 7.79 (d, J = 7.2 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.45-7.39 (m, 6H), 7.28-7.26 (m, 1H), 4.70
(s, 2H), 4.13 (s, 2H), 3.93-3.88 (m, 4H), 2.28-2.06 (m, 2H), 1.14-1.10 (m, 12H);

13

C NMR

(CDCl3): δ 184.04, 180.97, 168.17, 160.51, 159.03, 141.76, 136.22, 135.39, 134.68, 133.24,
128.86, 128.62, 128.19, 124.79, 120.77, 119.74, 118.74, 109.53, 108.48, 76.04, 75.90, 73.94,
69.43, 28.47, 28.41, 19.16. HRMS (ESI-TOF) m/z [M+Na]+ calcd. for C31H33NO6 538.2206, found
538.2222.
25e (BW-AQ-212), 4-Chloro-N-(4,5-diisobutoxy-9,10-dioxo-9,10-dihydroanthracen-2yl)butanamide
Isolated yield over two steps: 20%. 1H NMR (CDCl3): δ 8.22 (s, 1H), 8.08 (s, 1H), 7.78 (d,
J = 7.2 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.49 (d, J = 2 Hz, 1H), 7.29-7.26 (m, 1H), 3.92- 3.88
(m, 4H), 3.67 (t, J = 7.2 Hz, 2H), 2.69-2.65 (m, 2H), 2.26-2.21 (m, 4H), 1.13-1.10 (m, 12H); 13C
NMR (CDCl3): δ 184.46, 180.97, 170.77, 160.58, 159.08, 142.70, 135.27, 134.67, 133.27, 124.77,
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120.45, 119.85, 118.67, 109.67, 108.30, 76.05, 75.88, 44.27, 34.23, 29.71, 28.46, 28.42, 27.57,
19.16. HRMS (ESI-TOF) m/z [M+Na]+ calcd. for C26H30ClNO5 494.1710, found 494.1698.
1.3.8 Synthesis of 1,8-bis(isopentyloxy)anthracene-9,10-dione compounds
The 1,8-bis(isopentyloxy)anthracene-9,10-dione class of compounds consists of seven
analogs (27a-27f) synthesized from aniline 26. Compound 26 was synthesized following synthetic
Scheme 1.3.1. The aniline (26) was then reacted with the corresponding acyl chloride (Scheme
1.3.14) in 1,4-dioxane at room temperature to give compounds 27a-27f (Figure 1.3.8, see the
experimental section for yields).

Scheme 1.14 General synthetic route to compounds 27a-27f

Compound 27a was used as a starting material in the synthesis of azide 27g (Scheme
1.3.15). A substitution reaction between 27a and excess of sodium azide in acetone resulted in
compound 27g. The reaction was stirred at room temperature overnight to give 27g in
quantitative yields.
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Scheme 1.15 Synthesis of compound 27g

All synthesized compounds that belong to the 1,8-diisobutoxyanthracene-9,10-dione class
are summarized in Figure 1.3.8. The biological activity of these compounds is described in
Section 1.4. of this chapter.

Figure 1.3.8 Synthesized of 1,8-bis(isopentyloxy)anthracene-9,10-dione analogs

1.3.8.1 Experimental section
General experimental procedure for the synthesis of compounds 27a-27f:
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Compound 26 (1.0 eq.) was dissolved and stirred in 1, 4-dioxane at room temperature
followed by addition of the corresponding acyl halide (13, 1.5 eq.). After reaction completion, the
reaction mixture was diluted with distilled water/ice. Yellow to orange solids precipitated out and
were isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and
complete removal of water by putting the crude product in high vacuum pump system, or by
vacuum filtration. The crude product was purified by silica gel column chromatography using a
dichloromethane (DCM)/ethyl acetate (EtAc) gradient mixture to afford the pure product 27a-27f.
Experimental procedure for the synthesis of compound 27g:
Compound 27a (1.0 eq.) was dissolved and stirred in acetone at room temperature followed
by addition of sodium azide (2.0 eq.). After overnight stirring, the acetone was partially evaporated
and the remaining residue was diluted with water/ice. Yellow to orange solid precipitated out and
was isolated either by centrifugation at 5000 rpm for 10 min followed by decantation and complete
removal of water by putting the crude product in high vacuum pump system, or by vacuum
filtration.
27a (BW-AQ-181), N-(4,5-bis(isopentyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-2chloroacetamide:
Isolated yield over two steps: 47%. 1H NMR (CDCl3): δ = 8.64 (s, 1H), 8.14 (s, 1H), 7.81
(d, J = 7.8 Hz, 1H), 7.60 (t, J = 8 Hz, 1H), 7.56 (s, 1H), 7.31 (d, J = 7.6 Hz, 1H), 4.25 (s, 2H),
4.21-4.15 (m, J = 4.6 Hz, 4H), 2.04-1.98 (m, J = 8 Hz, 2H), 1.85-1.79 (m, 4H), 1.02 (s, 6H), 1.00
(s, 6H);

13

C NMR (CDCl3): δ = 183.8, 181.0, 164.4, 160.5, 159.0, 141.5, 135.5, 134.6, 133.5,

124.5, 121.0, 119.9, 118.9, 109.6, 108.8, 68.3, 68.2, 42.9, 37.8, 37.6, 25.0, 25.0, 22.6. HRMS (ESIESI-TOF): m/z [M+Na] + calcd for C26H30ClNO5: 494.1710, found: 494.1694.
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27b (BW-AQ-180), N-(4,5-bis(isopentyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-2bromoacetamide:
Isolated yield over two steps: 25%. 1H NMR (CDCl3): δ 8.74 (s, 1H), 8.15 (s, 1H), 7.80 (d,
J = 7.6 Hz, 1H), 7.59 (t, J = 8 Hz, 1H), 7.55 (s, 1H), 7.30 (d, J = 8.4 Hz, 1H), 4.20-4.14 (m, 4H),
4.08 (s, 2H), 2.06-1.96 (m, 2H), 1.83-1.75 (m, 4H), 1.00-0.98 (m, 12H);

C NMR (CDCl3): δ

13

183.92, 181.29, 164.90, 160.47, 159.04, 142.49, 135.22, 134.58, 133.52, 124.32, 120.46, 119.83,
118.83, 109.67, 108.92, 68.28, 37.74, 37.60, 29.56, 24.98. HRMS (ESI-TOF) m/z [M+Na]+ calcd.
for C26H30BrNO5 538.1205, found 538.1196.
27c (BW-AQ-209), N-(4,5-bis(isopentyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-3chloropropanamide:
Isolated yield over two steps: 55%. 1H NMR (DMSO-d6): δ 10.59 (s, 1H), 8.14 (s, 1H),
7.85 (s, 1H), 7.70-7.67 (m, 2H), 7.53-7.51 (m, 1H), 4.14-4.07 (m, 4H), 3.90 (t, J = 6.0 Hz , 2H),
2.89 (t, J = 6 Hz, 2H), 1.97 (m, 2H), 1.70-1.66 (m, 4H), 0.97-0.94 (m, 12H); 13C NMR (DMSOd6): δ 183.8, 180.3, 169.5, 159.8, 158.7, 144.2, 135.4, 134.6, 134.3, 124.2, 120.8, 119.7, 118.6,
109.3, 108.5, 67.9, 67.8, 55.4, 37.9, 37.8, 24.8, 22.9, 22.9.. HRMS (ESI-TOF) m/z [M+H]+ calcd.
for C27H32ClNO5 486.2042, found 486.2023.
27d (BW-AQ-211), N-(4,5-bis(isopentyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-4chlorobutanamide:
Isolated yield over two steps: 43%. 1H NMR (DMSO-d6): δ 10.50 (s, 1H), 7.87 (s, 1H),
7.85 (s, 1H), 7.69-7.67 (m, 2H), 7.53 (s, 1H), 4.14-4.06 (m, 4H), 3.72 (t, J = 6.4 Hz, 2H), 2.55 (t,
J = 7.2 Hz, 2H), 2.07-1.97 (m, 4H), 1.69-1.65 (m, 4H), 0.96-0.94 (m, 12H); 13C NMR (DMSOd6): δ 183.8, 180.3, 171.7, 159.8, 158.7, 144.5, 135.3, 134.6, 134.2, 124.3, 120.7, 119.5, 118.6,
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109.3, 108.5, 67.9, 67.7, 55.4, 45.4, 37.9, 37.8, 34.0,28.1, 24.8, 22.9, 22.9. HRMS (ESI-TOF) m/z
[M+H]+ calcd. for C28H34ClNO5 500.2198, found 500.2176.
27e

(BW-AQ-210),

2-(Benzyloxy)-N-(4,5-bis(isopentyloxy)-9,10-dioxo-9,10-

dihydroanthracen-2-yl)acetamide:
Isolated yield over two steps: 58%. 1H NMR (CDCl3): δ 8.48 (s, 1H), 7.82 (s, 1H), 7.80 (s,
1H), 7.59 (t, J = 8.4 Hz, 1H), 7.47-7.46 (m, 1H), 7.44-7.39 (m, 4H), 7.31-7.28 (m, 1H); 13C NMR
(CDCl3): δ 184.0, 180.9, 168.2, 160.6, 159.1, 141.8, 136.2, 135.4, 134.7, 133.3, 128.9, 128.6,
128.2, 124.6, 120.6, 119.9, 118.9, 109.6, 108.5, 69.4, 68.3, 37.8, 37.7, 25.0, 22.6. HRMS (ESITOF) m/z [M+Na]+ calcd. for C33H37NO6 566.2519, found 566.2498.
27f (BW-AQ-216), N-(4,5-bis(isopentyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-3bromopropanamide:
Isolated yield over two steps: 53%. 1H NMR (DMSO-d6): δ 10.56 (s, 1H), 7.86 (s, 1H),
7.82 (s, 1H), 7.68-7.64 (m, 2H), 7.51-7.49 (m, 1H), 4.12-4.05 (m, 4H), 3.73 (t, J = 6.4 Hz , 2H),
3.00 (t, J = 6.4 Hz , 2H), 1.98-1.92 (m, 2H), 1.69-1.64 (m, 4H), 0.95 -0.92 (m, 12H); 13C NMR
(DMSO-d6): δ 183.8, 180.3, 169.7, 159.8, 158.7,144.2, 134.3, 124.3, 120.8, 119.7, 118.6, 109.3,
108.5, 67.9, 67.8, 37.9, 37.8, 29.2, 24.8, 22.9, 22.9. HRMS (ESI-TOF) m/z [M+H]+ calcd. for
C27H32BrNO5 530.1537, found 530.1515.
27g (BW-AQ-217), 2-Azido-N-(4,5-bis(isopentyloxy)-9,10-dioxo-9,10-dihydroanthracen2-yl)acetamide:
Isolated yield: 97%. 1H NMR (CDCl3): δ 8.64 (s, 1H), 8.14 (s, 1H), 7.81 (d, J = 7.8 Hz,
1H), 7.60 (t, J = 8.0 Hz, 1H), 7.56 (s, 1H), 7.31 (d, J = 7.6 Hz, 1H), 4.25 (s, 2H), 4.21-4.15 (m, J
= 4.6 Hz, 4H), 2.04-1.98 (m, J = 8 Hz, 2H), 1.85-1.79 (m, 4H), 1.02 (s, 6H), 1.00 (s, 6H);
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C

NMR (CDCl3): δ 183.8, 181.0, 164.4, 160.5, 159.0, 141.5, 135.5, 134.6, 133.5, 124.5, 121.0, 119.9,
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118.9, 109.6, 108.8, 68.3, 68.2, 42.9, 37.8, 37.6, 25.0, 25.0, 22.6. HRMS (ESI-TOF) m/z [M+H]+
calcd. for C26H30N4O5 494.1710, found 494.1694.
1.3.9 Synthesis of additional anthracene-9,10-dione analogs
This section of the chapter describes three compounds that cannot be placed in a specific
structural class at this point, but exhibit potent activity. Compounds 29 and 31 were synthesized
following the general synthetic rout described in Scheme 1.3.1 with slight variations in
intermediate 2. Rhein (1) was reacted with iodomethane (1 eq.) in the presence of sodium
bicarbonate (2 eq.), in DMF. The reaction was stirred at room temperature overnight and yielded
intermediate 2; where R at the 1 and 8 positions are “H” and at position 3 is “CH3.” The described
intermediate (2) was then reacted with 1-chloro-2-methoxyethane or 1-chloro-3-methoxypropane
under basic conditions (K2CO3, NaI, Acetone, 90˚C, overnight) to give intermediate 2 (quantitative
yield) where R at the 1 and 8 positions are “CH2CH2OCH3” or “CH2CH2CH2OCH3” respectively
and at position 3 is “CH3.” Anilines 28 and 30 were synthesized as described in Scheme 1.3.1 from
the two respective intermediates (2). Compounds 29 and 31 were obtained upon reaction of 28 and
30 with chloroacetyl chloride in 1,4 –dioxane at room temperature (Scheme 1.3.16).
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Scheme 1.16 Synthesis of compound 29, 31, 33

Compound 33 was synthesized by reacting the commercially available aniline 32 with
chloroacetyl chloride at room temperature in 1,4-dioxqane (Scheme 1.3.16). All of the compounds
were purified via silica gel column chromatography. The biological activity of the compounds
shown in Figure 1.3.9 is described in Section 1.4. of this chapter.

Figure 1.3.9 Synthesized of various anthracene-9,10-dione analogs
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1.3.9.1 Experimental section
General experimental procedure for the synthesis of compounds 29, 31, and 33:
Compound 29, 31, or 33 (1.0 eq.) was dissolved and stirred in 1, 4-dioxane at room
temperature followed by addition of the corresponding acyl halide (20, 1.5 eq.). After reaction
completion, the reaction mixture was diluted with distilled water/ice. Yellow to orange solids
precipitated out and were isolated either by centrifugation at 5000 rpm for 10 min followed by
decantation and complete removal of water by putting the crude product in high vacuum pump
system, or by vacuum filtration. The crude product was purified by silica gel column
chromatography using a dichloromethane (DCM)/ethyl acetate (EtAc) gradient mixture to afford
the pure product 29, 31, and 33.
29 (BW-AQ-202), N-(4,5-bis(2-methoxyethoxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)2-chloroacetamide:
Isolated yield over two steps: 34%. 1H NMR (CDCl3): δ 8.68 (s, 1H), 8.09 (s, 1H), 7.82 (d,
J = 7.6 Hz, 1H), 7.61-7.57 (m, 2H), 7.33 (d, J = 8.4 Hz, 1H), 4.28 (s, 4H), 4.23 (s, 2H), 4.11 (s,
2H), 3.88 (s, 4H), 3.53-3.52 (m, 6H); 13C NMR (CDCl3): δ 183.39, 181.15, 164.61, 160.23, 158.84,
141.83, 135.40, 134.55, 133.71, 120.85, 120.77, 119.71, 110.12, 109.47, 70.93, 70.71, 69.68,
69.54, 59.48, 42.97, 29.70. HRMS (ESI-TOF) m/z [M+Na]+ calcd. for C22H22ClNO7 470.0982,
found 470.0960.
31 (BW-AQ-205), N-(4,5-bis(3-methoxypropoxy)-9,10-dioxo-9,10-dihydroanthracen-2yl)-2-chloroacetamide:
Isolated yield over two steps: 41%. 1H NMR (CDCl3): δ 8.60 (s, 1H), 8.08 (s, 1H), 7.80 (d,
J = 7.6 Hz, 1H), 7.60-7.57 (m, 2H), 7.32 (d, J = 8.4 Hz, 1H), 4.25-4.21 (m, 6H), 3.72-3.69 (m,
4H), 3.37 (s, 6H), 2.17-2.16 (m, 4H); 13C NMR (CDCl3): δ 183.66, 180.97, 164.43, 160.38, 158.97,
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141.63, 135.45, 134.60, 133.58, 124.30, 120.82, 119.88, 119.07, 109.69, 108.99, 69.06, 66.60,
66.53, 58.72, 58.68, 42.92, 29.48, 29.29. HRMS (ESI-TOF) m/z [M+Na]+ calcd. for C24H26ClNO7
498.1295, found 498.1312.
33 (BW-AQ-131), 2-chloro-N-(9,10-dioxo-9,10-dihydroanthracen-2-yl)acetamide:
Isolated yield: 70%. 1H NMR (DMSO-d6): δ 10.91 (s, 1H), 8.38 (s, 1H), 8.14 (s, 3H), 8.02
(d, J = 7.6 Hz, 1H), 7.88 (d, J = 2.8 Hz, 2H), 4.35 (s, 2H); 13C NMR (DMSO-d6): δ 182.72, 181.74,
166.01, 144.35, 135.02, 134.70, 134.57, 133.51, 128.99, 128.80, 127.17, 127.10, 124.41, 116.50,
44.06. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C16H10ClNO3 300.0409, found 300.0422.
1.3.10 Computational evaluation of the designed compounds
In the pursuit of developing new active MDM2-MDM4 inhibitors, we turned to molecular
modeling to examine the binding potential of the newly designed compounds. In a previous section
of this chapter, the hypothesis that BW-AQ-101 binds to the MDM2 RING homodimer to inhibit
MDM2-MDM4 formation was discussed. Biological and in silico studies of BW-AQ-101 with the
proposed target supported this hypothesis. We herein discuss molecular docking studies aimed at
evaluating the potential of the above-described BW-AQ-101 analogs as MDM2 RING binders.
Docking studies are based on two major protein structures; the MDM2-MDM4 heterodimer
RING domain and the MDM2 homodimer RING domain. The RING structure of the heterodimer
is available through the protein data bank (PDB) with a structure ID 2VJE (Figure 1.3.10, right).3
The heterodimer’s (2VJE) crystal structure was derived through X-ray crystallography with a
resolution of 2.2 A.3 The structure of the RING MDM2 homodimer is also available through the
PDB under the ID 2HDP; this structure however, was derived from solution NMR (Figure 1.3.10,
left).4
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Figure 1.3.10 Structures of the MDM2 RING homodimer and the MDM2-MDM4 RING
heterodimer
Left: The RING domain structure of MDM2 homodimer
Right: The RING domain structure of MDM2-MDMX heterodimer
*Highlighted in magenta are the key residues that form a binding pocket in the homodimer and
the same residues in the heterodimer that fail to form a binding pocket.
The study begins with careful analysis and preparation of the obtained structures. The
docking studies were done with constricted dielectric constant value of 80 (water), attempting to
simulate the physiological environment, which is aqueous. The homodimer was carefully
examined and its symmetric structure revealed two identical and symmetric binding pockets
formed by the two RING domains (Figure 1.3.11, left). It has been reported that the RING domains
are very unstable in solution and they easily form dimeric or other types of aggregate structures;
therefore it is safe to assume that the binding pockets that the homodimer forms exist under
physiological conditions. The critical amino acids that form a binding pocket in the MDM2 RING
homodimercis structures are: A/Val439, A/Ile 440, A/Leu468, A/Lys 473, A/Pro474, A/His452,
A/Gln480, A/Cys 478, A/Val 477, A/Pro 476, A/His457, A/Cys 475, B/Pro491, B/Leu432;
residues forming the deep inner surface of the pocket: A/His 457, A/Leu 458, A/Ala 460, A/Ile
450, A/ile482, A/Lys 469, A/Ala465. The surface that these residues form can be seen in Figure
1.3.10 (left, colored in magenta). The depth of the pocket formed by these residues can be seen in
Figure 1.3.11 (left, colored in blue and yellow). The identified critical residues do not form a
binding pocket when translated in the MDM2-MDM4 heterodimeric structure (Figure 1.3.11,
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right). The heterodimeric model reveals that the residues of the MDM2 RING responsible for the
pocket formation in the homodimeric structure have undergone structural perturbations and simply
form the outer surface of the MDM2-MDM4 heterodimer (Figure 1.3.11, right). Interestingly,
these residues do not have direct participation in the MDM2-MDM4 RING surface interactions
(Figure 1.3.11, bottom). Thus it is safe to assume that binding pocket collapse is due to major
conformational changes upon heterodimer formation. These observations support the hypothesis
established earlier that the anthraquinone compound described above bind to the homodimeric
binding pocket and stabilize the structure, thus locking it in place.

Figure 1.3.11: The Residues forming the binding cavity of the MDM2 RING homodimer
Left: The RING domain structure of MDM2’s homodimer showing the relative cavity
depth of the binding pocket.
Right: The RING domain structure of MDM2-MDM4’s heterodimer showing the lack of
cavity by coloring the MDM2 RING residues that form cavity in the homodimeric form.
*Coloring scheme showing the depth of the cavity: blue (no cavity), yellow (cavity)
Bottom: Space filling model of MDM2 (orange)-MDM4 (cyan) heterodimer and the
MDM2 amino acid residues (blue) participating in pocket formation in the homodimeric form.
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Comparative analysis of the MDM2 RING monomer extracted from the 2HDP and 2VJE
structures gave further insights into the significant structural differences of its heterodimeric vs
homodimeric form. Although the MDM2 RING sequences from the homodimer and the
heterodimer are identical, structural alignment revealed a major difference (Figure 1.3.12). As seen
in Figure 1.3.12, the RING domain of MDM2 from the homodimeric form clearly forms a cavity
(surface highlighted in purple) and the same domain from the heterodimer does not (surface
highlighted in red). These observations further indicate that the cavity of the MDM2 RING
homodimer can serve as a binding target for the development of therapeutics. The function of the
binding pocket is not yet known; however, it can be deduced that the conformational changes that
the MDM2 RING undergo in this region are important for the binding to the MDM4 RING.
Therefore, if a compound binds tightly to the pocket it will not allow for the RING motif to undergo
conformational changes therefore inhibiting the MDM2-MDM4 interactions.

Figure 1.3.12 Superimposed MDM2 RING domain extracted from the heterodimer and
the homodimer
*Surface areas derived by the residues participating in the binding pocket formation: in
the homodimer highlighted in purple and in the heterodimer highlighted in red.

The majority of the synthesized compounds were successfully docked into the MDM2
RING binding pocket. Example of some of the tighter binders can be seen in Figure 1.3.13. One
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can clearly see that the pocket accommodates the anthraquinone skeleton very well. In addition,
hydrogen bond interactions in the region just outside of the binding pocket can further stabilize
and anchor the compounds in the pocket.

Figure 1.3.13 View of successfully bound anthraquinone analogues
*Protein surface area is colored based on hydrogen bonding: H-bond acceptors (blue),
H-bond donors (red).

Docking Results
6
5
4
3
2
1
0

Figure 1.3.14: Relative docking score of selected compounds

The internal surface of the pocket is mostly lipophilic as it can be seen from the images in
Figure 1.3.15. The pocket is large enough to accommodate aliphatic functional groups such as
ethyl and propyl substituents. The relative binding score slightly drops with the introduction of
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propyl moieties at the 1,8 positions of the anthraquinone core (Figure 1.3.14). However, the pocket
accommodates bulky substituents like a benzyl group. In fact the relative docking results indicate
that the presence of aromatic substituents improves binding (Figure 1.3.14). The slight drop of
docking score for BW-AQ-127, with a single benzyl group, indicates the stabilizing interactions
that these groups carry. As these large substituents are being anchored in the pocket through Van
der Waals interactions the hydrogen bond donors and acceptors at the cavity opening can further
increase the binding interactions (Figure 1.3.15). All of the above discussed aspects have been
taken in consideration in the process of designing new anthraquinone analogues targeting MDM2MDM4 interactions. Of course another priority is the improvement of water solubility and the
introduction of aromatic substituents will not allow us to achieve that. Molecular modeling can
be a very beneficial tool in the drug discovery and development process. However, at this stage of
the project we can only use it as a guiding tool to build a library of successful inhibitors.

Figure 1.3.15 Various athraquinone analogs docked in the binding pocket
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Top left: View of successfully bound anthraquinone analogues containing bulky
substituents at 1,8- positions (H-bonding surface map).
Top right: View of successfully bound anthraquinone analogues containing bulky
substituents at 1,8- positions (lipophillicity surface map).
Bottom: View of successfully bound anthraquinone analogues containing propyl
substituents at 1,8- positions (lipophillicity surface map).
* Lipophillicity surface coloring: strong lipophilic character (brown), weak lipophilic
character (blue)

In summary, we have identified a clear binding cavity in the MDM2 RING homodimer.
This cavity can serve as a potential binding pocket for the developed anthraquinone analogs
described in the previous sections. A careful examination of the available MDM2 RING
homodimer and MDM2-MDM4 RING heterodimeric structures and docking studies support the
hypothesis that BW-AQ-101 and its analogs can bind to the MDM2 RING homodimer (Figure
1.3.16). This binding can potentially stabilize the homodimer and prevent the formation of MDM2MDM4 heterodimer formation.

Figure 1.3.16 The binding hypothesis
Left: MDM2 RING homodimer and its cavity
Middle: MDM2 RING and anthraquinone analogues bound to it
Left: Space filling model of the MDM2 RING heterodimer (cyan and orange) and BWAQ-101 (red) bound to it.
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1.3.10.1 Experimental Section
The NMR structure of the MDM2 RING homodimer is available through the Protein Data
Bank (PDB) under the ID 2HDP.4 The X-ray RING structure of the MDM2-MDM4 heterodimer
is also available through the PDB (ID 2VJE), with a resolution of 2.2 Å.3 We performed molecular
docking to see whether there was a potential binding pocket for AQ-101 in the MDM2 RING
protein. The target protein and AQ-101 were prepared by removing of all zinc ions, water residues,
and other ligands. All hydrogen atoms were added and the protein termini were fixed.
Minimization was performed by using Sybyl X 2.0 and applying standard parameters: Powell
method, Tripos force field, and Pullman charges. Simulated water environment were used by
assigning the dielectric constant to 80. Docking was performed by Surflex-Dock module in Sybyl
X 2.0. Virtual preparation of the heterodimeric structure was performed following the abovedescribed protocol.
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1.4

Biological evaluation of novel potent anthraquinone compounds as anticancer agents
All compounds disclosed in the previous section (1.3) of this chapter were tested

for anticancer activity against seven cell lines. Three of the cell lines were leukemia cell lines
(Molt4, EU1, and K562). The additional four cell lines are solid tumor cells: Hela (cervical cancer),
KB (cervical cancer derived from Hela), Cos7 (derived from monkey kidney tissue), and T98G
(glioblstoma). All experiments were done in triplicates and using a well-established protocol for
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The exact
protocol can be found in the experimental section (1.4.11). The initial testing of each compound
begins with high concentration (50 µM, 25 µM, 12.5 µM, 6.25 µM) screening against one/two
leukemia cell lines and one/two solid state cells to establish relative activity of the compound. The
IC50 (the concentration at which 50% of the cells are dead) values were then established with a
secondary screening of the active compounds at the appropriate concentration ranges. All potent
compounds (IC50 < 1 µM) were then tested against additional cell lines to determine the cellular
selectivity of the specific compounds. Data analysis of the various groups of compounds tested
can be found in the subsections below.
1.4.1 Evaluation of the 1,8-dimethoxyanthracene-9,10-dione compounds
Compound 8a was tested against all seven cell lines available while compounds
8b-8d and 11 were tested only against selected cell lines due to their general lack of activity. After
initial screening, compound 8a showed potency against solid and leukemia cells (Table 1.4.1). The
compound appears to be selectively more potent against leukemia cells where its IC50 values range
from 0.79 µM to 0.14 µM. The compound shows relatively good activity against Cos7 cells, but
the activity significantly decreased when tested against Hela and KB cells. Interestingly,
compound 8a shows activity against the drug resistant T98G cell line as well. When compared to
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the marketed doxorubicin 8a exhibits comparable activity against Cos7 and Hela cells, and
superiority against K562 and T98G cells.
IC50 values of synthesized 1,8-dimethoxyanthracene-9,10-dione analogs.* All values
reported are in µM concentration and determined via MTT assay.

Table 1.1 IC50 values of synthesized 1,8-dimethoxyanthracene-9,10-dione analogs
* All values reported are in µM concentration and determined via MTT assay.
Compound

BW-AQ ID

Hela

KB

Cos7

T98G

Molt4

K562

EU1

8a

112

3.3

4.3

1.2

2-12

0.14

0.79

0.74

8b
8c

132

>50

>50

>50

>12.5

>1.6

>6.3

ND

134

>50

>50

>50

>50

>1.6

>6.3

ND

8d

232

24

ND

ND

ND

>25

ND

ND

11

130

>50

42

29

>12

>1.6

>6.3

ND

Doxorubicin

2.5

1.6

2.1

>50

0.015

2.0

0.032

Unfortunately none of the other compounds form the 1,8-dimethoxyanthracene-9,10-dione
class showed potency against any of the cell lines. Comparison between the activity of compound
8a and BW-AQ-101 (Figure1.2.1) reveals that the alkylation at positions 1 and 8 of the
anthraquinone core is very important in terms of retaining or even improving activity. However,
the conclusion drawn from the data obtained for the 1,8-dimethoxyanthracene-9,10-dione
compounds is that the α-chloro acetamide substituent at position 3 is crucial for the activity of this
class of compounds.
1.4.2 Evaluation of the 1,8-diethoxyanthracene-9,10-dione compounds
Three (14a-14c) of the eight compounds that belong to the 1,8-diethoxyanthracene9,10-dione class showed potency against leukemia cell lines and some solid state cells (Table
1.4.2). Compound 14a showed activity in the mid nano molar range (120 nM - 480 nM) against
Molt4 and EU1. Compounds 14b and 14c also showed low IC50 values of 280 nM and 180 nM
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against Mol4 cells. In addition, these three compounds showed promise against the solid state Cos7
cell line with IC50 values in the low single digit micro molar concentrations (Table 1.4.2).
Unfortunately none of the other five (14d-14h) compounds that were synthesized showed high
potency in any of the cell lines.
Table 1.2 IC50 values of synthesized 1,8-diethoxyanthracene-9,10-dione analogs
* All values reported are in µM concentration and determined via MTT assay
Compound

BW-AQ ID

Hela

KB

Cos7

T98G

Molt4

K562

EU1

14a
14b

113

2.1

5.5

114

3.9

10

1.1

5.2

0.12

0.74

0.48

2.1

>13

0.28

0.84

ND

14c

115

3.9

6.6

1.6

10

0.18

0.83

0.89

14d

179

>50

>50

>50

~50

20

11

18

14e

182

47

>50

>50

>50

17

>25

17

14f

198

58

ND

>6.3

ND

>25

ND

>6.3

14g

199

70

ND

>6.3

ND

18

ND

>6.3

14h

159

>6.3

>6.3

23

36

>13

12

16

It appears that the addition of a two carbon aliphatic chains to the 1 and 8 positions of the
anthraquinone core retains and even slightly improves activity against leukemia cells when
position 3 is a α-halo acetamide. It is very interesting that the three active compounds also exhibit
activity against drug resistant T98G. It is important to note that compounds 14g and 14h contain
a halogen at the α-carbon of the amide substituent. However, the halogen present in compounds
14g and 14h is secondary carbon rather than primary as in the case of 14a-14c, which appears to
decrease their potency. These result lead to the conclusion of possible alkylation as mechanism of
action of the active compounds.
1.4.3 Evaluation of 1,8-dipropoxyanthracene-9,10-dione compounds
Because three of the 1,8-diethoxyanthracene-9,10-dione analogs showed potency against
leukemia cell lines, it was decided to develop a group of compounds with longer aliphatic chains
at the 1 and 8 positions of the antraquinone core. Ten 1,8-dipropoxyanthracene-9,10-dione analogs
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were synthesized an tested (Table 1.4.3). To our disappointment only three of these compounds
(16a-16c) showed potency against Molt4 (Table 1.4.3). Compound 16j has promising activity
against Molt4 (0.49 µM) and EU1 (1.09 µM) as well. However, none of the other six compounds
exhibited potency in the primary screening, thus they were not tested against all cell lines.
Compounds 16a-16c show IC50 values below or about 2 µM against Cos7, making this the only
solid tumor cell line susceptible to these compounds.
Table 1.3 IC50 values of synthesized 1,8-dipropoxyanthracene-9,10-dione analogs
* All values reported are in µM concentration and determined via MTT assay
Compound
16a

BW-AQ ID

Hela

KB

Cos7

T98G

Molt4

K562

EU1

116

2.5

6.6

1.2

8.0

0.12

1.1

3.5

16b

117

2.5

8.5

2.1

13

0.16

1.6

ND

16c

118

3.4

12

1.8

15

0.14

1.3

0.36

16d

160

15

16

8.1

25

4.0

6.9

4.8

16e

201

>13

ND

>13

ND

6.0

ND

>13

16f

200

>13

ND

>13

ND

13

ND

>13

16g

215

21

ND

ND

ND

>25

ND

>13

16h

213

25

ND

ND

ND

18

ND

>13

16i

214

>25

ND

ND

ND

>25

ND

>13

16j

156

1.5

3.0

3.0

18

0.49

2.8

1.09

One clear conclusion can be made from the obtained data; the presence of α-halo acetamide
at position 3 of the core anthraquinone is absolutely crucial for the activity of the compounds. The
potency of compound 16j against Molt4 and EU1 suggests that the α-aza acetamide can be another
alternative for a substituent at position 3 that may lead to an active anticancer agent.
1.4.4 Evaluation of 1,8-bis(benzyloxy)anthracene-9,10-dione compounds
The compounds that belong to the 1,8-bis(benzyloxy)anthracene-9,10-dione class
are significantly different from the three classes of compounds described in sections 1.4.1-1.4.3
above. Compounds 18a-18e have aromatic (benzyl) substituents at the 1 and 8 positions of the
anthraquinone core. The presence of these aromatic functionalities resulted in compound 18b,
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which exhibited low nanomolar IC50 values against Molt4 (28 nM) and EU1 (84 nM). Interestingly,
compound 18b has α-iodo acetamide as a substituent at position 3. In addition, compound 18a
shows potency against Molt4 (0.24 µM), but not against EU1 or K562 (Table 1.4.4).
Table 1.4 IC50 values of synthesized 1,8-bis(benzyloxy)anthracene-9,10-dione analogs
* All values reported are in µM concentration and determined via MTT assay
Compound

BW-AQ ID

Hela

KB

Cos7

T98G

Molt4

K562

EU1

18a

126

6.1

9

2.5

>13

0.24

3.3

1.1

18b

129

5.6

5.4

1.7

14

0.028

2.0

0.084

18c

128

8.6

5.7

5.5

9.8

0.98

>6.3

>1.6

18d

127

>50

>50

>50

>13

1.6

>6.3

ND

18e

162

1.6

0.594

11

25

>25

>20

18

The compounds with a Michael acceptor (18c) and α-aza acetamide (18e) at position 3 do
not show significant activity except in Molt4 and KB. This class of compounds serves as evidence
that the combination of α-halo acetamide at position 3 and the presence of lipophilic/ conjugated
system at positions 1 and 8 leads to active anticancer compounds. The presence of aromatic
systems at position 1 and 8, however, leads to more lipophilic character of the analogs, which are
expected have decreased water solubility.
1.4.5 Evaluation of 1,8-bis(2-azidoethoxy)anthracene-9,10-dione compounds
In an attempt to explore the biological effects of various unsaturated substituents at the 1
and 8 positions of the anthraquinone core, the 1,8-bis(2-azidoethoxy)anthracene-9,10-dione class
of compounds was developed. This class of compounds introduces an azidoethyl group, which can
be helpful in a number of ways. For example, the azidoethyl groups are linear, yet they carry an
electron rich unsaturated system that can potentially participate in pi-pi interactions with the
binding pocket of the targeted protein. In addition, the azido group can be involved in ionic
interactions, thus improving solubility and/or protein binding. The two compounds (21a and 21b)
that were tested showed consistent potency against Molt4 and EU1 at sub-micro molar values
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(Table 1.4.5). Compound 21a even showed low nano molar activity against Mot4 (77 nM). What
is interesting about this pair of compounds is that they have selectivity towards leukemia cell, yet
retain IC50 values in the 2-3 µM range against solid tumor cells.

Table 1.5 IC50 values of synthesized 1,8-bis(2-azidoethoxy)anthracene-9,10-dione
analogs
* All values reported are in µM concentration and determined via MTT assay
Compound

BW-AQ ID

Hela

KB

Cos7

T98G

Molt4

K562

EU1

21a

124

2.4

3.6

0.85

4.8

0.077

1.1

0.28

21b

140

3.1

3.4

2.2

14

0.21

3.2

0.69

In addition, 21a has α-halo acetamide at position 3 and 21b has α-aza acetamide
functionality. Although very different in chemical characters it appears that these groups do not
significantly alter the biological activity of the 1,8-bis(2-azidoethoxy)anthracene-9,10-dione
compounds. Compound 21b is the first compound, thus far, that shows nano molar activity against
leukemia and low micro molar activity against solid tumor cells and yet lacks an -halo moiety in
its structure. Thus the azidoethoxy groups at the 1 and 8 positions are important for the cytotoxic
effects of this pair.
1.4.6 Evaluation of 1,8-bis(allyloxy)anthracene-9,10-dione compounds
The attachment of allyl groups at the 1 and 8 positions were done in order to further explore
the effects of a unsaturated functional groupson the anthraquinone analogs. None of the three
developed compounds showed significant activity against either solid or leukemia cancer cells that
were tested (Table 1.4.6). In fact all compounds showed poor solubility; thus it is clear that this
class of compounds will not lead to a pharmaceutically relevant agent.
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Table 1.6 IC50 values of synthesized 1,8-bis(allyloxy)anthracene-9,10-dione analogs
* All values reported are in µM concentration and determined via MTT assay
Compound

BW-AQ ID

Hela

KB

Cos7

T98G

Molt4

K562

EU1

23a

161

23b

163

>20

>20

>20

>50

>10

>10

>10

>50

14.7

>50

>50

>25

>25

>25

23c

164

>50

>50

>50

>50

>25

>25

>25

1.4.7 Evaluation of 1,8-diisobutoxyanthracene-9,10-dione compounds
Based on the positive data obtained from the classes of compounds containing
ethyloxy and propyloxy substituents at the 1 and 8 positions of the anthraquinone core, the
biological activity of compounds containing branched aliphatic chains was evaluated. Compounds
25a and 25b show potency against Molt4 and EU1; however they do not show significant activity
against all other cell lines (Table 1.4.7). The observed activity of compounds 25a and 25b can be
related to the fact that both of these compounds have an α-halo acetamide as substituent at position
3.
Table 1.7 IC50 values of synthesized 1,8-diisobutoxyanthracene-9,10-dione analogs
* All values reported are in µM concentration and determined via MTT assay
Compound

BW-AQ ID

Hela

KB

Cos7

T98G

Molt4

K562

EU1

25a

177

4.3

5.2

1.7

11

0.2-1.1

2.8

0.52

25b

183

4.0

6.3

3.6

17

0.93

3.8

1.3

25c

176

7.2

5.6

17

>50

>25

15

18

25d

178

>50

>50

>50

>50

>25

>25

>25

25e

212

>13

ND

>13

ND

>13

ND

>13

None of the other three compounds (25c-25e) exhibit potency against either leukemia or
solid tumor cells. This again suggests that in the case of aliphatic substitutions at the 1 and 8
positions, the presence of an α-halo acetamide at position 3 is important for the activity of these
compounds.
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1.4.8 Evaluation of 1,8-bis(isopentyloxy)anthracene-9,10-dione compounds
Another seven compounds containing branched chain aliphatic substituents at the 1 and 8
positions were tested against various cell lines. Only two (27a and 27b) of the compounds that
belong to the 1,8-bis(isopentyloxy)anthracene-9,10-dione analogs showed some activity against
Molt4 and EU1 cells (Table 1.4.8). None of the other compounds showed significant activity
against any of the seven cell lines tested. Compounds 27a and 27b were ineffective against solid
tumor cells.
Table 1.8 IC50 values of synthesized 1,8-bis(isopentyloxy)anthracene-9,10-dione analogs
* All values reported are in µM concentration and determined via MTT assay
Compound

BW-AQ ID

Hela

KB

Cos7

T98G

Molt4

K562

EU1

27a

181

>50

>50

1.9

>50

0.2-1.0

ND

0.70

27b

180

17

13

2.0

>50

0.63

7.3

0.68

27c

209

23

ND

ND

ND

11

ND

>13

27d

211

>25

ND

ND

ND

19

ND

>13

27e

210

>25

ND

ND

ND

>25

ND

>13

27f

216

10

ND

ND

ND

3.0

ND

8.8

27g

217

>12.3

ND

>13

ND

ND

ND

>13

The obtained data suggests that extension and branching of the side chains at the 1 and 8
positions of the anthraquinone core do not improve activity. The presence of α-halo acetamide at
position 3 appears to be important for activity against some leukemia cell lines, but has no effect
against solid cancer cells.
1.4.9 Evaluation of additional anthracene-9,10-dione analogs
The final group of compounds described in this work was developed with the idea
of testing the effects of methoxyethyl (29) and methoxypropanyl (31) functional groups at
positions 1 and 8. In addition the lack of functional groups (compound 33) at the 1 and 8 positions
was also studied. All of the tested compounds showed effects against Mol4 and EU1 cells (Table
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1.4.9). The developed compounds showed activity in the low micro molar range against Cos7 cell
line.
Table 1.9 IC50 values of synthesized anthracene-9,10-dione analogs
* All values reported are in µM concentration and determined via MTT assay
Compound

BW-AQ ID

Hela

KB

Cos7

T98G

Molt4

K562

EU1

29

202

>13

ND

1.5

ND

<3.3

ND

2.1

31

205

>13

ND

1.9

ND

<3.3

ND

<0.78

33

131

2.6

5.6

1.4

ND

0.26

1.42

0.68

The three compounds (29, 31, 33) have one similar structural feature in addition to the
anthraquinone core: the α-halo acetamide substituent at position 3. Although further investigation
of the activity of potential analogs of compounds 29, 31, and 33 is needed to draw specific
conclusions, it is fairly clear that the α-halo acetamide is the key moiety responsible for the
selective activity against leukemia cells.
1.4.10 Summary/Discussions
All tested compounds were separated into nine classes based on structural features
of the core and the substituents present at the 1 and 8 positions of the core anthraquinone structure.
The compounds were tested against seven cell lines; three leukemia and four solid tumor cells.
The majority of the active analogs have the α-halo acetamide moiety at position 3 of the core. It
is safe to conclude that this structural feature is of great importance for the activity of these
anthraquinones. In addition these compounds appear to have preferential cytotoxic effect over
leukemia cells. Among all the compounds disclosed, nine compounds stand out in terms of activity
against more than two cell lines; 14a, 14b, 14c, 16c, 16j, 18b, 21a, 21b, and 33. Only two (16j
and 21b) out of these nine compounds do not contain the α-halo acetamide functionality at position
3. The importance of this lies beneath the reactivity of the α-halo acetamide group. A halide in an
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alpha position to a carbonyl group is an excellent alkylating agent and highly susceptible to
nucleophilic attacks. Thus, the presence of this functional group in a drug candidate is not desirable
as it can easily undergo substitution reaction under physiological conditions with some of the
naturally occurring nucleophiles (thiols, free amines, etc). The reactivity of these α-halo
acetamides is also affected by the halogen itself. A “Cl” substituent will be much less likely to
undergo alkylation reaction at physiological conditions compared to “Br” or “I”. Therefore, the
presence of a reactive functional groups from this type (“Br” or “I”) may lead to non-specific
bindings and undesired side reactions in vivo. This can lead to serious side effects of the drug
candidates as well. Nevertheless, marketed compounds like Nasonex and Asmanex contain highly
reactive functionalities such as α-chloro ketones or/and Michael acceptors, yet they lack significant
side effects and have been approved for clinical use. All these issues need to be considered
seriously and the compounds should be carefully evaluated before further development. With this
in mind the two compounds (16j and 21b) are good candidates for further evaluation.
In conclusion, the attachment of aliphatic side chains at position 1 and 8 of the core
compound appeared as a successful strategy in the development of active anticancer agents. The
attachment of benzyl and azido ethyl groups at the 1 and 8 positions resulted in some of the most
potent compounds described in this work. All of the developed anthraquinone analogs that showed
activity have a common structural feature; the α-halo acetamide functionality at position 3.

1.4.11 Experimental section
HeLa and Cos7 cell lines were cultured in DMEM medium and T98G and KB cell lines in
MEM medium. All other cell lines (Molt4, K562, EU1) were cultured in RPMI-1640 medium. The
medium was supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. For the
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cytotoxicity assays, cells were seeded into 96-well plate (3.0 × 104 for all solid state cell lines and
3 × 105 for all leukemia cell lines in 100 µL per well). The compounds were dissolved in DMSO
to make 10 mM stock solutions. The stock solution was diluted using DMSO to various
concentrations. 1µL of each concentration was diluted 100 fold with medium into the well plate
keeping the DMSO < 1% throughout the experiment. Addition of compounds was performed after
adherent cells reached 40-50% confluence. After incubation for 24 h. at 37

o

C in humidified

atmosphere with 5 % CO2, 10 µL of MTT (5 mg/mL in PBS) was added. After addition of MTT
the cells were incubated for another 4 h. The culture medium was then aspirated and 100 µL of
DMSO was added to each well. The 96-well plate was read by microarray reader for optical density
at 490 nm. All tests were performed in triplicates and IC50 values were estimated from the averaged
response curves.
1.5

Solubility, formulation, and stability studies of selected anthraquinone analogs
After careful evaluation of the synthesized anthraquinone compounds (section 1.3

and 1.4), a group of potent analogs was selected and their physicochemical properties were further
evaluated. As previously mentioned, this class of anthraquinone analogs exhibits poor water
solubility. In order to identify the most water-soluble compounds and evaluate their potential to
become drug candidates, water solubility studies were performed (section 1.5.1). To address the
solubility issues with the active compounds, various non-toxic formulations were developed.
(section 1.5.2). Another potential issues with this class of compounds is the fact that the majority
of the active rhein analogs contain an α-halo acetamide, which i) is a reactive functional group that
may undergo substitution reactions and ii) may affect the compounds’ stability under physiological
conditions. Thus the stability of selected group of active rhein analogs was evaluated under various
conditions (section 1.5.3).
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1.5.1 Solubility evaluation of potent anthraquinone analogs
The identification of active and non-toxic agents is merely the beginning of the
drug discovery and development process. In order to become a drug candidate, every active
compound should possess favorable physicochemical properties; i.e. good water solubility, blood
brain barrier permeability, and of course favorable absorption, distribution, metabolism, and
excretion (ADME). One of the major hurdles in the drug development process is the ability to
develop water-soluble compounds. Poorly water-soluble compounds carry issues with drug
delivery, targeting, bioavailability etc. In the herein described study we aimed to identify potential
anthraquinone drug candidates through the evaluation of their physicochemical properties.
Two major solubility determination techniques stand out in the literature; the saturation
shake-flask method and turbidimetric method.1,2 Before the introduction of these two methods, the
commonly perceived definition of solubility should be introduced. When discussing solubility two
important terms need to be considered: kinetic solubility and thermodynamic/ equilibrium
solubility. The term kinetic solubility deals with the concentration of a compound at which
precipitation appears in solution after predetermined amount of time. Thermodynamic/
equilibrium solubility refers to the concentration of a compound under saturation conditions in the
presence of excess solid, where the solid and solution are at equilibrium. These two terms are very
important as the turbidimetric method measures kinetic solubility and the shake flask method
measures thermodynamic solubility. While the turbidimetric method can be done on a high
throughput scale and requires minimum amount of compound, it cannot give exact solubility
values, but an approximation. Nevertheless this method is widely used in pharmaceutical settings
and is very suitable for early stage drug development studies. The shake-flask method can give a
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precise solubility reading, however, it is time-consuming and requires large amounts of compound
samples.
The basic idea behind the turbidimetric solubility assay is to dissolve a given compound in
organic solvent such as DMSO. The stock solution is then aliquoted into a buffer and the turbidity
at different concentrations is read typically by a UV instrument at 620 nm. The solubility can be
estimated by a plot of turbidity vs concentration. Although a very rapid method, it lacks precision
of the estimation and can give large solubility variations. The shake-flask method on the other
hand can give relatively quantitative value of the thermodynamic solubility of a given compound
as the data is obtained normally by HPLC. The general principle behind this method is that excess
amount of a compound is saturated in a buffer and shaken in a closed vessel for 24 hours. Then
the suspension is filtered off and the solution is analyzed via HPLC. Additional downside of this
methodology is that basic or acidic compounds, which in excess can alter the pH of the buffer,
cannot be tested. Of course there are more compound specific solubility determination methods
such as potentiometric titrations, pH-solubility profiling, and salt solubility studies.2-4 In addition
there are computational methods that can predict the solubility of given class of compounds,
however, these methods will not be discussed in detail in this work.5
In an attempt to determine the solubility of the developed anthraquinone compounds,
dynamic light scattering (DLS) instrumentation was used. Since, precise solubility data cannot be
obtained from the UV turbidometric assay, we attempted to pair this method with a particle size
analyzer instead. Dynamic light scattering can give precise information of particles size and
homogeneity in solution. The improved precision in the solubility determination when using DLS
technique comes from the fact that DLS uses laser with a beam size of approximately 60 nm (HeNe laser). As the laser beam goes through the sample it “hits” the particles thus scattering the light.
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The scattered light is detected and analyzed. Because particles are not static in solution, DLS
detects the Brownian motion of the particles and translates it to size; larger particles have slower
Brownian motion than smaller particles. A correlation software compares the detected particle
sizes, as a function of time, and establishes a dispersity curve. The function gives information of
the dispersity of the various particles in solution. This allows us to track the specific concentration
at which the compounds start precipitating out of solution.
The ability of the instrument to read the particle dispersity in solution and the particle size
allows for improved estimation of the compounds’ solubility. The selected compounds were
dissolved in an array of concentrations from 0 µM to 150 µM in phosphate buffer (PBS), pH 7.4
at room temperature from 10 mM stock solutions in DMSO. The final concentration of DMSO in
the aliquoted solutions is 1%. The solutions are then allowed to sit at room temperature overnight
to obtain thermodynamic equilibrium and then tested for precipitations. The solubility of the
compounds is then determined to be the point of an exponential curve that monodisperse particles
were observed. The curve indicates the uniform particle formation at the tested concentration. The
obtained data can be seen in Table 1.5.1. The utilized protocol requires overnight equilibration of
the solutions and allows for the measurement of thermodynamic solubility without the use of large
quantities of the active compounds. Precipitations are visually observed for some compounds at
high concentrations and these samples are not analyzed, as the precipitation is obvious.
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Table 1.10 Physicochemical characteristics of selected rhein analogs
Compounds
BW-AQ-101
BW-AQ-112
BW-AQ-113
BW-AQ-114
BW-AQ-115
BW-AQ-116
BW-AQ-117
BW-AQ-118
BW-AQ-124
BW-AQ-126
BW-AQ-128
BW-AQ-129
BW-AQ-131
BW-AQ-140

MW [g/mol]
331.70
369.76
387.81
432.27
479.27
415.87
460.32
507.32
469.84
511.96
489.15
603.41
299.71
476.41

Solubility
[μM]
3
20
30
100
30
20
100
5
10
1
1
1
30
10

Log P

2.28
2.79
3.69
3.81
4.05
4.38
4.57
4.81
3.2
5.77
5.66
6.21
2.92
3.15

Log S
-3.65
-4.42
-4.74
-5.08
-4.81
-5.26
-5.49
-5.3
-3.98
-6.7
-6.34
-6.51
-4.5
-3.49

H-bond
donors
3
1
1
1
1
1
1
1
1
1
1
1
1
1

H-bond
acceptors
6
6
6
6
6
6
6
6
12
6
6
6
4
15

Some of the most active compounds show extremely poor solubility; full solubilization
achieved in the ranges from 1 µM to 3 µM (Table 1.5.1). However, poor solubility can be overcome
by the development of proper formulation. In order to fully evaluate the potential of a compound
to become a drug candidate, other physicochemical properties need to be considered. In the process
of selecting potent compounds at early drug development stage, the evaluation of the basic
physicochemical parameter is of extreme importance. Thus, the selected anthraquinone analogs
were evaluated against the Lipinski’s “rule of five”. The partition coefficient (log P) and the
solubility coefficient (log S) were calculated using VCCLAB online software.6 These coefficients
predict the absorption properties of the drug candidates. Additional factor that affects the
permeability properties of the drugs is the number of hydrogen bond donors and acceptors in the
molecule. Too many hydrogen bond donors/acceptors negatively affects membrane permeability
of the compound. Thus the Lipinski’s rule of five states that “poor absorption or permeation are
more likely when: i) there are more than five hydrogen bond donors, ii) log P is over 5, iii)
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molecular weight of the compound is over 500, iv) there are more than 10 hydrogen bond
acceptors.”5 In addition a favorable log S value below zero and greater than -4 entails good
permeability.
The derived parameters disclosed in Table 1.5.1 show that the majority of compounds fall
within the Lipinski’s rule of five, and solely based on this analysis can be considered as drug
candidates. However, as previously discussed the presence of reactive functionalities like α-iodo
acetamide or α-bromo acetamide is undesirable in a potential drug candidate. Therefore,
compounds BW-AQ-115, BW-AQ-118, BW-AQ-129 should not be considered for further
evaluation. Although BW-AQ-101 has poor solubility all its predicted physiochemical parameters
fit within the Lipinski’s rule of five. Development of proper drug delivery system/ formulation can
solve the solubility issue for this compound, so it can be considered for further evaluations.
Compounds BW-AQ-113 and BW-AQ-131 also appear as good drug candidates based on the
examined physicochemical properties. Compound BW-AQ-124 has 12 hydrogen bond acceptors
thus falling out of the Lipnski’s rule. However, this calculation is based on the number of Ns and
Os present in the molecule. The compound has two azido groups and it will be unreasonable to
consider them as six hydrogen acceptors. Therefore, compound BW-AQ-124 can be considered
an exception and a potential drug candidate. Formulations for all compounds that exhibit
reasonable physicochemical parameters were developed and discussed in section 1.5.2 below.
1.5.1.1 Experimental Section
All solvents used in this experiment were purchased from Sigma-Aldrich; and the
nylon filters were purchased form Fisher Scientific. The solubility was determined using BIC 90
Plus Particle Size Analyzer. The DMSO and PBS used in the experiments were filtered through
0.22 µm nylon filters. All compounds were dissolved in pre-filtered DMSO giving a 10 mM stock
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solution. All tubes, vials and cuvettes were rinsed with nano-pure filtered water and dried under
reduced pressure to ensure that no dust particles are present in them. Various concentrations from
0 µM to 150 µM were prepared through dilution of the stock solution into the filtered buffer. The
total DMSO amount per sample was kept at 1%. The prepared samples were allowed to sit at room
temperature overnight then the solubility was determined via a particle size analyzer instrument.
1.5.2 Formulation of selected anthraquinone analogs
One of the more direct ways to overcome the issues related to compounds with poor
solubility is to develop a formulation that will allow for the compounds to stay in solution. In
various in vitro studies and evaluation techniques, compounds are often dissolved in DMSO and
introduced to the media. This method cannot be utilized in vivo due to intrinsic toxicity issues and
the fact that DMSO is an irritant and should not be allowed to come in contact with live tissue. In
addition, DMSO carries in vitro cytotoxicity, which is the reason why this chemical should be kept
at levels no more than 5% (v/v) during any given set of experiments. An alternative compound
delivery method would be through the use of non-toxic solvents such as isopropanol and ethanol.
However, lipophilic/ nonpolar compounds will not be dissolved in these solvents, thus limiting
their utility. The development of water-soluble pro-drugs and colloidal systems (micelles,
liposomes, nanoparticle, etc.) are other feasible alternatives for compound delivery. However,
these methods require time and sufficient effort in their development and are not useful at the early
drug discovery stage. An efficient method to overcome poor compound solubility and the related
issues is through the development of pharmaceutical formulation. A commonly used solubilization
method in the cancer drug discovery process is the development of formulation using surfactants,
i.e. Tween 80, Solutol, and Cremophor.7 The utilization of various formulations aims to prepare
the compounds for i.v. (intravenous) or i.p. (intraperitoneal) administration. With the use of
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isopropanol and ethanol as co-solvents and the three surfactants (Tween 80, Solutol, and
Cremophor), various formulations were developed in an attempt to overcome the issues related
with the poorly soluble compounds disclosed in this work.
The formulation studies were designed so that the developed solvent/surfactant
combinations allow for the delivery of the highest possible dose at the lowest possible volume.
This experimental design allows for the development of a delivery system without knowing the
therapeutic or the maximum tolerated doses of the tested compounds. The use of clinically
approved formulation components stands for the safety of the developed methodology.
Formulation for six of the active compounds was developed (Tables 1.1.52-1.57).
Table 1.11 Formulation of BW-AQ-101

1

Amount of
compound
(mg)
1.075

Solvent
Combination
(1/4) (v/v)
Solutol/ Ethanol

Total
Volume
(µL)
700

Final
Concentration
(mM)
4.6

2

1.02

700

4.4

3

1.035

Cremophor/
Ethanol
Tween 80/
Ethanol

Results
48 h. at
6 x PBS
Room
dilution
Temp
Solubilized
Minor
Precipitated
after 1.5 h.
Solubilized
Solubilized

700

4.5

Solubilized

4

0.966

400

7.3

Solubilized

5

1.079

400

8.1

Solubilized

6

1.2

400

9.1

Solubilized

7

1.118

Cremophor/
Isopropanol
Soluto/
Isopropanol
Tween 80/
Isopropanol
Isopropanol

800

4.2

Solubilized

Entry

Minor
Precipitated
after 1.5 h.
Precipitated
after 40 min.
Precipitated
after 20 min.
Precipitated
after 10 min.
Precipitated

Compound BW-AQ-101 showed to be completely soluble below 3 µM in PBS. In order to
improve its solubility, seven formulation conditions were examined (Table 1.5.2). The compound
was solubilized completely at various surfactant/solvent combinations. However, after six fold
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dilution with PBS buffer the compound either precipitated immediately or within one and a half
hours in six out of the seven tested conditions (Table 1.5.2). The combination of cremophor and
ethanol in one to four ratio (v/v) was the only one that did not result precipitation after dilution
with buffer.
Table 1.12 Formulation of BW-AQ-112

Entry

1
2

Amount of
compound
(mg)
1.092
1.067

3

1.13

4

1.141

5

1.094

6

1.028

7

1.083

Solvent
Combination
(1/4) (v/v)
Solutol/ Ethanol
Cremophor/
Ethanol
Tween 80/
Ethanol
Cremophor/
Isopropanol
Solutol
/Isopropanol
Tween 80/
Isopropanol
Isopropanol

Results
24 h. at
6 x PBS
Room
dilution
Temp
Precipitated
Precipitated
-

Total
Volume
(µL)
1100
1300

Final
Concentration
(mM)
2.8
2.3

1100

2.9

Precipitated

-

1000

3.2

Solubilized

Solubilized

1000

3

Solubilized

Solubilized

1000

2.9

Solubilized

Solubilized

1200

2.5

Solubilized

Precipitated
after 20 min.

Compound BW-AQ-112 showed significantly better solubility (20 µM) compared to BWAQ-101 (Table 1.5.1). Three out of the seven formulation combinations showed to be successful
in keeping BW-AQ-112 in solution (Table 1.5.3). Combination of all tested surfactants with
isopropanol appeared to be a successful formulation for compound BW-AQ-112. On the other
hand, the use of ethanol did not show any positive effects on BW-AQ-112.
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Table 1.13 Formulation of BW-AQ-113

Entry

1

Amount of
compound
(mg)
0.885

2

1.296

3

1.242

4

1.425

5

1.195

6

1.124

7

1.162

Solvent
Combination
(1/4) (v/v)
Solutol/
Ethanol
Cremophor/
Ethanol
Tween 80/
Ethanol
Solutol/
Isopropanol
Cremophor/
Isopropanol
Tween 80/
Isopropanol
Isopropanol

Results
48 h. at
6 x PBS
Room
dilution
Temp
Solubilized Solubilized

Total
Volume
(µL)
600

Final
Concentration
(mM)
3.8

600

5.6

Solubilized

Solubilized

600

5.3

Solubilized

Solubilized

400

9.2

Solubilized

400

7.7

Solubilized

400

7.2

Solubilized

600

5

Solubilized

Precipitated
after 2 h.
Precipitated
after 2 h.
Precipitated
after 2 h.
Precipitated

Interestingly compound BW-AQ-113, which is structurally very similar to BW-AQ-112,
was more favorable towards surfactant combinations with ethanol and not isopropanol. Although
BW-AQ-113 stayed in solution for two hours after the six fold dilution in PBS, the combinations
of ethanol with cremophor, tween 80, and solutol respectively allowed it to stay in solution for a
longer period of time. Based on the absorption, distribution, metabolism and excretion profile of a
given compound, formulation that allows for the compound to stay in solution between two and
three hours can be useful for drug delivery. The ADME profiles of the developed compounds
remain to be determined.
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Table 1.14 Formulation of BW-AQ-124

Entry

1

Amount of
compound
(mg)
1.115

Solvent
Combination
(1/4) (v/v)
Solutol/ Ethanol

Total
Volume
(µL)
500

2

0.94

500

3

1.343

4

1.064

5

0.975

6

1.205

7

1.04

Cremophor/
Ethanol
Tween 80/
Ethanol
Cremophor/
Isopropanol
Solutol/
Isopropanol
Tween 80/
Isopropanol
Isopropanol

Results
Final
24 h. at
6 x PBS
Concentration
Room
dilution
(mM)
Temp
4.7
Solubilized Precipitated
after 3 h.
4
Solubilized Solubilized

600

4.8

400

5.7

400

5.2

400

6.4

600

3.7

Solubilized Precipitated
after 3 h.
Solubilized Precipitated
after 3 h.
Solubilized Solubilized
Solubilized Precipitated
after 3 h.
Solubilized Precipitated
after 0 min.

A successful formulation of compound BW-AQ-124 was achieved through the
combination of solutol and isopropanol in ¼ (v/v) ratio. The combination did not result in any
precipitation after dilution with PBS (Table 1.5.5). All other tested combinations resulted at initial
solubilization. However, upon dilution, the compound precipitated out after three hours, or in the
case of the sole use of isopropanol immediately. These combinations can prove to be
therapeutically useful as precipitation after three hours occurred only at fairly high concentrations:
1.2 mM for Entry 6 (Table 1.5.5).
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Table 1.15 Formulation of BW-AQ-126

Entry

1
2

Amount of
compound
(mg)
1.194
1.085

3

1.241

4

1.232

5

1.235

6

1.184

7

1.215

Solvent
Combination (1/4)
(v/v)
Solutol/ Ethanol
Cremophor/
Ethanol
Tween 80/
Ethanol
Cremophor/
Isopropanol
Solutol/
Isopropanol
Tween 80/
Isopropanol
Isopropanol

Total
Volume
(µL)
1100
1300

Results
Final
24 h. at
6 x PBS
Concentration
Room
dilution
(mM)
Temp
2.1
Precipitated
1.6
Solubilized Solubilized

1100

2.2

Precipitated

-

600

4

Precipitated

-

800

3

Solubilized

Solubilized

600

3.8

Precipitated

-

1000

2.4

Precipitated

-

Although highly potent, compound BW-AQ-126 showed poor solubility (Table 1.5.1).
Formulation development for this compound was proven difficult and only the combination of
cremophor/ethanol and solutol/isopropanol resulted in complete solubilization at fairly low
concentrations (Table 1.5.6). All other tested combinations gave immediate precipitation upon
PBS dilution.
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Table 1.16 Formulation of BW-AQ-131
Results
Entry

1
2

Amount of
compound
(mg)
1.137
1.25

3

1.043

4

1.15

5

1.102

6

1.054

7

1.056

Solvent
Combination
(1/4) (v/v)
Solutol/ Ethanol
Cremophor/
Ethanol
Tween 80/
Ethanol
Cremophor/
Isopropanol
Soluto/
Isopropanol
Tween 80/
Isopropanol
Isopropanol

Total
Volume
(µL)
1000
900

Final
Concentration
(mM)
3.7
4.6

24 h. at
Room Temp

6 x PBS
dilution

Solubilized
Solubilized

Solubilized
Solubilized

800

4.4

Solubilized

Solubilized

600

6.4

Solubilized

Solubilized

800

4.6

Solubilized

Solubilized

600

5.8

Solubilized

Solubilized

800

4.4

Precipitated

-

Because BW-AQ-131 showed fairly good solubility in preliminary experiments (Table
1.5.1), it was not a surprise that all of the tested formulation combinations were successful (Table
1.5.7). At some instances solubilization was achieved at fairly high concentrations: entries 4 and
6 (Table 1.5.7). Not surprisingly, the sole use of isopropanol was not successful.
The majority of the rhein analogs exhibit poor water solubility. The development of a
successful formulation allows for the active compounds to be further evaluated and potentially
considered as drug candidates. After physicochemical and structure-activity evaluation of the
synthesized analogs, various formulations for six of the most promising compounds were
developed. These formulations can be used for further evaluation of the compounds’ stability and
in vivo studies.
1.5.2.1 Experimental Section
General procedure for the formulation development
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All surfactants, Cremophor RH 40, Kholliohor HS 15 (solutol) and Tween 80, were
purchased from Sigma Aldrich. All solutions were prepared by suspending the reported amount
of compound in a surfactant (Cremophor RH 40, Kholliohor HS 15 (Solutol) and Tween 80)/
solvent (ethanol, isopropanol) mixture, heating it for approximately one minute at 40 °C, followed
by vortexing for approximately 15 seconds and sonication for one minute. 100 µL increments from
the solvent/surfactant mixture were added repeatedly until the compound was fully solubilized.
The fully solubilized samples were allowed to sit at room temperature for 24 or 48 hours at room
temperature. 200 µL of each sample were then added to 1 mL of PBS buffer at room temperature.
The solutions were thoroughly mixed and allowed to sit at room temperature. The solutions were
examined for precipitation formation every 10 to 15 minutes.

1.5.3 Stability studies of selected anthraquinone analogs
The stability evaluation of a selected group of compounds was done in three different
experiments aiming to answer the following questions: i) are the compounds stable at physiological
conditions, ii) are the compounds stable in the formulation solutions and iii) what would be the
ideal storage conditions for the compounds. In order to answer these questions, three sets of
experiments were designed. The first one consists of dissolving the compounds in the abovedescribed formulations followed by six times dilution in PBS (pH = 7.4) and incubation at 37 ˚C
for 24 hours. Samples were periodically injected into an HPLC instrument and the real-time
decomposition of the compound was monitored. Compounds BW-AQ-112, BW-AQ-124, and
BW-AQ-131 appeared to be relatively stable (Table 1.5.8). The compounds showed about 5.5 %,
4.9 %, and 0.8 % respective decomposition at simulated physiological conditions. The lead
compound BW-AQ-101 showed about 8.3 % decomposition at the same condition after 24 hours,
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however, only 1.6 % after two hours incubation. These results are indicative for the general
stability of the structures and their therapeutic potential. Unfortunately compound BW-AQ-126
showed significant decomposition of over 38 % (Table 1.5.8) at close to physiological conditions.
The lack of stability if this compound eliminates it from further consideration for a drug candidate.
Nevertheless, the other four compounds that were tested showed good stability and promise to be
taken for further pre-clinical evaluations.
Table 1.17 Stability studies in solution at 37 ˚C
* 0 min. readings indicate the initial purity of the compounds.

0 min.
120 min.
24 h.

BW-AQ-101
97.2 %
95.6 %
88.9 %

BW-AQ-112
98.6 %
98.4 %
93.0 %

BW-AQ-124
99.1 %
97.6 %
94.2 %

BW-AQ-131
87.7 %
87.2 %
86.9 %

BW-AQ-126
95.3 %
91.2 %
56.4 %

The purpose of the second stability study that was performed was to evaluate the storage
capability of the active compounds in the established formulation solutions for an extended period
of time (up to eight weeks). This long-term stability test was done on BW-AQ-101, BW-AQ-112,
BW-AQ-113, and BW-AQ-124 based on their activities and physicochemical properties. These
compounds were dissolved in the most appropriate formulations (discussed in section 1.5.2) and
stored under three different conditions: room temperature, 4 ˚C, and -20 ˚C. None of the
compounds exhibited significant decomposition at -20 ˚C after eight weeks (data shown in the
appendix). Compounds BW-AQ-101 and BW-AQ-124 showed about 1 % and 2 % decomposition
at 4 ˚C and the solutions of BW-AQ-112, BW-AQ-113 appeared completely stable at this
temperature. Eight-week solution storage at room temperature resulted in minor decomposition of
all compounds. While BW-AQ-101 and BW-AQ-112 showed only 3 % and 4 % decomposition,
compounds BW-AQ-124 and BW-AQ-113 showed 9 % and 7 % decomposition respectively. The
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eight-week study revealed that solution storage may be suitable for some of the rhein analogs at
low temperatures (4 ˚C, and -20 ˚C), but cannot be utilized at room temperature.
The third storage stability evaluation of these compounds was done at solid state and under
the following temperature conditions: room temperature, 4 ˚C, and -20 ˚C. The compounds showed
no significant decomposition after 17 weeks storage in a solid form at 4 ˚C, and -20 ˚C (data
presented in the appendix). Compounds BW-AQ-101 and BW-AQ-124 showed about 1 %
decomposition when stored in a solid form at room temperature. Furthermore, BW-AQ-112 and
BW-AQ-113 showed no significant evidence for decomposition when stored as solids at room
temperature.
The above-described stability studies show that the active rhein analogs are
relatively stable compounds and can be stored as solids for prolonged periods of time. Ideal storage
conditions will require low temperatures (4 ˚C or -20 ˚C). Most compounds appear tolerable to
storage at room temperature as well. Short-term storage in a solution form at -20 ˚C are plausible
for these compounds, however, long term (over 8 weeks) solution storage at these conditions is
not recommended.
1.5.3.1 Experimental section
All solutions for the stability determination of compounds BW-AQ-101 and BW-AQ-124
were prepared using ethanol/cremophor 4/1 (v/v) ration. All solutions for the stability
determination

of

compounds

BW-AQ-112

and

BW-AQ-113

were

prepared

using

isopropanl/solutol 4/1 (v/v) ration. 1 mM stock solutions of each compound were prepared in the
appropriate formulation. 30-fold dilution in PBS was done to achieve 30 µM final concentration
samples of the tested compounds. The prepared samples were then injected into the HPLC
(Shimadzu UFLC SIL-20AHT) with Waters SinFire C18, 3.5 µm, 4.6 × 100 mm column. The
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mobile phase was either acetonitrile/water (0.25 % TFA) (50/50, v/v) for BW-AQ-101 and BWAQ-124, or acetonitrile/water (0.25 % TFA) (40/60, v/v) for BW-AQ-112 and BW-AQ-113 with
flow rate of 1 mL/ min. The data was collected at 250 nm with threshold 50 and minimum
detectable are of 7000 (< 1 %).
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1.6

Conclusions
Nine distinct groups of rhein analogs, were synthesized as potential anticancer agents. In

vitro and in silico mechanistic evaluations of the lead compound BW-AQ-101 suggest that these
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classes of anthraquinone compounds could potentially be binding to MDM2, inhibiting its
interactions with MDM4, thus upregulating the tumor suppressor p53. Further mechanistic studies
of the active compounds are needed to support the consistency of this hypothesis within the
different classes of developed anthraquinones. The activity of all compounds were tested against
seven different cancer cell lines, including leaukemia and solid state tumor cells. A number of
active compounds exhibiting mid to low nanomolar activity were identified. Majority of the
developed compounds exhibited selectivity towards the leukemia cell lines. The physiochemical
properties of selected group of compounds were studied in an attempt to evaluate their potential to
become drug candidates. The majority these compounds exhibit poor water solubility, thus various
non-toxic formulations were developed to overcome this drawback and to allow for the further
evaluation of these active anthraquinones.
2
2.1

A NEW TYPE OF NEIGHBORING GROUP ASSISTED CLICK REACTIONS
Introduction
Click chemistry describes reactions that are fast and versatile, require mild

conditions, and achieve high yields after minimum purification effort.1 A number of reactions in
this category has been reported. Some examples are the well-known copper-catalyzed and strain
promoted/copper-free azide-alkyne cycloaddition reactions,2-4 tetrazine and strained alkyne/alkene
Diels-Alder type of reactions,5-7 and the Staudinger–Bertozzi ligation.8 These types of reactions
have found wide-spread utility in a number of applications including bioconjugation, drug
delivery, development of libraries of compounds, materials chemistry, and DNA modifications.912

In many such applications, the ability to undergo a secondary reaction will be very useful.13,14

The idea of orthogonal click-click reactions is also reflected in our earlier effort in tuning reaction
rates for staged labeling.7 A recent and very significant report of protecting strained alkynes with
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Cu(I) also allows for sequential click reactions.15 Incorporation of the azido/alkyne chemistry and
cyanobenzothiazole/1,2-aminothiol chemistry pairs into a single molecule would also allow for
sequential click reactions and thus staged labeling.16-18 Herein, we report a simple system, which
allows for sequential reactions by utilizing a neighboring boronic acid-mediated click cyclization.
The boronic acid functional group can then be used for a secondary modification reaction under
mild conditions. The initial cyclization is very fast, complete within minutes in excellent yields
(up to > 95 %), does not need an external catalyst, and uses mild/inert conditions. The key aspects
of the developed methodology are 1) the reaction is promoted through activation of the aldehyde
by an ortho-positioned boronic acid; 2) the reaction is tolerant of various substituents on the formyl
aromatic ring; and 3) the benzothiazole product carries a boronic acid moiety that can be used as
a handle for further modifications using a large number of well-established conditions.19-25
2.1.1 Click and click: biorthogonal reactions allowing for secondary functionalization
There is a wide array of different types of biorthogonal reactions suitable for
bioconjugation that have been developed and there is a number of outstanding reviews that
thoroughly describe them.1,26-30 Thus this chapter will not focus on the in depth analysis of this
type of chemistry. Herein we describe a brief overview of the utility of sequential biorthogonal
reactions in chemical biology. The combination of the following biorthogonal reactions have been
successfully utilized in the development of sequential dual or multi click systems: coper catalyzed
alkyne-azide conjugations (CuACC), Diels-Alder reactions (DA), strain promoted alkyne-azide
conjugations (SPACC), oxime ligations (OL), thiol promoted Michael additions (TMA), thiol
halogen ligations (THL), thiol-ene reactions (TER), inverse electron demand Diels-Alder reactions
(IEDA), and native chemical ligations (NCL).2,15,31-57 The combinations of these reactions have
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been utilized in dual or multi sequential conjugations and have found various applications in
polymer chemistry and biocompatible ligations.
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Table 2.1 Biorthogonal reactants used in single molecule for sequential “click”
reactions/ conjugations.

Ref: 37
DA –
CuAAC
Surface
immobilizat
ion

Ref: 38, 41
OL – CuAAC
Heteropeptide
conjugation

-

Ref: 38
OL – SPAAC
Protein
conjugation

-

-

Ref: 38, 51
OL–SPAAC
Protein and
sugar
conjugations

Ref: 30, 50, 52
CuAAC –
CuAAC
Two step
synthesis and
fluorophore
conjugations

Ref: 57
IEDA – CuAAC
Fluorophore
conjugation

-

-

-

Ref: 31, 32, 34
CuAAC – TER
Peptide
crosslink.

-

-

-

-

-

Ref: 41
TMA – IEDA
TMA – SPAAC
Protein-drug
conjugation

-

-

-

-

-

Ref: 38
TMA – SPAAC
Targeting
conjugation

-

-

-

-

-

-

-

-

-

-

-

-

Ref: 31, 32, 34
SPAAC – TER
Peptide
crosslink

-

Ref: 41
OL – TMA
cRGD
conjugation

-

-

Ref: 38
IED – TMA
Drug conjugation

-

-

Ref: 41
OL – THL
cRGD
conjugation

-

-

-

-

-

-

-

Ref: 34
NCL – CuAAC
Glucose
conjugation

-

-

-

-

Ref: 15, 40
SPAAC –
CUAAC
Fluorophore
conjugation
Ref: 34
NCL – CuAAC
Glucose
conjugation
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2.1.2 Dual orthogonal conjugations
Click chemistry carries the huge advantage of reaction selectivity. The reactions
occur only between specific click pairs, thus allowing for multi-functionality conjugations to occur
in a one pot fashion. This strategy could be utilized for various biologically relevant conjugations
such as protein labelling, protein – carbohydrate conjugations, protein – protein conjugations,
DNA conjugations etc. Table 2.1 summarizes some biorthogonal functionalities that have been
incorporated in a single molecule and recently used for sequential conjugation reactions. There is
one major concern that needs to be kept in mind when designing a double click labelled reagents:
reactions should not be possible between the two click tags or their corresponding reaction
partners. Hosoya’s and Koning’s groups have developed methodologies where two alkyne
functionalities in a single molecule can be sequentially reacted in a copper catalyzed fashion with
azides.15,50 These methodologies, however, require either alkyne protection-deprotection step.
Koning and co-workers utilized triisopropylsilyl ether (TIPS) alkyne protection to achieve two
steps sequential biorthogonal ligation.50 Hosoya utilized (MeCN)CuBF4 as a “protecting” ligand
for strained cyclooctynes allowing for the functionalization of the terminal alkyne in the same
molecule.15 These two examples show that sequential click labeling can occur in the presence of
identical functionalities in a single molecule, however, the methodologies are not suitable for
single step bioconjugations.
An excellent example of the proper selection of click pairs that allow for one pot
bioconjugation was presented by Kent’s group.33 The one pot conjugation of two peptides followed
immediately by ligation with azido-labelled GalNac was achieved in up to 95 % yields.33 One of
the peptides was modified though the installation of a propargyl alkyne, a substrate for a CuAAC
reaction, and a thioester, a potential substrate for NCL. The peptide moieties were conjugated via
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native chemical ligation between a free cysteine of one peptide and the preinstalled thioester of the
other. The alkyne functionalities were then reacted with the azido-labelled GalNac in the presence
of CuSO4.33 One down side of this methodology is the use of toxic copper as a catalyst for the
secondary functionalization. The ideal bioconjugation methodology would consist of a pair of
selective reactants that are safe and do not require addition of potentially toxic catalysts.
The use of stain promoted alkyne-azide conjugation pair or inverse Diels-Alder
tetrazene-alkyne ligation allow for facile reactions without the need for any catalysts. These
ligations are compatible, and have been utilized in sequential manner with thiol-malemide Michael
addition reactions.29,38 In an effort to deliver antibody Fc fragments possessing a C-terminal
selenocysteine residue (Fc-Sec), Burke and co-workers developed folate conjugated molecule
containing malemide functionality on one end and strained cyclooctyne on the other.38 The Fc-Sec
was linked to the malemide through Michael type of addition. Consecutive inverse Diels-Alder
reaction between the developed cyclooctyne – Fc-Sec – folate conjugate and a tetrazene tagged
biotin, resulted in the successful synthesis of this anticancer “warhead”.38 The use of biotin
established the feasibility of the methodology, and it can be replaced with an active cytotoxic agent
for therapeutic purposes. This type of chemistry can also be used not only as a pair couplings, but
also for tri and multi biorthogonal conjugations.
2.1.3 Multiple orthogonal conjugations
As previously exemplified click chemistry has found a number of applications
through sequential ligations. This type of conjugation chemistry has been utilized in chemical
biology in triple or multiple sequential click reactions manner.29 Click chemistry is an excellent
tool for biomolecular modifications in a rapid and safe manner without the need of extensive
purification. The fact that the different types of biothrogonal reactions can be combined in
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sequential manner truly elevates the utility of this technique. The application of more than two
click pairs for bioconjugation purposes can be of significant contribution to the fields of chemical
biology. Table 2.1 shows pairs of click reagents that have been utilized in a single molecule,
however, combinations of these functionalities can exist in multiples rather than just as a pair. For
example Renard and co-workers, incorporated an azide, free thiol, and an oxime in a single
molecule.42 The application of this “tripod” was exemplified through the development of Forster
energy transfer (FRET) cassette and fluorescent renewable immunoassay biochips based on the
trifunctional molecules. One major consideration that has to be taken when developing single
molecule with multiple click functionalities is not just cross reactivity, but also stability and
reactivity sequence of the click pairs. Thiols can be oxidized in the presence of copper, thus the
TMA or THL reaction has to happen before the CuAAC conjugation. Although innovative and
useful, major down side of the developed methodology is that it cannot be accomplished in one
pot manner.
Successful examples of one pot multi-click conjugations were published by Boturyn and
co-workers.40,41 A modified cyclodecapeptide containing multiple free alkyne functionalities, a
free aldehyde, and a malemide was synthesized. In addition, RGD peptides were modified by
installing azido functionalities that react in a CuAAC fashion with the free alkyne groups on the
cyclodecapeptide. Glc-β-ONH2 was reacted with the free aldehyde and a thiol containing nucleic
acid was reacted in Michael addition fashion with the malemide.41 Number of other
cyclodecapeptide analogues containing three different functional groups and three different
conjugation methods were successfully synthesized.41 The key aspect in this work was the correct
choice of click reaction sequence. In the presence of a free aldehyde, the CuAAC reaction was
utilized last, as aldehydes are not stable in the presence of copper. Another interesting aspect of
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this work is not just the three different types of ligations used, but their utility in the presence of a
variety of biomolecular functionalities.41 The use of three different biomolecules (peptides, nucleic
acids, and sugars) in this proof of principle example stands to show how versatile and powerful is
the sequential click conjugation methodology.
2.2

Neighbouring boronic acid promoted click reaction
In the process of searching for new bioorthogonal click reactions, we are interested in

condensations involving aldehydes. It is well known that aldehydes can undergo facile
condensation reactions with compounds that have vicinal nucleophiles. Aldehyde condensations
with aryl diamines, aminobenzothiols, aminophenols, and cysteine have been previously
reported.58-60 For example, aminobenzothiols and aminophenols have been condensed with an
aldehyde in the presence of ZnO nanoparticles60 or in toluene at refluxing temperature; and similar
reactions using cysteine analogs took 6-15 hours to complete at room temperature.58 Recently, Ai
and colleagues reported a facile oxidative condensation of aldehydes with o-phenylenediamine
analogs under acid catalysis.61 This was used for protein conjugation for various applications. Such
reactions are also similar to the cyanobenzothiazole-cysteine condensation reactions.16,17,62 We are
interested in taking advantage of this class of reactions by developing mild and facile conjugation
chemistry that occurs without the use of acid. In doing so, we were interested in exploring the
ability of a boronic acid group to function as a Lewis acid. Our lab has had a long-standing interest
in boronic acid chemistry, exploring its applications in sensing,63-68 catalysis,69,70 drug
design,39,71,72 and imaging73-76 as well as its behavior in mass spectrometry.73 It is well known that
a Lewis base/nucleophile in a 1,5-relationship with an arylboronic acid can donate its lone pair
electrons to the boron open shell. This has been shown with amino and hydroxyl groups. 77-83 Our
lab has also shown that an aldehyde carbonyl oxygen can also engage in such coordination and
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intermolecular aldehyde-boronic acid interactions facilitate aldehyde reduction.70 In addition, it
has been previously reported that o-formyl boronic acids can easily form imines with an amine
under physiological conditions.84 Recently, Gillingham and co-workers reported oxime
condensation with o-formylphenylboronic acid as a linking tool for various chemical biology
applications.85 This could very well be due to the ability for boronic acid to catalyze the reaction
through coordination. Another piece of evidence seems to suggest that the boron atom in an oformyl arylboronic acid tends to stay in the tetrahedral form, suggesting coordination.39 For all
these reasons, we envisioned that a boronic acid group ortho to the aldehyde would be able to
interact with the aldehyde oxygen atom and thus promote its acid-mediated cyclization reaction.
Thus, we examined whether o-formylphenylboronic acid would undergo facile cyclization
reactions with compounds containing vicinal nucleophiles at room temperature (Table 2.2).

Table 2.2 Design of boronic acid facilitated “click” reaction

X

Y

R

Isolated
Yield
(%)

34

NH2

OH

2-B(OH)2

-

35

NH2

NH2

2-B(OH)2

-

36

NH2

SH

2-B(OH)2

85

37

NH2

SH

3-B(OH)2

-

38

NH2

SH

4-B(OH)2

-

39

NH2

SH

H

10

Compound

117

We first tried the reaction with phenylenediamine. Much to our surprise, the reaction
generated a complex mixture. We did not examine the detailed composition of the reaction mixture
because it was clear that this was not going to be a successful click reaction. However, all
indications are that polymerization and cross-linking are possible side reactions. With this in mind,
we were interested in using a structural moiety that has only one of the nucleophiles being
“divalent.” In such a case, polymerization becomes not possible. With this consideration, we
studied the same reaction with o-aminophenol and o-aminobenzothiol. With o-aminophenol, the
cyclization product was not isolated. However, when the reaction was conducted with oaminobenzothiol, it was very fast (Tables 2.2 and 2.3). We hypothesize that the open shell of the
boron atom can serve as Lewis acid and coordinate with the oxygen of the adjacent aldehyde group
in facilitating the first step of the reaction (Scheme 2.1). Furthermore, we reasoned that the boron
atom could also coordinate with the nitrogen of the imine intermediate and thus facilitate the
second step of the reaction as well (Scheme 2.1). In order to examine whether the cyclization was
indeed facilitated by the O-B interaction that afforded the enhanced reactivity of the aldehyde
group, we examined the same reactions using m- and p-formylphenylboronic acids and
benzaldehyde. Not surprisingly, reacting aminobenzothiol and benzaldehyde without the boronic
acid moiety gave no more than 10% of the cyclized product 39. Furthermore, the reaction did not
reach completion even after 24 h. Indeed, when the boronic acid is not positioned ortho to the
aldehyde functional group, no such cyclization happened (Table 2.2). Thus, the presence of a
boronic acid moiety at a position ortho to the aldehyde was crucial to the reaction. The reaction
was also examined using cysteine and homocysteine as naturally occurring molecules with two
adjacent nucleophiles. However, no new spots or consumption of the starting material was
observed by TLC within one hour of stirring at room temperature; consequently, the reaction was
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not further examined. Thus, a system with two adjacent nucleophiles is needed for the click-like
cyclization with o-formyphenylboronic acid to occur.
In order to examine the scope of this reaction, six o-formylbenzylboronic acids, with
various substitutions on the aromatic ring, were examined for their reactivity against three different
o-aminobenzothiols (Table 2.3). The substituents did not seem to have much of an effect on the
reaction outcome. The difference in the isolated yield of the oxidized final products was largely
due to purification issues as TLC indicated full conversion in all reactions. The purification issues
arise from the challenge of separating the cyclized intermediate 63 and the oxidized final product
64 (Scheme 2.1).
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Table 2.3 Scope of the developed cyclization reaction

a

Compound

R1

R2

Conversion (%)

Isolated
Yield (%)

40

4-Mea

Ha

100

95

41

4-OCF3a

Ha

100

97

42

3-OBna

Ha

100

60

43

4-Fa

Ha

100

78

44

3-OMea

Ha

100

95

45

Ha

Clb

100

84

46

4-Mea

Clb

100

75

47

3-OBna

Clb

100

77

48

4-Fa

Clb

100

52

49

3-OMea

Clb

100

74

50

Ha

CF3c

100

56

51

4-Mea

CF3c

100

79

52

4-OCF3a

CF3c

100

56

53

3-OBna

CF3c

100

74

54

4-Fa

CF3c

100

68

55

3-OMea

CF3c

100

94

1 equivalence of the reagent used. b 2 equivalence of the reagent used. c 1.2 equivalence of the reagent used.

It should be noted that the reaction sequence also involves oxidation, which we assume is
air-oxidation because no other reagent was added. The oxidation step appears to be much slower
compared to the click-like cyclization reaction. Addition of one equivalent of DDQ and stirring
for 30 min substantially increased the oxidation rate and isolated yields (data not shown).
However, the use of harsh oxidizing reagents is undesirable and simple overnight air oxidation
resulted in the desired fully oxidized products (example: compounds 40, 41, 44, 55, Table 2.3).
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This is also consistent with the condensation work by others that air-oxidation would drive the
reaction to produce the fully aromatized system.86

Scheme 2.1 Proposed mechanism (R1 = H, Me, OMe, OBn, OCF3, F; R2 = H, Cl, CF3)

To further explore the scope of the reaction, commercially available 2-amino-4(trifluoromethyl)thiophenol and 2-amino- 4-chlorothiophenol were selected. One of these reagents
introduces an electron withdrawing group in the nucleophilic system and the other a slightly
electron donating group that can potentially be used as a functionalization site (Table 2.3,
compounds 45-55).
Although aminobenzothiol has two nucleophilic groups, we propose that imine formations
happens first (59, Scheme 2.1), followed by intramolecular cyclization driven by 1) boronic acid
activated imine (61) and 2) energetically favorable five-membered ring formation (62, Scheme
2.1). As previously mentioned, the presence of a boronic acid at a position ortho- to the aldehyde
not only is crucial for the cyclization reaction, but also provides a handle for further modifications
of the synthesized benzothiazole.
The functionalization of the synthesized boronic acid benzothiazoles can easily be achieved
through a number of coupling methods for various applications.16,17,62 For example, molecules can
be conjugated to the benzothiazole via Suzuki coupling or the Chan – Lam reaction (Scheme 2.2).
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In one such test, we conjugated biotin to the cyclization product benzothiazole. This can be
extremely useful for the evaluation of biologically active compounds in binding studies such as
SPR, QCM, QCM-D, and ELISA studies. Therefore, this new neighboring group assisted
benzaldehyde cyclization reaction can be a versatile tool for various applications.

Scheme 2.2 The use of the boronic acid as a handle for further modifications
2.3

Conclusion
In summary, a facile neighboring group assisted cyclization reaction between

formylphenylboronic acid and amino thiol has been developed. The reaction achieves full
conversion at room temperature without the use of harsh conditions. The benzothiazole products
can easily be modified through various boronic acid-based coupling methodologies for different
applications such as bioconjugation, biolabeling, and fluorescent tagging, thus giving two
sequential facile reactions. In addition, benzothiazole compounds have shown a wide array of
biological activities including anticancer,87-92 anti-inflammation,93 antiviral,94 antidiabetic,95-97
antimicrobial98,99 and anticonvulsant100-103 activities. This class of compounds is perhaps most
useful in the area of diagnostics where it has been clinically used for amyloid fibrils imaging for
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Alzheimer’s disease detection.104-106 More recently, benzothiazole analogs have been utilized in
studying the biologically important and naturally occurring gasotransmitter molecules, hydrogen
sulfide107,108 and carbon monoxide.109 Consequently, the new chemistry described here has a
wealth of synthetic applications as well.
2.4

Experimental section
All reagents and solvents were of reagent grade. All formylphenylboronic acids were

provided by Frontier Scientific Inc.; 2-aminobezothiol and 2-amino-4 (trifluoromethyl)thiophenol
were purchased from Alpha Aeser; and 2-amino-4-chlorothiophenol was purchased from SigmaAldrich. Column chromatography was carried out on flash silica gel (Sorbent 230–400 mesh). TLC
analysis was conducted on silica gel plates (Sorbent Silica G UV254). NMR spectra were recorded
at 400 MHz for 1H and100 MHz for 13C on a Bruker instrument. Chemical shifts (δ values) and
coupling constants (J values) are given in ppm and hertz, respectively, using the appropriate
deuterated solvents as references.
General procedure for the preparation of compounds 36-55:
2-Formylphenylboronic acid (120 mg, 0.8 mmol) was dissolved in 4 ml methanol. 2Aminobenzothiol (100 mg, 85.5 µL, 0.8 mmol) was added and the reaction was stirred at room
temperature open to air. Full consumption of the starting materials was achieved within 5 min
(confirmed by TLC, DCM: EtOAc = 9:1) of stirring. The organic solvent was then evaporated and
the yellow oily residue was purified via gradient silica gel flash column chromatography (eluent
DCM: EtOAc = 100:1 and DCM: MeOH= 200:1; 100:1; 50:1).
Compound 36, (2-(benzo[d]thiazol-2-yl)phenyl)boronic acid:
Isolated yield 85 %. 1H NMR (CD3OD): δ 8.00 (t, J = 6.8 Hz, 2H), 7.82 (d, J = 7.6 Hz,
1H), 7.55–7.42 (m, 6H); 13C NMR (CD3OD): δ 170.6, 149.9, 135.0, 134.6, 131.1, 130.8, 128.6,
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126.9, 126.3, 125.8, 125.6, 122.3, 121.2. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C13H10BNO2S
256.0598, found 256.0600.
Compound 39, 2-phenylbenzo[d]thiazole:
Spectroscopic data matches that of literature report.110
Compound 40, (2-(benzo[d]thiazol-2-yl)-5-methylphenyl)boronic acid:
Isolated yield 95%. 1H NMR (CD3OD): δ 7.98 (d, J = 8 Hz, 1H), 7.93 (d, J = 8 Hz, 1H),
7.66 (d, J = 7.6 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.39 (t, J = 7.6 Hz, 1H), 7.29 (s, 1H), 7.22 (d, J
= 7.6 Hz, 1H), 2.38 (s, 1H); 13C NMR (CD3OD): δ 170.7, 149.8, 141.8, 134.5, 132.5, 131.5, 129.2,
126.8, 125.8, 125.4, 122.3, 121.0, 20.4. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C14H12BNO2S
270.0755, found 270.0757.
Compound 41, (2-(benzo[d]thiazol-2-yl)-5-(trifluoromethoxy)phenyl)boronic acid:
Isolated yield 97%. 1H NMR (CD3OD): δ 8.01 (d, J = 8 Hz, 1H), 7.96 (d, J = 8 Hz, 1H),
7.86 (d, J = 8 Hz, 1H), 7.55 (t, J = 7.2 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.35 – 7.29 (m, 2H); 13C
NMR (CD3OD): δ 170.5, 152.7, 136.1, 134.9, 130.2, 128.7, 128.5, 127.2, 124.1, 123.8, 123.1,
122.5, 122.0, 120.5. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C14H9BF3NO3S 340.0421, found
340.0423.
Compound42, (2-(benzo[d]thiazol-2-yl)-4-(benzyloxy)phenyl)boronic acid:
Isolated yield 60%. 1H NMR (DMSO-d6): 8.13 (d, J = 8.0 Hz, 1H), 8.07 (s, 1H), 7.98 (d,
J = 8.0 Hz, 1H), 7.57- 7.52 (m, 2H), 7.50-7.46 (m, 3H), 7.45-7.39 (m, 3H), 7.34 (d, J = 8.0 Hz,
1H), 7.18 (d, J = 8.0 Hz, 1H), 5.23 (s, 2H).
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C NMR (DMSO-d6): 169.7, 158.9, 153.3, 137.5,

137.3, 135.4, 135.3, 129.0, 128.4, 128.1, 127.0, 125.9, 123.1, 122.7, 116.8, 115.4, 69.7, 48.4, 48.2,
48.0, HRMS (ESI-TOF) m/z [M+1]+ calcd. for C20H16BNO3S 362.1017, found 362.1009.
Compound 43, (2-(benzo[d]thiazol-2-yl)-5-fluorophenyl)boronic acid:
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Isolated yield 78%. 1H NMR (CD3OD): δ 8.03 (d, J = 8.4 Hz, 2H), 7.91-7.87 (m, 1H), 7.59
(t, J = 7.2 Hz, 1H) 7.48 (t, J = 7.6 Hz, 1H), 7.24-7.16 (m, 2H); 13C NMR (CD3OD): δ 170.2, 163.9,
148.4, 134.5, 131.1, 127.7, 127.3, 125.8, 122.6, 120.7, 117.6, 117.4, 115.5, 115.2. HRMS (ESITOF) m/z [M+1]+ calcd. for C13H9BFNO2S 274.0504, found 274.0507.
Compound 44, (2-(benzo[d]thiazol-2-yl)-4-methoxyphenyl)boronic acid:
Isolated yield 95%. 1H NMR (CD3OD): δ 8.00 (t, J = 3.2 Hz, 2H), 7.56 (t, J = 7.6 Hz, 1H),
7.46–7.38 (m, 3H), 7.11 (d, J = 7.6 Hz, 1H), 3.88 (s, 3H);

13

C NMR (CD3OD): δ 169.9, 160.3,

150.7, 136.5, 134.7, 132.1, 126.7, 126.3, 125.5, 122.1, 121.6, 116.4, 111.8, 54.5. HRMS (ESITOF) m/z [M+1]+ calcd. for C14H12BNO3S 286.0704, found 286.0706.
Compound 45, (2-(5-chlorobenzo[d]thiazol-2-yl)phenyl)boronic acid:
Isolated yield 84%. 1H NMR (CD3OD): δ 7.96-7.94 (m, 2H), 7.84 (d, J = 7.2 Hz, 2H), 7.547.39 (m, 4H); 13C NMR (CD3OD): δ 171.9, 152.3, 134.8, 133.2, 132.6, 131.1, 131.0, 128.7, 126.7,
125.7, 123.2, 121.3. HRMS (ESI-TOF) m/z [M+1]+ calcd. for C13H9BClNO2S 290.0251, found
290.0215.
Compound 46, (2-(5-chlorobenzo[d]thiazol-2-yl)-5-methylphenyl)boronic acid:
Isolated yield 75%. 1H NMR (CD3OD): δ 8.00-7.95 (m, 2H), 7.78 (d, J = 8 Hz, 1H), 7.44
(d, J = 8 Hz, 1H), 7.33-7.30 (m, 2H), 2.43 (s, 3H);

13

C NMR (CD3OD): δ 172.0, 152.3, 142.0,

133.1, 132.6, 132.3, 131.7, 129.4, 127.1, 126.6, 125.5, 123.2, 121.1, 20.3. HRMS (ESI-TOF) m/z
[M+1]+ calcd. for 304.0387, found 304.0370.
Compound 47, (4-(Benzyloxy)-2-(5-chlorobenzo[d]thiazol-2-yl)phenyl)boronic acid:
Isolated yield 77%. 1H NMR (CD3OD): δ 8.00 (d, J = 32.0 Hz, 2H), 7.50-7.31 (m, 8H),
7.22 (d, 1H), 5.19 (s, 2H); 13C NMR (CD3OD): δ 171.5, 159.4, 152.7, 136.9, 136.3, 133.3, 132.5,
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132.4, 128.2, 127.6, 127.2, 125.6, 123.1, 121.4, 117.5, 113.4, 69.8; HRMS (ESI-TOF) m/z: [M +
1]+ calcd for C20H15BClNO3S 396.0622, found: 396.0632.
Compound 48, (2-(5-Chlorobenzo[d]thiazol-2-yl)-4-fluorophenyl)boronic acid:
Isolated yield 52%. 1H NMR (CD3OD): δ 8.04 (d, J = 22.0 Hz, 2H), 7.97 (dd, J =
13.0, 22.0 Hz, 1H), 7.49 (dd, J = 5.0, 22.0 Hz, 1H), 7.26-7.22 (m, 2H);

13

C NMR (CD3OD): δ

171.1, 151.2, 133.2, 132.9, 131.0, 128.6, 125.8, 123.3, 120.9, 117.9, 117.7, 115.7, 115.4; HRMS
(ESI-TOF) m/z: [M + 1]+ calcd for C13H8BClFNO2S 308.0115, found: 308.0118.
Compound 49, (2-(5-chlorobenzo[d]thiazol-2-yl)-4-methoxyphenyl)boronic acid:
Isolated yield 74%. 1H NMR (CD3OD) δ 8.01 (s, J = 8.8 Hz, 1 H), 7.97 (s, 1 H), 7.46 (dd,
J = 8.8, 2.0 Hz, 1 H), 7.41 (s, 1 H), 7.39 (d, J = 8.4 Hz, 1 H), 7.15 (dd, J = 8.4, 2.4 Hz, 1 H), 3.90
(s, 3 H); 13C NMR (CD3OD) δ 173.0, 161.8, 154.1, 137.7, 134.7, 133.9, 133.8, 127.0, 125.7, 124.5,
122.8, 117.9, 113.7, 55.9; HRMS (ESI-TOF) m/z: [M + 1]+ calcd for C20H15BClNO3S 320.0241,
found: 320.0303.
Compound 50, (2-(5-(trifluoromethyl)benzo[d]thiazol-2-yl)phenyl)boronic acid:
Isolated yield 56%. 1H NMR (CD3OD): δ 8.24 (d, 1 H), 8.22 (s, 1 H), 7.93 (d, 1 H), 7.71
(d, 1 H), 7.60-7.48 (m, 3 H); 13C NMR (CD3OD): δ 173.4, 153.2, 140.0, 136.0, 132.6, 132.5, 130.5,
130.2, 128.5, 124.6, 122.8, 122.8, 120.1, 120.0; HRMS (ESI-TOF) m/z [M+1]+ calcd. for
C14H9BF3NO2S 324.0399, found 324.0474.
Compound 51, (5-methyl-2-(5-(trifluoromethyl)benzo[d]thiazol-2-yl)phenyl)boronic acid:
Isolated yield 56%. 1H NMR (CD3OD): δ8.21 (s, 1H), 8.19 (s, 1H), 7.80 (d, J = 8 Hz), 7.69
(d, J = 8.4 Hz, 1H), 7.33 (d, J = 8 Hz, 1H), 7.309 (s, 1H), 2.43 (s, 3H); 13C NMR (CD3OD): δ172.0,
142.5, 138.7, 132.0, 131.9, 129.7, 128.5, 127.3, 123.1, 122.7, 121.3, 118.8, 20.2. HRMS (ESITOF) m/z [M+1]+ calcd. for C15H11BF3NO2S 338.1245, found 338.0632.
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Compound

52,

(5-(trifluoromethoxy)-2-(5-(trifluoromethyl)benzo[d]thiazol-2-

yl)phenyl)boronic acid:
Isolated yield 58%. 1H NMR (CD3OD): δ8.27 (d, 1 H), 8.24 (s, 1 H), 8.06 (d, 1 H), 7.75,
(d, 1 H), 7.44 (d, 1 H), 7.38 (s, 1 H);

13

C NMR (CD3OD): δ171.9, 152.8, 140.2, 134.76, 132.3,

130.8, 130.5, 130.3, 126.9, 124.8, 124.6, 124.2, 123.1, 122.3, 120.5, 120.1, 120.0; HRMS (ESITOF) m/z [M+1]+ calcd. for C15H8BF6NO3S 408.0301, found 408.0302.
Compound 53, (4-(benzyloxy)-2-(5-(trifluoromethyl)benzo[d]thiazol-2-yl)phenyl)boronic
acid:
Isolated yield 74%. 1H NMR (CD3OD): δ 8.20 (s, 1 H), 8.19 (d, 1 H), 7.69 (d, 1 H), 7.47
(d, 3 H), 7.386 (t, 3 H), 7.32 (d, 1 H), 7.20 (d, 1 H), 5.184 (s, 2 H); 13C NMR (CD3OD): δ 173.0,
160.8, 153.4, 140.0, 138.2, 137.5, 133.9, 130.5, 130.1, 129.6, 129.5, 129.0, 128.6, 128.6, 124.5,
124.2, 122.8, 122.7, 120.2, 120.2, 118.9, 115.2, 71.2; HRMS (ESI-TOF) m/z [M+1]+ calcd. for
C21H15BF3NO3S 430.0818, found 430.0895.
Compound 54, (5-fluoro-2-(5-(trifluoromethyl)benzo[d]thiazol-2-yl)phenyl)boronic acid:

Isolated yield 68%. 1H NMR (CD3OD): δ 8.24 (d, 1 H), 8.22 (s, 1 H), 7.98-7.95 (m, 1 H),
7.71 (d, 1 H), 7.26-7.22 (m, 2 H); 13C NMR (CD3OD): δ 171.1, 138.6, 130.9, 129.3, 123.3, 121.5,
118.4, 118.0, 117.8, 115.7, 115.5; HRMS (ESI-TOF) m/z [M+1]+ calcd. for C14H8BF4NO2S
342.0305, found 342.0378.
Compound

55,

(4-methoxy-2-(5-(trifluoromethyl)benzo[d]thiazol-2-yl)phenyl)boronic

acid:
Isolated yield 94%. 1H NMR (CD3OD): δ 8.24 (d, 1 H), 8.22 (s, 1 H), 7.72 (d, 1 H), 7.45
s, 1 H), 7.41 (d, 1 H), 7.165 (d, 1 H), 4.85 (s, 3 H);
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C NMR (CD3OD): δ 172.1, 159.6, 152.6,
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139.3, 136.6, 134.9, 127.6, 127.3, 123.9, 123.0, 119.4, 119.3, 116.0, 114.1, 55.4; HRMS (ESITOF) m/z [M+1]+ calcd. for C15H11BF3NO3S 354.0584, found 354.0586.
Compound 65, 4-(benzyloxy)-2-(5-chlorobenzo[d]thiazol-2-yl)-N-(p-tolyl)aniline:
A 10 mL vial containing arylboronic acid 47 (20 mg, 0.0506 mmol), p-toluidine (6.5 mg,
0.0607 mmol), NiCl2.6H2O (1.3 mg, 0.0101 mmol), 2,2'-bipyridyl (1.5 mg, 0.0101 mmol), DBU
(15.3 mg, 0.101 mmol) and acetonitrile (2 mL) was stirred at room temperature under atmospheric
conditions. The progress of the reaction was monitored by TLC using EtOAc and n-hexane as
eluent. After completion, the reaction mixture was treated with EtOAc (5 mL) and water (5 mL).
The organic layer was separated, and the aqueous layer was extracted with EtOAc (3 × 5 mL). The
combined organic phase was washed with water (2 × 5 mL), dried over anhydrous Na2SO4, and
concentrated to yield a residue, which was purified by silica gel column chromatography using
hexane/ethyl acetate to yield a pale yellow oil (13 mg, 56%). 1H NMR (CDCl3): δ 10.1 (s, 1H),
7.99 (d, 1H, J = 5.0 Hz), 7.81 (d, 1H, J = 21 Hz), 7.50 (d, 2H, J = 18 Hz), 7.43 (t, 2H, J = 18 Hz),
7.38-7.35 (m, 3H), 7.32 (d, 1H, J = 21 Hz), 7.25-7.19 (m, 4H), 7.03 (dd, 1H, J = 7.0, 23.0 Hz),
5.11 (s, 2H), 2.36 (s, 3H); 13C NMR (CDCl3): δ 170.2, 154.3, 150.7, 139.2, 137.0, 132.4, 132.2,
131.7, 129.9, 128.6, 128.1, 127.6, 125.5, 122.3, 121.9, 121.7, 121.6, 120.4, 116.8, 115.8, 71.0,
20.8; HRMS (ESI-TOF) m/z: [M + 1]+ calcd for C27H21ClN2OS 457.1163, found: 457.1141.
Compound

67,

N-((2'-(benzo[d]thiazol-2-yl)-5'-(trifluoromethoxy)-[1,1'-biphenyl]-3-

yl)methyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide:
A flame-dried, two-neck round bottom flask was charged with compound 41 (50 mg, 0.147
mmol), aryl halide 66 (45 mg, 0.11 mmol), flame-dried CsF (49 mg, 0.323 mmol), and Pd(PPh3)4
(8.5 mg, 7.3 × 10-3 mmol) under argon atmosphere. Distilled DME (8 ml) was added and after
immediate evacuation of the gas atmosphere in the flask via a vacuum pump, the reaction mixture
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was stirred overnight at reflux temperature under argon. After stirring overnight, TLC
(DCM:MeOH = 20:1) showed full consumption of the starting materials. The reaction mixture was
cooled to room temperature and diluted with water (15 mL). The residue was extracted with ethyl
acetate (2 × 50 mL) and the organic layers were combined and washed with water (1 × 20 mL),
1N NaOH solution (1 × 5 mL), water (1 × 30 mL), and brine (1 × 20 mL). The organic layer was
then dried over Na2SO4 and evaporated in vaccuo. The brown/yellow residue was purified via
silica gel flash column chromatography (eluent DCM: MeOH= 200:1; 100:1; 50:1; 30:1) to give
55 mg of an off-white solid (85% yield). 1H NMR (CD3OD): δ 8.13 (d, J = 8.8 Hz, 1H), 7.98 (d,
J = 8 Hz, 1H), 7.82(d, J = 8 Hz, 1H), 7.53 – 7.48 (m, 2H), 7.39 (t, J = 7.2 Hz, 1H), 7.38 – 7.33
(m, 3H), 7.27 (s, 1H), 7.21 – 7.18 (m, 1H), 4.44 (dd, J1 = 4.4 Hz, J2 = 4.8 Hz, 1H), 4.33 (d, J =
2.4 Hz, 2H), 4.22 (dd, J1 = 4.4 Hz, J2 = 4.4 Hz, 1H), 3.12 – 3.07 (m, Hz, 1H), 2.87 (dd, J1 = 5.2
Hz, J2 = 4.8 Hz, 1H), 2.67 (d, J = 12.4 Hz, 1H), 2.08 (t, J = 7.6 Hz, 2H),1.69 – 1.53 (m, 5H), 1.39
– 1.31 (m, 2H);

13

C NMR (CD3OD): δ 174.4, 166.6, 164.6, 152.2, 150.1, 143.9, 139.5, 138.9,

136.2, 132.1, 131.1, 128.6, 128.5, 128.1, 127.5, 126.2, 125.3, 122.6, 122.5, 121.8, 121.3, 119.7,
61.9, 60.2, 55.5, 42.3, 39.6, 35.2, 28.3, 28.0, 25.3. HRMS (ESI-TOF) m/z [M+1]+ calcd. for
C31H29F3N4O3S2 [M+H]+ 627.1704, found 627.1710.
2.5
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Appendix B HPLC data for the stability studies described in Chapter 1
Stability Studies at Simulated Physiological Conditions of Selected Compounds
HPLC spectra of BW-AQ-101.
0 min. at 37 ˚C.

240

120 min. at 37 ˚C.

24 h. at 37 ˚C.

241

HPLC spectra of BW-AQ-112.
0 min. at 37 ˚C.

120 min. at 37 ˚C.

242

24 h. at 37 ˚C.

HPLC spectra of BW-AQ-124.
0 min. at 37 ˚C.

243

120 min. at 37 ˚C.

24 h. at 37 ˚C.

244

HPLC spectra of BW-AQ-131.
0 min. at 37 ˚C.

245

120 min. at 37 ˚C.

24 h. at 37 ˚C.

246

HPLC spectra of BW-AQ-126.
0 min. at 37 ˚C.

120 min. at 37 ˚C.

247

24 h. at 37 ˚C.

248

Long Term Stability Studies of Selected Compounds
HPLC spectra of BW-AQ-101.
Week 1: solid storage at room temperature.

249

Week 1: solid storage at 4˚ C.

Week 1: solid storage at -20˚ C.

250

Week 1: solution storage at room temperature.

251

Week 1: solution storage at 4˚ C.

Week 1: solution storage at -20˚ C.

252

HPLC spectra of BW-AQ-112.
Week 1: solid storage at room temperature.

Week 1: solid storage at 4˚ C.

253

Week 1: solid storage at -20˚ C.

Week 1: solution storage at room temperature.

254

Week 1: solution storage at 4˚ C.

Week 1: solution storage at -20˚ C.

255

HPLC spectra of BW-AQ-113.
Week 1: solid storage at room temperature.

Week 1: solid storage at 4˚ C.

256

Week 1: solid storage at -20˚ C.

Week 1: solution storage at room temperature.

257

Week 1: solution storage at 4˚ C.

Week 1: solution storage at -20˚ C.

258

HPLC spectra of BW-AQ-124.
Week 1: solid storage at room temperature.

259

Week 1: solid storage at 4˚ C.

Week 1: solid storage at -20˚ C.

260

Week 1: solution storage at room temperature.

Week 1: solution storage at 4˚ C.

261

Week 1: solution storage at -20˚ C.

HPLC spectra of BW-AQ-101.

262

Week 4: solid storage at room temperature.

Week 4: solid storage at 4˚ C.

263

Week 4: solid storage at -20˚ C.

Week 4: solution storage at room temperature.

264

Week 4: solution storage at 4˚ C.

Week 4: solution storage at -20˚ C.

HPLC spectra of BW-AQ-112.
Week 4: solid storage at room temperature.

265

Week 4: solid storage at 4˚ C.

Week 4: solid storage at -20˚ C.

266

Week 4: solution storage at room temperature.

Week 4: solution storage at 4˚ C.

267

Week 4: solution storage at -20˚ C.

HPLC spectra of BW-AQ-113.
Week 4: solid storage at room temperature.

268

Week 4: solid storage at 4˚ C.

Week 4: solid storage at -20˚ C.

269

Week 4: solution storage at room temperature.

Week 4: solution storage at 4˚ C.

270

Week 4: solution storage at -20˚ C.

HPLC spectra of BW-AQ-124.
Week 4: solid storage at room temperature.

271

Week 4: solid storage at 4˚ C.

Week 4: solid storage at -20˚ C.

272

Week 4: solution storage at room temperature.

Week 4: solution storage at 4˚ C.

273

Week 4: solution storage at -20˚ C.

HPLC spectra of BW-AQ-101.
Week 9: solid storage at room temperature.

274

Week 9: solid storage at 4˚ C.

Week 9: solid storage at -20˚ C.

275

Week 8: solution storage at room temperature.

276

Week 8: solution storage at 4˚ C.

Week 8: solution storage at -20˚ C.

277

HPLC spectra of BW-AQ-112.
Week 9: solid storage at room temperature.

Week 9: solid storage at 4˚ C.

278

Week 9: solid storage at -20˚ C.

Week 8: solution storage at room temperature.

279

Week 8: solution storage at 4˚ C.

Week 8: solution storage at -20˚ C.

280

HPLC spectra of BW-AQ-113.
Week 9: solid storage at room temperature.

281

Week 9: solid storage at 4˚ C.

282

Week 9: solid storage at -20˚ C.

Week 8: solution storage at room temperature.

283

Week 8: solution storage at 4˚ C.

Week 8: solution storage at -20˚ C.

284

HPLC spectra of BW-AQ-124.
Week 9: solid storage at room temperature.

285

Week 9: solid storage at 4˚ C.

Week 9: solid storage at -20˚ C.

286

Week 8: solution storage at room temperature.

Week 8: solution storage at 4˚ C.

287

Week 8: solution storage at -20˚ C.

HPLC spectra of BW-AQ-101.
Week 12: solid storage at room temperature.

288

Week 12: solid storage at 4˚ C.

289

Week 12: solid storage at -20˚ C.

HPLC spectra of BW-AQ-112.
Week 12: solid storage at room temperature.

290

Week 12: solid storage at 4˚ C.

Week 12: solid storage at -20˚ C.

HPLC spectra of BW-AQ-113.

291

Week 12: solid storage at room temperature.

Week 12: solid storage at 4˚ C.

Week 12: solid storage at -20˚ C.

292

HPLC spectra of BW-AQ-124.
Week 12: solid storage at room temperature.

Week 12: solid storage at 4˚ C.

293

Week 12: solid storage at -20˚ C.

HPLC spectra of BW-AQ-101.

294

Week 17: solid storage at room temperature.

Week 17: solid storage at 4˚ C.

295

Week 17: solid storage at -20˚ C.

HPLC spectra of BW-AQ-112.

Week 17: solid storage at room temperature.
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Week 17: solid storage at 4˚ C.

Week 17: solid storage at -20˚ C.

297

HPLC spectra of BW-AQ-113.
Week 17: solid storage at room temperature.
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Week 17: solid storage at 4˚ C.

Week 17: solid storage at -20˚ C.
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HPLC spectra of BW-AQ-124.
Week 17: solid storage at room temperature.

Week 17: solid storage at 4˚ C.
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Week 17: solid storage at -20˚ C.

301

Appendix C NMR data for the compounds described in Chapter 2
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